



Medical Coverage Policy

Effective Date9/15/2025

Next Review Date8/15/2026

Coverage Policy Number..... 0019

Minimally Invasive Anti-Reflux Procedures and Peroral Endoscopic Myotomy (POEM) Procedures

Table of Contents

Overview	2
Coverage Policy	2
Health Equity Considerations.....	3
General Background.....	3
Medicare Coverage Determinations	41
Coding Information	42
References.....	43
Revision Details.....	63

Related Coverage Resources

[Botulinum Toxins – Botox](#)
[Gastric Pacing/Gastric Electrical Stimulation \(GES\)](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s).

Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses minimally invasive anti-reflux procedures for the treatment of gastroesophageal reflux disease (GERD) and Peroral Endoscopic Myotomy (POEM) for the treatment of esophageal achalasia and gastroparesis.

Coverage Policy

Esophageal peroral endoscopic myotomy (POEM) is considered medically necessary when ALL of the following criteria are met:

- the individual is age 18 years or older
- achalasia type I, II or III is diagnosed using esophageal manometry
- Eckardt symptom score is greater than three

Esophageal peroral endoscopic myotomy (POEM) for ANY other indication is considered not medically necessary.

Gastric peroral endoscopic myotomy (G-POEM) is considered medically necessary for the treatment of refractory gastroparesis when ALL of the following criteria are met:

- absence of mechanical obstruction confirmed by Esophagogastroduodenoscopy (EGD)
- a gastric emptying scintigraphy (GES) has confirmed delayed gastric emptying with gastric retention > 20% at four hours
- chronic, intractable nausea and vomiting secondary to gastroparesis
- failure of conservative medical management, including dietary modification, prokinetics and antiemetics

Diverticular peroral endoscopic myotomy (D-POEM) is considered experimental, investigational or unproven.

Each of the following endoscopic or laparoscopic anti-reflux procedures for gastroesophageal reflux disease (GERD), or any other indication, is considered experimental, investigational or unproven:

- radiofrequency energy to the gastroesophageal junction (e.g., Stretta® System)
- endoluminal gastroplasty/gastroplications (e.g., Medigus Ultrasonic Surgical Endostapler [Muse™] System, GERDx™)
- transoral incisionless fundoplication (TIF) (e.g., EsophyX™, MUSE System)
- injection/implantation of biocompatible material (e.g., plexiglas or polymethylmethacrylate [PMMA], Durasphere™)
- magnetic sphincter augmentation (e.g., LINX™ Reflux Management System)

- resection and plication (RAP) (e.g., Apollo Overstitch)

Health Equity Considerations

Health equity is the highest level of health for all people; health inequity is the avoidable difference in health status or distribution of health resources due to the social conditions in which people are born, grow, live, work, and age.

Social determinants of health are the conditions in the environment that affect a wide range of health, functioning, and quality of life outcomes and risks. Examples include safe housing, transportation, and neighborhoods; racism, discrimination and violence; education, job opportunities and income; access to nutritious foods and physical activity opportunities; access to clean air and water; and language and literacy skills.

General Background

Peroral Endoscopic Myotomy (POEM) Procedures

Achalasia is a rare motility disorder of the esophagus and is defined by three elements: the reduction or absence of the primary peristaltic waves in the distal two thirds of the esophagus, incomplete or no relaxation of the lower esophageal sphincter (LES) during swallowing and increased resting LES tone. There is degeneration of the esophageal muscle and the nerves that control the muscles. The cause of primary or idiopathic achalasia is unknown. Secondary achalasia is due to diseases that cause esophageal motor abnormalities (e.g., Chagas disease, esophageal cancer, Fabry disease, amyloidosis). Men and women are affected with equal frequency, with no racial predilection and achalasia is usually diagnosed in patients between the ages of 30 and 60 years. Symptoms of achalasia include dysphagia, heartburn, difficulty belching, chest pain, regurgitation of undigested food and liquid, and weight loss (Spechler and Pandolfino, 2025; Vaezi, et al., 2020a; Tefas, et al., 2018; National Organization for Rare Disorders [NORD®], 2017).

Achalasia is defined by aperistalsis and abnormal LES relaxation (integrated relaxation pressure [IRP] > 15 mmHg). The disorder is characterized manometrically by insufficient relaxation of the lower esophageal sphincter (LES) and loss of esophageal peristalsis; radiographically by aperistalsis, esophageal dilation, with minimal LES opening, "bird-beak" appearance, poor emptying of barium; and endoscopically by dilated esophagus with retained saliva, liquid, and undigested food particles in the absence of mucosal stricturing or tumor (Spechler and Pandolfino, 2025; Vaezi, et al., 2020b).

The three types of achalasia based on the Chicago Classification of patterns of esophageal pressurization on high-resolution manometry (HRM) (CC v3.0) include the following:

- Type I (classic achalasia) – Incomplete LES relaxation, aperistalsis and absence of esophageal pressurization. Swallowing results in no significant change in esophageal pressurization and has 100% failed peristalsis with a distal contractile integral (DCI, an index of the strength of distal esophageal contraction) < 100 mmHg.
- Type II – Incomplete LES relaxation, aperistalsis and panesophageal pressurization in at least 20% of swallows. Swallowing results in simultaneous pressurization that spans the entire length of the esophagus. Type II achalasia has 100% failed peristalsis and pan-esophageal pressurization with ≥ 20 percent of swallows.
- Type III (spastic achalasia) – Incomplete LES relaxation and premature contractions (distal latency [DL] < 4.5 seconds) in at least 20% of swallows. Swallowing results in abnormal, lumen-obliterating contractions or spasms. Type III achalasia has no normal peristalsis and

premature (spastic) contractions with DCI >450 mmHg-sec-cm with ≥ 20 percent of swallows (Spechler and Pandolfino, 2025; Schlottmann, et al., 2017).

The Eckardt symptom score is used to quantify the severity and frequency of symptoms. It attributes points (0 to 3 points) for four symptoms of the disease (dysphagia, regurgitation, chest pain and weight loss), ranging from 0 to 12. Scores of 0-1 corresponds to clinical stage 0, 2-3 to stage I, 4-6 to stage II, and a score >6 to stage III (Laurino-Neto et al., 2018).

Eckardt score for symptomatic evaluation in achalasia:

Score	Weight loss (kg)	Dysphagia	Retrosternal Pain	Regurgitation
0	None	None	None	None
1	< 5	Occasional	Occasional	Occasional
2	5-10	Daily	Daily	Daily
3	> 10	Each meal	Each meal	Each meal

The primary treatment objective for achalasia is to relieve obstruction in the distal esophagus by decreasing the resting pressure in the lower esophageal sphincter (LES) to a level at which the sphincter no longer impedes the passage of undigested food and liquid. Established treatment options include pharmacotherapy (e.g., injection of botulinum toxin into the esophagus, use of oral nitrates) or mechanical disruption of the muscle fibers of the LES by surgical interventions (i.e., endoscopic balloon dilation, surgical Heller myotomy [LHM] with or without fundoplication) to reduce the incidence of gastroesophageal reflux disease (GERD). LHM is the treatment of choice and has an 85%–90% effect in treating the condition. When a patient has dysphagia following surgical myotomy, the first suspicion is incomplete myotomy (Spechler and Pandolfino, 2025; Fernandez-Ananin, et al., 2018; Tefas, et al., 2018).

Peroral endoscopic myotomy (POEM)

POEM is a minimally invasive intervention that aims to treat achalasia. It is regarded as the endoscopic equivalent of Heller myotomy. The POEM technique involves guiding an endoscope through the esophagus, making an incision in the mucosa, creating a submucosal tunnel for access to the lower esophagus and gastroesophageal junction, and cutting the muscle fibers in the lower esophagus and proximal stomach. Internal incisions are closed with clips after myotomy is complete. The proposed advantage of POEM is that it can deliver a longer myotomy than pneumatic dilation or the Heller procedure. The length of myotomy from the esophageal to the gastric side can be adjusted on a case-by-case basis while achieving functional durability of traditional surgical myotomy. A longer myotomy may be more effective in controlling symptoms. POEM includes no antireflux procedure and can therefore result in GERD. POEM is a proposed treatment. Reasonable treatment options following a failed surgical myotomy include pneumatic dilation or redo myotomy using either the same or an alternative myotomy technique (POEM or laparoscopic Heller myotomy) (Khashab, 2023; Spechler and Pandolfino, 2025; Inoue, et al., 2018).

POEM is a complex procedure, demanding skilled hands to avoid serious complications. Endoscopists should be able to recognize structures beyond mucosa, including vasculature nerves and the anatomy of the mediastinum. POEM should be performed in highly specialized centers by experienced endoscopists or surgeons (Ahmed and Othman, 2019).

Literature Review – POEM: Randomized controlled trials (RCT) have compared POEM to laparoscopic Heller myotomy with Dor fundoplication (LHD) for the treatment of achalasia. A RCT by Werner et al. (2019) concluded that POEM is non-inferior to laparoscopic Heller myotomy with

Dor fundoplication with shorter operative times and minimal serious adverse events. Another RCT compared the efficacy of POEM to pneumatic dilation as the initial treatment of patients with treatment-naïve achalasia with a clinically significant treatment success rate at two years in the POEM group (Ponds, et al., 2019). Numerous case studies, systematic reviews and systematic reviews with meta-analysis have been published evaluating POEM for the treatment of achalasia (Modayil, et al., 2021; Costantini et al., 2020; Lee, et al., 2019; Li, et al., 2018; Schlottmann, et al., 2018; Akintoye, et al., 2016).

Gastric Peroral Endoscopic Myotomy (G-POEM)

Gastroparesis (GP) is a chronic motility disorder defined as a functional disorder with objective delayed gastric emptying in the absence of a mechanical obstruction. The symptoms of gastroparesis include nausea, vomiting, early satiety, belching, bloating, and/or upper abdominal pain. Initial management of gastroparesis consists of dietary modification, optimization of glycemic control and hydration, and pharmacologic therapy with prokinetic and antiemetic medications. Patients who are refractory to medical therapy may require surgical interventions in the forms of tube gastrostomy, subtotal gastrectomy, or pyloroplasty. Surgical pyloroplasty (eg, Heineke-Mikulicz pyloroplasty) can lead to sustained improvement of symptoms in patients with refractory gastroparesis. The POEM procedure has been adapted to be performed in the stomach (G-POEM). Gastric-POEM is a proposed, less invasive alternative treatment of severe gastroparesis that is refractory to medical therapy in selected patients. G-POEM consists of creating a prepyloric submucosal tunnel extending to the pylorus before dissecting circular and oblique muscle bundles, as per the peroral endoscopic myotomy (POEM) (Khashab, 2023; Camilleri, 2022; Gregor, et al., 2021; Azzolini, et al., 2020; Spadaccini, et al., 2020; Aghaie Meybodi, et al., 2019)

Literature Review – G-POEM: A number of prospective observational studies, systematic reviews with meta-analysis and retrospective studies have evaluated the efficacy and safety of G-POEM in treating refractory gastroparesis. The studies used the Gastroparesis Cardinal Symptom Index (GCSI) and gastric emptying scintigraphy (GES) to assess gastroparesis symptoms. GCSI measures the following symptoms: nausea, retching, vomiting, stomach fullness, inability to finish a meal, excessive fullness, loss of appetite, bloating and abdominal distension. GES measures half gastric-emptying time, retention at two and four hours (Chung, et al., 2022; Gregor, et al., 2021; Azzolini, et al., 2020; Spadaccini, et al., 2020; Aghaie Meybodi, et al., 2019).

Aziz et al. (2023) conducted a systematic review and meta-analysis that compared gastric peroral endoscopic myotomy to surgical pyloromyotomy/pyloroplasty for managing refractory gastroparesis. Four studies were included that consisted of two retrospective studies, one prospective study and one case-controlled study. A total of 385 patients were included (n=216/G-POEM group, n=169/surgical group). Follow-up ranged from not reported to 90 days. The studies included were based on the following: (1) Adult patients (≥ 18 years old with refractory gastroparesis of any etiology; (2) intervention: G-POEM; (3) control: surgical pyloromyotomy (laparoscopic, robotic, and/or open) and (4) outcomes: procedure duration, length of stay (LOS), complications, clinical success and post operative GCSI score. The mean procedure time and LOS was significantly lower for G-POEM compared to surgery (both $p < 0.001$). Three studies assessed clinical success on follow-up and reported no significant difference between groups. The post-procedure GCSI was evaluated by all four studies and was not significantly different. Lastly, the overall rates of adverse events (AEs) were assessed by all studies and no significant difference was noted between GPOEM and surgery. Author noted limitations were the lack of RCTs as well as low number of included studies with small patient population. Further, the included studies mostly included patients at highly advanced tertiary care centers and cannot be generalized to other populations. Lastly, the follow-up of patients was not consistent across the studies and outcomes such as duration and timing of improvement in symptoms, GES and reduction in GCSI were not consistently assessed. The authors concluded that G-POEM appears promising as it may provide a

cost-effective approach for managing refractory gastroparesis compared to surgical techniques. There were more females in both groups than men, no other disparities were noted.

Stojilkovic et al. (2023) conducted a systematic review of the long-term clinical success of gastric peroral endoscopic myotomy for refractory gastroparesis. Eleven studies were eligible for inclusion (n=900), which included four prospective studies and seven retrospective studies with follow-up between 1-4 years. Five of the studies are from the USA, two from France, one from the Czech Republic, one from the Netherlands, one from China, and one from Mexico. Of the 900 patients, 294 had idiopathic, 295 had diabetic, 269 had postsurgical, and 44 had other for the etiology of gastroparesis. The outcomes assessed clinical success, adverse reactions and length of stay. Clinical success was described as an average decrease of Gastroparesis Cardinal Symptom Index (GCSI) scale by 1 point compared to baseline GCSI for all patients. Author reported clinical success was found in 662 patients out of 713 (92.8%) at one-year follow-up, 421 out of 460 (91.5%) at two-year follow-up, 270 out of 270 (100%) at three-year follow-up, and 102 out of 102 (100%) at four-year follow-up. Adverse events occurred in 62 out of 835 patients (in nine studies), with two of the most frequent being bleeding and mucosal tears. An acknowledged study limitation included that not all patients who were part of the baseline cohort continued with the follow-up throughout the study. Additionally, the review was done by two authors, which could have led to some bias. The authors reported that GPOEM is an effective and safe treatment option for patients with refractory gastroparesis, with symptom improvement noted up to four years postoperatively. There were more females in both groups than men, no other disparities were noted.

Martinek et al. (2022) conducted a prospective randomized controlled trial that compared endoscopic pyloromyotomy (G-POEM) to sham in patients with severe gastroparesis. Patients aged 18 years or older with a diagnosis of severe gastroparesis (GP) refractory to > 6 months of treatment were included in the study. Patients (n=41; n=17 diabetic, n=13 postsurgical, n=11 idiopathic) were randomized either the G-POEM group (n=21) or to the sham group (n=20). After six months, those in the sham group with persistent symptoms were offered cross-over G-POEM. The primary outcome measured the proportion of patients with treatment success which was defined as a decrease in the Gastroparesis Cardinal Symptom Index (GCSI) by at least 50% at six months. The secondary outcomes measured the procedure-and safety parameters and the change in Gastric Emptying Study (GET) after G-POEM and sham. There were two patients lost to follow-up and 12 patients from the sham group were offered G-POEM after six months of follow-up. Treatment success in patients with diabetic, postsurgical and idiopathic gastroparesis was 89%, 50% and 67% after G-POEM. Respectively, the sham group reported success rates of 17%, 29% and 20%. The median gastric retention at four hours decreased from 22% to 12% after G-POEM and did not change following sham. Twelve patients crossed over to G-POEM with nine of them (75%) reporting treatment success. Ten serious adverse events (SAEs) occurred, seven after G-POEM and three in the sham group.

The authors noted the following limitations:

- short-term follow-up of six months
- premature termination of the study due to the significant results, therefore the planned number of randomized patients was not met
- gastric emptying was done at a different time than primary endpoint and the change in gastric emptying and symptomatic improvement was not accurately assessed
- the relevant pathophysiological parameters (antroduodenal and small intestinal dysmotility, vagal function) were not investigated which could play a role in development of symptoms or post-G-POEM adverse events
- all G-POEMs were performed by a single endoscopist which limits the generalizability the results

An additional limitation of the study included that the study was conducted in Europe and the results may not be applicable to other ethnic groups. The study concluded that G-POEM is beneficial in a substantial proportion of patients with severe and refractory GP. No health disparities were identified by the investigators.

Labonde et al. (2022) conducted a retrospective analysis of a prospectively multicenter cohort of patients who underwent G-POEM in two expert French centers for refractory gastroparesis. The aim of the study was to evaluate the success of G-POEM at three years and to develop a scoring system to predict the patients that would most likely benefit from the procedure. Patients (n=46) were included in the study if they were age ≥ 18 years, diagnosed with gastroparesis and experiencing persistent symptoms despite dietary control and prokinetic treatment for ≥ 6 months. The primary outcome measured clinical success at three years which was defined as a decrease of at least one point in the gastroparesis cardinal symptom index (GCSI) compared with the pre-procedure GCSI. Patients were followed up in person or via phone at one, three and six months; they were then followed up at six-month intervals. Gastric emptying scintigraphy was performed three months after G-POEM. The clinical success of G-POEM for refractory gastroparesis was 65.2% at 36 months. There was significant improvement in symptom severity ($p < 0.0001$). There were ten (22%) patients categorized as late responders. Late responders exhibited clinical failure at one or two years, then demonstrated a clinical response at three years. In contrast, 13 (28%) patients were relapsers. The relapsers showed a clinical response at one or two years and then shifted to clinical failure at three years. Additionally, the authors created a "G-POEM predictive score" which was based on preoperative symptoms and gastric emptying scintigraphy. The score could predict clinical success with a good area under the curve (0.825) and sensitivity (93.5%). Patients with a clinical score of 0 or 1 had an 18% clinical success rate, while 80% of patients with a score of ≥ 2 had clinical success at three years. This tool is proposed to help physicians perform patient selection for G-POEM and should be confirmed in other studies. Author noted limitations included the potential of selection bias due to the study design, small patient population and short-term follow-up. Lastly, "multiple testing" was performed to identify predictive factors of clinical success; such a strategy is associated with a risk of false positives. The study concluded that the clinical success of G-POEM for refractory gastroparesis was stable over a 36-month period. Patient selection based on symptoms most strongly related to delayed gastric emptying may constitute a useful approach. No health disparities were identified by the investigators.

Hernández Mondragón et al. (2022) reported on a retrospective study with data collected from a prospective cohort conducted in a referral tertiary-care center in Mexico City that evaluated the four-year follow-up efficacy of G-POEM and predictive factors in patients with refractory gastroparesis (RG). Patients were included in the study if they were age > 18 years with a confirmed diagnosis of RG. After G-POEM, 374 patients were included, 141 had diabetic (DG); 115 idiopathic (IG); 102 postsurgical (PSG) gastroparesis; and 16 patients with other etiologies. The primary outcome measured the efficacy of G-POEM after four years of follow-up. Secondary outcomes measured the safety; quality of life (QOL) evaluation; differences in clinical success (CS) among the different RG etiologies and evaluation of predictive factors for CS after four years. Gastroparesis Cardinal Symptom Index (GCSI), retention percentage at 4 hours (RP4H), mean half emptying time (MHET) and short form survey (SF-36) were performed at baseline, one, six, 12, 18, 24, 30, 36, 42 and 48-months following G-POEM. One hundred and two patients completed the 48-month follow-up (DG=58/IG=22/PSG=18 and others=4). At baseline GCSI, RP4H and MHET were 3.84 ± 0.53 , 44% and 246 minutes and significantly improved to 2.1 ± 0.70 , ($p < 0.001$); 15.5%, ($p = 0.021$) and 135 minutes, ($p = 0.045$), respectively, at the 48-month follow-up. At the 48-month evaluation, clinical success (CS) was 77.5% with DG showing the best outcomes (DG 86.5% vs IG 72.5%, $p = 0.001$; vs PSG 72.1%, $p = 0.003$ and other 68.8%, $p < 0.001$). Long-term success predictors were DG ($p = 0.035$), early diagnosis ($p = 0.042$), nausea/vomiting ($p = 0.012$), GCSI score 1.5–2 ($p = 0.022$) and RP4H $< 10\%$ ($p = 0.039$) at six

months. Additionally, the median baseline SF-36 score significantly improved from 37 to 47 after 48-months ($p=0.003$). Adverse events were presented in 8.6% and all treated endoscopically or with conservative management. Laparoscopic gastrectomy, Roux-en-Y gastric bypass and gastric stimulator were performed for failures and recurrences in 22 (CS=72%), 34 (CS=88%) and 28 (CS=66%), respectively. Author noted limitations included the single center study design, lack of a comparator, number of patients lost to follow-up and the lack of an objective assessment of the pyloric function. The authors concluded that the study reports that G-POEM is an effective four-year treatment in patients with RG, especially, in DG. No health disparities were identified by the investigators.

Pioppo et al. (2021) conducted an international comparative study that retrospectively compared the efficacy and safety of gastric per-oral endoscopic myotomy to pyloromyotomy for gastroparesis. Patients who underwent GPOEM or laparoscopic pyloromyotomy for refractory gastroparesis from four centers across the USA and Latin America were included in a dedicated registry. One-hundred and two patients were included: GPOEM ($n=39$) and surgical pyloromyotomy ($n=63$). Technical success was 100% in both groups. Clinical success was not significant between the groups, 92.3% in the GPOEM group and 82.5% in the surgery group ($p=0.164$). The GPOEM group had a significantly higher post-op GCSI score reduction by 1.3 units ($p<0.00001$), post-op retention reduction at two hours by 18% ($P < 0.00001$), post-op retention reduction at four hours by 25% ($p<0.00001$) and a lower procedure time by 20 minutes ($p<0.00001$) as compared with surgery. GPOEM also had a lower hospital length of stay by 2.8 days ($p<0.00001$). Adverse events were significantly fewer in the GPOEM group (13%) compared to the surgery group (33.3%; $p=0.021$). Additionally, mean blood loss in the GPOEM group was only 3.6 mL compared with 866 mL in the surgery group. Mean follow-up time was 5.5 months for GPOEM and 15.6 months for surgery. Limitations included the retrospective study design, short term follow-up and small patient population. The study concluded that GPOEM may be a less invasive, safer, and more efficacious procedural treatment for refractory gastroparesis when compared to surgical pyloromyotomy.

Vosoughi et al. (2021) conducted an international prospective trial at five tertiary centers (four USA, one South America) that investigated the efficacy and safety of G-POEM in patients with refractory gastroparesis. Adults ($n=80$) with refractory gastroparesis were included in the study, the mean age was 49.3 ± 14.9 with 57 (71.3%) females. The most common etiology of gastroparesis was idiopathic ($n=33$, 41.3%), followed by postsurgical ($n=28$, 35%) and diabetic ($n=19$, 23.8%). The primary outcome measured clinical success of G-POEM which was defined as at least one score decrease in Gastroparesis Cardinal Symptom Index (GCSI) with $\geq 25\%$ decrease in two subscales, at 12 months. Secondary outcomes evaluated safety, change in quality of life and change in gastric retention over the course of the study. The GCSI Score and subscales, adverse events (AEs) and 36-Item Short Form questionnaire of quality of life were evaluated at baseline and one, three, six and 12 months after G-POEM. A gastric emptying study was performed before and three months after the procedure. Five patients were lost to follow-up with 75 patients (94%) completing the 12-month follow-up. Clinical success at one month, three months, six months and 12 months following G-Poem were 57.5%, 61.5%, 60.3% and 56%, respectively. At 12 months, the GCSI Score (including subscales) improved moderately after G-POEM ($p<0.05$). Clinical success rate at 12 months was generally not significant across gastroparesis subtypes ($p=0.913$). There was a significant improvement in the majority of the quality-of-life aspects both at 12 months and over time. Physical functioning, role limitation due to physical health and bodily pain, showed no significant change. Three months after G-POEM, GES was performed in 53 of the 80 patients (66%). Gastric retention at four hours decreased significantly at three months from baseline, which resulted in GES improvement in 64.2% (34 of 53 cases). Mild procedure-related AEs occurred in five (6%) patients. Author noted limitations included the lack of a control group and the inability to sufficiently control important confounding variables, such as the use of prokinetics could be a major threat to the study's internal validity.

Lastly, gastric emptying was not evaluated at 12 months after the study and several patients were not available for repeat gastric emptying study at three months post procedure. The authors concluded that G-POEM is a safe procedure but showed only modest overall effectiveness in the treatment of refractory gastroparesis. No health disparities were identified by the investigators.

Spadaccini et al. (2020) evaluated the efficacy and safety of G-POEM for refractory gastroparesis (GP) in a systematic review and meta-analysis (n=10 studies/292 patients). The authors noted that symptomatic improvement was achieved after 83.9% of procedures. When comparing the mean values of pre- and post-procedural gastric emptying scintigraphy (GES), there was a significant decrease of the gastric retention percentage at two and four hours $74.9\% \pm 5.2\%$ versus $52.5\% \pm 10.8\%$ ($p<0.001$) and $44.1\% \pm 13.0\%$ versus $20.6\% \pm 9.5\%$ ($p<0.001$), respectively. The overall adverse events rate was 6.8% ($p=0.006$). Limitations included short term follow-up and the lack of head-to head comparison with either surgical or endoscopic pylorus directed therapies. Additionally, G-POEM is a relatively new technique and long-term data on symptom relief are still lacking. The authors concluded that G-POEM appears to be a promising approach for GP in terms of safety and efficacy outcomes in the short term.

Yan et al. (2020) also used a systematic review and meta-analysis that evaluated the efficacy and safety of G-POEM for refractory gastroparesis (GP) using the GCSI scale and GES (n=9 studies/235 patients). The authors noted that the technical success rate was 100%. After G-POEM, patients reported significant changes in GCSI score ($p<0.0001$), GCSI reduction ($p<0.0001$), gastric emptying scintigraphy at four hours (GES-4h) ($p<0.00001$) and GES time (GET) reduction ($p<0.00001$). The intra-procedure complication rate was 5.1 %, including capnoperitoneum (seven cases) and accidental mucotomy (five cases). The post-procedure complication rate was 6.8 %, including abdominal pain (three cases), bleeding (three cases), ulcer (one case), difficulty swallowing (one case) and others (eight cases). Both intra and post-procedure complications were easily managed by conservative or endoscopic treatments. Limitations noted by the authors included: the quality of the included studies was relatively low, studies had a high risk of bias, lack of RCT's, and heterogeneity between studies was significant, probably due to the mismatching of baseline information. The authors concluded that the outcome of this meta-analysis is significant, caution is still needed to draw a conclusion as to whether G-POEM can be a complete treatment for the treatment of gastroparesis.

Landreneau et al. (2019) used propensity-matched cohort study to evaluate Laparoscopic pyloroplasty versus endoscopic per-oral pyloromyotomy (POP) for the treatment of gastroparesis. Propensity scoring was used to match these patients 1:1 to patients undergoing POP during this time period based on gender, age, and etiology of gastroparesis. Symptom scores using the Gastroparesis Cardinal Symptom Index (GCSI), scintigraphic gastric emptying studies (GES), and perioperative outcomes were compared between matched cohorts. Patients underwent LP for gastroparesis (n=30) during the study period and were matched 1:1 with patients undergoing POP. Patients who underwent LP had a longer average length of stay (4.6 vs. 1.4 days, $p=0.003$), operative time (99.3 vs. 33.9 min, $p<0.001$), and estimated blood loss (12.9 vs. 0.4 mL, $p<0.001$). There were more complications in the LP cohort (16.7 vs. 3.3%, $p=0.086$), which included surgical site infection (6.7 vs. 0%, $p=0.153$), pneumonia (6.7 vs. 0.0%, $p=0.153$), and unplanned ICU admission (10.0 vs. 0.0%, $p=0.078$). LP and POP both resulted in similar, significant improvements in both in GCSI scores and objective gastric emptying. Limitations of the study included the retrospective design and the study was conducted at a single, tertiary-referral center that has now accumulated the largest known case series in the world for conducting POP, so its ability to be reproduced at other centers is not known. The small patient population was sufficiently powered to demonstrate significant differences in certain procedural details and functional outcomes of gastroparesis; however, it was underpowered to definitively demonstrate differences in other perioperative outcomes. Lastly, in some patients GCSI scores were not prospectively recorded, and while many patients had follow-up information at 90 days, many of

these patients did not complete GES following their procedure. The authors concluded that peroral endoscopic pyloromyotomy (POP) is safe and effective for the treatment of medical refractory gastroparesis with less perioperative morbidity compared to LP with comparative functional outcomes.

Aghaie Meybod et al. (2019) conducted a systematic review and meta-analysis (n=7 studies/196 patients) that concluded that treating refractory gastroparesis with G-POEM results in a high rate of clinical success and low rate of adverse events. The clinical success weighted pool rate (WPR) was 82%. The post procedure mean values of GCSI were reduced significantly at five days ($p<0.001$) when compared to pre-procedure GCSI. The mean values of gastric emptying were significantly decreased 2–3 months after the procedure ($p<0.05$). Author noted limitations included the small patient population of the included studies and high level of heterogeneity in the secondary outcome measures. This finding could be attributed to different inclusion criteria in the studies. The authors also noted that G-POEM is a relatively new technique and the studies that reported outcomes have short follow-up duration.

Diverticular peroral endoscopic myotomy (D-POEM)

Esophageal diverticula are rare outpouchings of the esophagus that can cause dysphagia, regurgitation, chest pain and aspiration pneumonia as they progress. Interventional treatment should be considered for symptomatic cases. Surgical resection of the diverticulum has traditionally been considered to be the only curative option. The D-POEM technique is unique in that, through the creation of submucosal tunneling, the cricopharyngeus muscle or the diverticular septum can be methodically exposed, allowing for careful complete septotomy under direct endoscopic visualization. The D-POEM technique for the treatment of esophageal diverticula has only been reported in limited case reports (Yang, et al., 2019).

Literature Review - D-POEM: Studies in the peer-reviewed literature investigating D-POEM are primarily in the form of small prospective studies with patient populations ranging from 11–25 with follow-up of 12 months. Further well-designed studies with large patient populations are needed to assess the efficacy and safety of D-POEM (Khashab, 2023; Wessels et al., 2023; Zhang, et al., 2022; Orlandini, et al., 2020; Yang, et al., 2019, Maydeo, et al., 2019).

There is insufficient evidence in the published peer-reviewed literature to support the safety and efficacy of D-POEM for the treatment of esophageal diverticula or any other indication.

Minimally Invasive Anti-Reflux Procedures

Gastroesophageal reflux disease (GERD) is defined as symptoms or mucosa damage resulting from the reflux of gastric content into the esophagus. Mucosa damage can vary from none to mild esophagitis, to more severe esophagitis, and, less commonly, Barrett's esophagus and esophageal carcinoma. The goal of therapy is to control both the symptoms and mucosal damage.

According to Richter and Vaezi, 2021, "gender is not a factor in North America and Europe, but women have a 40% higher rate of GERD symptoms compared with men in South America and the Middle East. There is no clear association between gender and peptic stricture, but men are at a greater risk of esophagitis, Barrett's esophagus, and adenocarcinoma than women. Advancing age has been inconsistently associated with an increase in GERD symptoms but is strongly associated with complications of GERD, including esophagitis, esophageal stricture, and Barrett's esophagus with cancer. In the US, there appears to be a similar prevalence of GERD symptoms among different races, but whites are at a greater risk for erosive esophagitis, Barrett's esophagus, and adenocarcinoma of the esophagus."

Treatment for GERD may include lifestyle changes (e.g., elevating the head of the bed, decreasing fat intake, quitting smoking, diet), pharmacological therapy (e.g., acid suppressants) or anti-reflux

surgery. Most GERD patients have mucosal disease and symptoms are controlled with medical therapy. Anti-reflux surgery may be an option for patients who have failed pharmacotherapy or for those who choose not to continue medication therapy for the long term. An open or laparoscopic Nissen fundoplication is considered the standard surgical therapy.

A variety of endoscopic therapies for the treatment of GERD have been developed and proposed as alternatives to pharmacological therapy or anti-reflux surgery. These techniques include the delivery of radiofrequency energy to the gastroesophageal junction, injection of bulking agents, or implantation of a bioprosthesis into the lower esophageal sphincter, implantation of titanium beads with magnetic cores and suture plication of the proximal gastric folds. These therapies are designed to alter structures at the gastroesophageal junction to prevent reflux of gastric contents (Richter and Vaezi, 2021).

Textbook report that randomized controlled trials with follow-up for at least five years with meticulous monitoring of these devices will be required. Furthermore, none of the new devices have been compared in randomized studies with the gold standard, Nissen fundoplication (Richter and Vaezi, 2021).

Radiofrequency Energy

Radiofrequency energy for the treatment of GERD requires a special single-use catheter and radiofrequency energy generator (Stretta® System, Respiratory Technology Corporation [Restech], Houston TX).

The precise mechanisms of radiofrequency (RF) energy in gastroesophageal reflux disease (GERD) are unclear, RF treatment appears to reduce postprandial transient lower esophageal sphincter relaxations and decrease compliance of the gastroesophageal junction, may decrease esophageal acid sensitivity by inducing healing of esophageal erosive disease and may improve gastroparesis (Triadafilopoulos, 2023).

U.S. Food and Drug Administration (FDA): The Stretta System is FDA approved for “general use in the electrosurgical coagulation of tissue and intended for use specifically in the treatment of GERD” (FDA, 2000a). In 2015 the FDA approved a Stretta catheter as a 510(k) Class II accessory “intended for general use in the electrosurgical coagulation of tissue and intended for use specifically in the treatment of GERD” (FDA, 2015).

Literature Review - Radiofrequency Energy: Improvements in symptoms, quality of life, reduction in proton pump inhibitor (PPI) use and decreased acid exposure following treatment with radiofrequency energy have been reported in some studies but outcomes are conflicting. Studies have been limited by small patient populations, short-term follow-ups, high dropout rates, loss of data and/or lack of randomization. In some studies, outcomes were measured solely on patient questionnaires. Adverse events including chest pain, dysphagia, and pneumonia have been reported. Larger randomized controlled trials with longer follow-up are needed to better define the risks and benefits of this procedure (Jiang, et al., 2022; He, et al., 2020; Viswanath, et al., 2019; Liang, et al., 2015; Hu, et al., 2015; Yan, et al., 2015; Noar, et al., 2014; Arts, et al., 2012)

Zerbib et al. (2020) conducted a double-blind, sham-controlled multicenter randomized controlled trial to determine the efficacy of esophageal radiofrequency in patients with PPI refractory heartburn. Sixty-two patients were randomized into two groups, the esophageal radiofrequency group (n=29) or to the sham group (n=33). Patients aged 18–78 years, with persistent moderate-to-severe heartburn at least three times per week despite continuous PPI therapy, without esophagitis > grade A were included. The primary outcome measured clinical success at week 24 which was defined as an adequate symptom relief together with a PPI intake of less than seven doses over the two preceding weeks. If clinical success was not reached, the patient was defined

as therapeutic failure. The secondary endpoints measured clinical success at week 48, number of days without heartburn and digestive symptoms over the two preceding weeks at weeks 24 and 48, PPI consumption and number of patients not taking PPIs during the last two weeks at weeks 24 and 48. The Gastrointestinal Symptoms Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) scores at weeks 24 and 48, 24-hour pH-impedance parameters associated with clinical success at week 24 and side effects of the procedure were assessed. In the intention-to-treat population, there was no significant difference in patients that achieved clinical success between the esophageal radiofrequency and sham groups, 1/29 (3.4%) and 5/33 (15.2%), respectively ($p=0.158$). At week 24, esophageal radiofrequency was proposed to the patients who failed to achieve therapeutic success in the esophageal radiofrequency group ($n=24$) and a first procedure in the sham group ($n=19$). There was no significant difference in success rates in patients who received a second procedure compared to patients in whom only one procedure was performed ($p=0.285$). Among the 49 patients who completed the week 48 visit, 16 were considered to have a therapeutic success, without significant difference between patients who received one and two ($p=0.611$). Among the five patients who received no procedure, three were lost to follow-up at 48 weeks, one had a therapeutic success and one had a therapeutic failure. No patient had esophagitis at follow-up endoscopy. There was no significant difference between esophageal radiofrequency and sham groups at weeks 24 and 48 regarding days without heartburn, days without any other digestive symptoms, PPIs and antacids intake, and the number of patients not taking PPIs. No pH-impedance parameter was identified as a predictive factor of therapeutic success. Author noted limitations included: difficulty recruiting patients (70 were recruited over a five-year period), small patient population, and pH-impedance monitoring off therapy was not performed. Additional limitations include population only included women and the results may not be applicable to other races or ethnic groups. The authors concluded that the study did not demonstrate any efficacy of esophageal radiofrequency for the treatment of PPI-refractory heartburn regarding symptom relief and PPIs consumption. The technique cannot be recommended for the treatment of refractory heartburn.

Fass et al. (2017) conducted a systematic review and meta-analysis to determine the efficacy of Stretta for the treatment of GERD. Inclusion criteria included: studies with at least three months follow-up; study design was a controlled trial or cohort study; and study had sufficient data for at least one of the six selected outcome variables. Primary outcomes were the relief of associated GERD symptoms. Twenty-eight studies (four randomized controlled trials, 23 cohort studies, and one registry) ($n=2468$) met inclusion criteria and were included in meta-analysis. Mean follow-up time ranged from 3–120 months (mean 25.4 months). Pooled results (two studies) showed that Stretta significantly improved health-related quality of life scores ($p<0.001$) and pooled heartburn standardized score ($p<0.001$). Stretta significantly reduced the incidence of erosive esophagitis by 24% ($p<0.001$) and esophageal acid exposure ($p<0.001$). Lower esophageal sphincter (LES) basal pressure was increased following Stretta by a mean of 1.73 mmHg, not significant. A total of 49% of patients required continuation of PPI following Stretta vs. 51% who did not ($p<0.001$). Adverse events for Stretta included small erosions and mucosal lacerations. Subcutaneous emphysema was the most frequent adverse event for LF (3%). Limitations of the studies included: heterogeneity of the studies with respect to inclusion criteria, previous surgeries, protocols for the use of antacids, monitoring of PPI use and follow-up time. Heterogeneity was highly significant ($p<0.001$) in all Stretta subgroups. Additional limitations of the studies include the lack of a comparator; small heterogeneous patient populations; and short-term follow-ups.

Lipka et al. (2015) conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to assess the safety and efficacy of Stretta for the treatment of GERD. Four trials ($n=165$) met inclusion criteria. Any RCT evaluating the efficacy of Stretta compared with sham or medical treatment for GERD patients requiring PPIs was eligible for inclusion. GERD was established by the presence of erosive esophagitis on endoscopy, or abnormal ambulatory esophageal pH monitoring (defined by DeMeester score > 14.7 or percentage total time pH < 4 of

> 4.0%). Patients also were defined as having GERD by scores on health-related quality of life (HRQOL) surveys or by symptom scores, were previously on PPIs, and treated with Stretta vs. either sham or PPI therapy. Three trials compared Stretta vs sham, and one trial compared Stretta vs. PPI therapy. The primary outcomes were physiological parameters, including normalization of the percentage of a 24-hour period spent at a pH < 4 and augmentation of the lower esophageal sphincter pressure (LESP). The overall quality of evidence was "very low". The pooled results showed no difference between Stretta and sham or management with PPI in patients with GERD for the outcomes of mean percent of time the pH was less than 4 over a 24-hour time course, LESP, ability to stop PPIs, or HRQOL.

Yan et al. (2015) conducted a non-randomized comparative study to compare outcomes of patients treated with Stretta (n=47) or laparoscopic toupet fundoplication (LTF) (n=51) for the treatment of GERD-related extra-esophageal symptoms. The patients had either failed to respond to medical treatment or opted for surgery despite effective medical management. Other inclusion criteria were lower than normal lower esophageal sphincter (LES) pressure detected by esophageal manometry; endoscopically confirmed Los Angeles grade A or B esophagitis; non-hiatal hernia or small (< 2 cm) hiatal hernia; and age > 18 years. The primary outcome measures were frequency and severity of the extra-esophageal GERD symptoms, including cough, sputum, wheezing, and globus hystericus. Other outcome measures included: medication independence, satisfaction and reoperation complications. At the three-year follow-up (n=90), the total of the frequency and severity scores for every symptom significantly improved within both groups from baseline (p<0.05) with no significant differences between the groups (p>0.05). There were no significant differences in symptom scores of cough, sputum, and wheezing between the two groups (p>0.05) and PPI independence following surgery (p=0.835). The score for globus hystericus was significantly improved in the Stretta group vs. the LTF group (p<0.05). Patients in the LTF group were more satisfied with their quality of life than those in the Stretta procedure group (p<0.05). In the Stretta group, one patient underwent re-operation during the first postoperative year, and six patients underwent re-operation within three postoperative years. Reported complications included: fever, pharyngeal pain, retrosternal discomfort, diarrhea, abdominal distention, and dysphagia. Most complications resolved without intervention within two weeks. Author noted limitations of the study included: small, patient population; pH and motility outcomes were not reported; and changes in respiratory drug use were not examined. Other limitations are the lack of randomization and criteria for which subjects received Stretta vs. LTF.

In an open-label, prospective trial (n=149), Noar et al. (2014) evaluated the 10-year safety, efficacy, and durability of response to radiofrequency treatment (Stretta) of the lower esophageal sphincter. The primary outcome measure was normalization of GERD-health-related quality of life (GERD-HRQL) in 70% or greater of patients at 10 years. Secondary outcomes were 50% reduction or elimination of proton pump inhibitors (PPIs) and 60% or greater improvement in satisfaction at 10 years. Successful treatment was defined as achievement of secondary outcomes in a minimum of 50% of patients. Subjects had daily recurring symptoms of heartburn and regurgitation despite twice-daily PPI use. Exclusion criteria included: stenosis, stricture or ulceration of the pylorus, pregnancy, poor surgical risk, achalasia, previous non-Nissen fundoplication (NF) esophageal surgery, scleroderma-type collagen vascular disease, or severe uncontrolled medical illness. A total of 72% of patients achieved the primary outcome, 64% of patients experienced a 50% or greater reduction in PPI use, and 54% of patients reported a 60% or greater increase in satisfaction. Pre-existing Barrett's metaplasia regressed in 85% of biopsied patients (28/33) and 28 had no further dysplasia. Due to dissatisfaction with first procedure results, 11 patients underwent a second Stretta procedure and one underwent a Nissen fundoplication (NF). Reported adverse events included two patients who had self-limited, minor gastric bleeding. Procedure-related side effects included: short-term chest pain, dyspepsia, increased flatulence and abdominal pain. Limitations of the study included: lack of a comparator; no long-term pH and motility data; number of patients lost to follow-up (n=68) from original study (n=217); missing

data from the 149 subjects (50 patients did not complete 10-year follow-up questionnaires; 68 patients had not reached ten-year time point); and not all patients had undergone final endoscopic screening.

Perry et al. (2012) conducted a systematic review and meta-analysis of randomized controlled trials and cohort studies to assess the impact of endoscopic application of radiofrequency energy to the lower esophageal sphincter for the treatment of GERD. The studies included in this meta-analysis were two randomized sham-controlled trials and 18 cohort series, 1441 patients, with a mean follow-up of 15 months. Outcomes analyzed included GERD symptom assessment, quality of life, esophageal pH, and esophageal manometry. There were significant improvements reported in heartburn scores (n=525) ($p=0.001$), and quality of life as measured by GERD-health-related quality-of-life scale ($p=0.001$) and quality of life in reflux and dyspepsia scores (n=433) ($p=0.001$). Esophageal acid exposure decreased from a preprocedure Johnson-DeMeester score of 44.4 to 28.5 (n=267) ($p=0.007$). The authors reported that the meta-analysis is limited by differences in methodology and definition of criteria for some variables between studies, and absence of blindness in most of the included studies. Additionally, the heterogeneity of the study population across these reports may also influence the interpretation of the pooled results. The author's conclusion suggested that radiofrequency ablation produces significant improvement in GERD symptoms, patient satisfaction, and QOL at short and intermediate term follow-up. However, the definition of the appropriate patient populations for Stretta therapy remains controversial. Larger and longer-term studies are required to establish the durability of the treatment effect, and to identify the patient populations that gain the greatest benefit from this treatment.

Arts et al. (2012) conducted a double-blind randomized cross-over study of Stretta and sham treatment. Patients underwent two upper gastrointestinal endoscopies with three months interval, during which active or sham Stretta treatment was performed in a randomized double-blind manner. In all, 22 GERD patients participated in the study; 11 in each group. Barostat distensibility test of the gastro-esophageal junction (GEJ) before and after administration of sildenafil was the main outcome measure. Initial sham treatment did not affect any of the parameters studied. Three months after initial Stretta procedure, no changes were observed in esophageal acid exposure and lower esophageal sphincter (LES) pressure. In contrast, symptom score was significantly improved and gastro-esophageal junction (GEJ) compliance was significantly decreased. Administration of sildenafil, an esophageal smooth muscle relaxant, normalized GEJ compliance again to pre-Stretta level, arguing against GEJ fibrosis as the underlying mechanism. The authors reported that Stretta improved GERD symptoms and decreased GEJ compliance. According to the authors, the limitation of this study was reflux evaluation did not include impedance monitoring. The study was also limited by a small sample size, short term follow-up and lack of comparison to other surgical alternatives.

Aziz et al. (2010) conducted a 12-month randomized, double-blind, sham-controlled trial to assess the Stretta procedure. Thirty-six patients with antisecretory medication-dependent GERD for more than six months were randomized to receive a single-session radiofrequency (RF) procedure, a double-session RF procedure for patients who had < 75% improvement of GERD-HRQL at four months, or a sham procedure. Each patient in the active treatment groups received 56 RF lesions per session. With the double-session group, the authors examined whether 112 lesions created in two sessions several months apart were safer than 112 lesions created during a single session, which was the initial "dose" applied during development of the procedure and resulted in esophageal perforation in a few cases. Ten of 12 patients in the double-session group (83%) underwent both sessions. At 12 months, two of 12 patients (17%) in the single-session group, six of 12 patients (50%) in the double-session group, and zero of 12 patients in the sham group had discontinued antisecretory medication therapy. Within group comparisons showed statistically significant improvements in GERD-HRQL in all three treatment groups: In the single-session RF

group, GERD-HRQL scores improved from a mean of 30 at baseline off meds to 14 post-treatment; in the double-session RF group, GERD-HRQL scores improved from 31 to 11; and in the sham group, GERD-HRQL scores improved from 30 to 25. Post-treatment values in the active treatment groups were significantly greater than the sham group ($p < 0.001$) but did not differ from each other ($p > 0.05$). Lower esophageal sphincter pressure increased in the active treatment groups to a statistically significant degree (from 12 mmHg to 16 mmHg in the single-session group, and from 12 mmHg to 20 mmHg in the double-session group; $p < 0.01$ for both groups) but not in the sham group (14 mmHg at baseline to 16 mmHg post-treatment, $p > 0.05$). The total time esophageal pH was less than 4.2 in a 24-hour period decreased to a statistically significant degree in the active treatment groups (from 9.4 minutes to 6.7 minutes in the single-session group ($p < 0.01$), and from 8.8 minutes to 5.2 minutes in the double-session group ($p < 0.01$) but not in the sham group (9.9 minutes at baseline to 8.2 minutes post-treatment [$p > 0.05$]). The clinical relevance of these changes is uncertain. Transient post-procedure adverse events (retrosteral discomfort requiring oral analgesics, mild fever, nausea/vomiting, and dysphagia) were experienced by more patients in the active treatment groups than in the sham groups. Serious adverse events occurred in one patient in the single-session group who developed pneumonia and bilateral pleural. Two patients who received double sessions of RF treatment developed prolonged gastroparesis. During 12 months of follow-up evaluation, one of these two patients showed mild improvement, whereas the other showed no improvement despite high doses of prokinetic medication. The authors reported that "worsening gastroparesis may be due to vagal injury during Stretta treatment, especially with a greater number of RF lesions."

Endoluminal Gastroplasty/Gastroplication

Basic techniques were designed to place sutures or staples at the cardia, including submucosal stitching devices and deep transmural plicating devices. The technique is proposed to create pleats or plications of tissue just beneath the gastroesophageal junction. Sedation and procedure time vary. An examples of suturing/plication devices included the EndoCinch™ or Bard Endoscopic Suturing System (BESS) (Bard Endoscopic Technologies, Billerica, MA); and the Syntheon ARD Plicator (Syntheon, Miami, FL) (Trad, 2016).

Endoscopic full-thickness plication was initially performed using the Plicator device (Ethicon Endo-Surgery) which was withdrawn from the market. A new device, called GERDx, uses the same plicator technology and is meant for single use. The device uses hydraulic elements for control and requires a slim gastroscopy that works as a light source (Nabi and Reddy, 2019).

U.S. Food and Drug Administration (FDA): The Medigus Ultrasonic Surgical Endostapler, or MUSE™ system, formerly the SRS Endoscopic Stapling System, is FDA indicated "for endoscopic placement of surgical staples in the soft tissue of the esophagus and stomach in order to create anterior partial fundoplication for treatment of symptomatic chronic Gastro Esophageal Reflux Disease (GERD) in patients who require and respond to pharmacological therapy" (FDA, 2014, 2015a, 2015b).

The GERDx™ has not received FDA approval.

The EndoGastric Solutions EsophyX2™ System with SerosaFuse Fastener (K092400, FDA, 2009b) was approved as substantially equivalent to the EsophyX System (K071651, FDA, 2007) and "is indicated for use in transoral tissue approximation, full thickness plication and ligation in the GI tract and is indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy" It is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia < 2cm in size in patients with symptomatic chronic gastroesophageal reflux disease".

In 2014 the EsophyX®2 HD device with SerosaFuse Fasteners and Accessories (K142113) was approved as substantially equivalent to the previously cleared EsophyX2 System (K092400) without a change to the indication.

The EndoGastric Solutions EsophyX Device models (EsophyX2 HD and EsophyX Z) were 510(k) approved (K171307 & K172811) in 2017 for the same indications as the predicate device, with one additional statement "patients with hiatal hernias larger than 2 cm may be included, when a laparoscopic hiatal hernia repair reduces the hernia to 2cm or less" (FDA, 2017a, 2017b).

The EndoCinch™ or Bard Endoscopic Suturing System (FDA, 2000b), NDO Surgical Endoscopic Plication System (FDA, 2003, 2007, 2008), SRS™ Endoscopic Stapling System (FDA, 2012) and StomaphyX™ (FDA, 2007, 2008, 2009) have been approved through the 510(k) premarket notification process. The Syntheon ARD Plicator is not an FDA-approved device.

The Bard® Endoscopic Suturing System FDA indications for use state, "used for endoscopic placement of suture(s) in the soft tissue of the esophagus and stomach and for the approximation of tissue for the treatment of symptomatic GERD" (FDA, 2000b).

The StomaphyX (K062875) is FDA "indicated for use in endoluminal transoral tissue approximation and ligation in the GI tract" (FDA, 2007).

The StomaphyX system with SerosaFuse Fastener (K073644 & K091832) are FDA "intended for tissue approximation, ligation and full-thickness plication in the GI tract" (FDA, 2008, 2009a).

The NDO EP NDO Surgical Endoscopic Plication System FDA indications is for "the treatment of the symptoms of chronic GERD in patients who require and respond to pharmacological therapy" (FDA, 2003).

Literature Review - Endoluminal Gastroplasty/Gastroplication - GERDx™: Kalapala et al. (2021) conducted a single-center, sham randomized controlled trial at the Asian Institute of Gastroenterology (India) to determine the efficacy and safety of an endoscopic full-thickness fundoplication (EFTP) device (GERD-X) in patients with PPI-dependent GERD. The study included patients aged 18–60 on PPI therapy for the last six months with the following: a gastroesophageal flap valve grade I–III (Hill's classification); pathological esophageal acid exposure, abnormal DeMeester score ≥ 14.7 or total reflux episodes > 73 ; and lower esophageal sphincter pressure (LESP) between 5–15 mm Hg. Seventy patients were randomized to the GERD-X treatment group (n=35) or the sham group (n=35). All patients underwent the EFTP or sham under general anesthesia and endotracheal intubation after overnight fasting. The median (IQR) age was 36 (29–42) years, with 71.4% males. The primary measured outcome was a $\geq 50\%$ improvement in the health-related quality of life (GERD-HRQL) score at three months. Secondary outcome measurements included improvement in GERD-HRQL, reflux symptom scores, PPI usage, esophageal acid exposure and reflux episodes and endoscopic findings at three, six and 12 months. In patients who resumed taking PPIs after the assigned intervention, these assessments were made after stopping PPI therapy for at least three days. A statistically significant improvement in the GERD-HRQL total score at three months post intervention was achieved by the treatment group ($p < 0.001$), thus meeting the primary endpoint of the study. There was not a significant difference noted between males and females. The GERD-HRQL total score, the median percentage improvement in the heartburn symptom score and the regurgitation symptom score were significantly higher in the EFTP group compared to the sham group at three, six and 12 months (all $p < 0.001$). At 12 months post intervention, a significantly higher proportion of patients in the EFTP group compared to the sham group, had elimination of heartburn and regurgitation ($p < 0.001$ and $p < 0.001$, respectively). The EGD evaluation conducted on the EFTP group at three, six and 12 months showed Hill's grade 1 in 100%, 91.5% and 77.8%, respectively. The sham

group endoscopic Hill's grade did not change from baseline. Mucosal wrap and suture were intact in all patients at 12 months. There was no symptomatic dysphagia nor endoscopic evidence of luminal narrowing at the GE junction. At 12 months, endoscopy showed no esophagitis in the EFTP group (n=18) and 29.4% (5/17) of the sham group had grade A esophagitis. No major procedure-related adverse events were encountered in either group. Author noted limitations included a small patient population, study was conducted at a single center, initial screening and enrollment of PPI-dependent patients were based on historical details and PPI dependency was not confirmed objectively. Lastly, the reflux was not assessed objectively at the end of 12-month follow-up in all patients. An additional limitation is that the population only included patients at the Asian Institute of Gastroenterology (India) and the results may not be applicable to other races or ethnic groups. The authors concluded that this endoluminal procedure is a promising alternative option to surgery. However, large, prospective trials with long-term follow-up are required to conclude the benefits of this procedure after one year. No health disparities were identified by the investigators.

Weitzendorfer et al. (2018) conducted a prospective one-arm trial that assessed the clinical safety and efficiency of the GERDx™ device by evaluating clinical parameters, reflux symptom scores, and quality of life (QoL). The study included patients (n=40) with at least one typical reflux symptom despite treatment with a PPI for > 6 months, pathologic esophageal acid exposure, hiatal hernia of size < 2 cm, and endoscopic Hill grade II–III. Outcomes measured Evaluation of Gastrointestinal Quality of Life Index (GIQLI), symptom scores, esophageal manometry, and impedance-pH-monitoring which were performed at baseline and at three months after surgery. The authors noted no intraoperative complications, however four out of forty patients experienced postoperative complications requiring intervention. Seven of forty patients were subjected to laparoscopic fundoplication three months after endoscopic plication due to persistent symptoms and were lost to further follow-up. Thirty patients were available at the three-month follow-up. There were significant improvements in the GIQLI score, general reflux-specific score, and DeMeester score ($p < 0.001$). There was no significant change in manometric data after intervention. Three of thirty patients continued daily antireflux medication. The authors concluded that in well selected patients endoscopic full-thickness plication using the GERDx™ device improves the distal acid exposure of the esophagus, typical reflux-related symptoms and QoL. However, randomized controlled trials with long term follow-up are necessary to compare the outcome of patients treated with PPIs and patients undergoing endoscopic plication with the GERDx™ device.

There is insufficient evidence in the published peer-reviewed scientific literature to support the safety and efficacy of GERDx™ device for the treatment of GERD.

Literature Review - Endoluminal Gastropasty/Gastroplication - EndoCinch Suturing

System: Comparative studies with EndoCinch have failed to show an improvement in acid exposure time when compared to sham. The studies report that there is a high rate of loss of intact sutures at follow-up. Large, well-designed, controlled trials showing long-term safety and efficacy outcomes are lacking.

In a randomized sham-controlled trial, Schwartz et al. (2007), reported on endoscopic gastroplication by the EndoCinch suturing system. A total of sixty patients with GERD were randomly assigned to three endoscopic gastroplications (n=20), a sham procedure (n=20) or observation (n=20). The primary outcome measures were PPI use and GERD symptoms. The secondary measure was 24-hour esophageal acid exposure. Follow-up assessments were performed at three, six, and 12 months. At three months, the percentage of patients who had reduced drug use by $\geq 50\%$ was greater in the active treatment group (65%) than in the sham (25%) or observation groups (0%) ($p < 0.02$). GERD symptoms improved more in the active group than in the sham group ($p < 0.01$). Esophageal acid exposure was modestly decreased after active treatment ($p < 0.02$) but was not significantly greater than after the sham procedure ($p = 0.61$). The active treatment effects on PPI use and symptoms persisted after six and 12 months of open-label

follow-up (n=41), but 29% of patients were re-treated in this period. The authors stated, "Widespread use of the endoscopic suturing device should probably be avoided until the technique is improved and efficacy on objective end points has been proved in a sham-controlled fashion".

Montgomery et al. (2006) reported data from 46 patients enrolled in a single-center, randomized, sham-controlled trial of EndoCinch plications. There was no difference in the use of PPIs between the sham and the EndoCinch groups at six weeks or 12 months, whereas at three months, there was a significant reduction in the use of PPIs in the treatment group compared to controls ($p < 0.05$). Compared to baseline, there was a significant improvement in QOL as assessed by the gastrointestinal symptom rating scale (GSRS) at six weeks, as well as at three- and 12-months post-procedure in both groups. At three months (but not at six weeks and 12 months), there was a significant difference in GSRS scores between the groups, favoring the treatment group versus the control group. Similarly, to the sham group, the EndoCinch treatment group had no significant changes in esophageal acid exposure, as indicated by pH monitoring at three and 12 months, in any of the groups. Also noted was a marked loss of sutures, with 67% remaining at 12 months.

Earlier studies have primarily been in the form of case series with small patient populations and short-term follow-ups with over 50% treatment failures or short-term improvement in symptoms were not maintained (Schiefke, et al., 2005; Mahmood, et al., 2003).

Literature Review - Endoluminal Gastroplasty/Gastroplication - Endoscopic Plication™

System: Studies in the peer-reviewed literature investigating endoscopic plication systems are primarily in the form of case series. Large, well-designed, controlled trials showing long-term safety and efficacy are lacking. The website www.clinicaltrials.gov states that several studies with the NDO Plicator have been terminated, since the sponsoring company (NDO Surgical, Inc.) has ceased business operations.

In a multicenter prospective, open-label, postmarket registry study, Birk et al. (2009) assessed full-thickness fundoplication using the Plicator for the treatment of GERD. The study included 131 patients variably responsive to PPI therapy. At 12 months, 50 patients (38%) were lost to follow-up or had not yet reached their 12-month follow-up visit. Sixty-six percent of the remaining 81 patients demonstrated a 50% reduction in their GERD-Health Related Quality of Life (GERD HRQoL) score compared to their pre-fundoplication (off meds) score. No serious adverse events were reported. The lack of a control or comparison group limits the use of these findings.

The safety and efficacy of the Plicator procedure was studied in a prospective multicenter trial and evaluated in four subsequent reports with follow-up of 6, 12, 36 and 60 months, respectively (Pleskow, et al., 2004; Pleskow, et al., 2005; Pleskow, et al., 2007; Pleskow, et al., 2008). Sixty-four patients initially underwent plication to assess the safety and efficacy of endoscopic full-thickness plication. At six months after plication, PPI therapy had been eliminated in 74% of previously medication-dependent patients. Twenty-nine patients completed the 12-month and 36-month follow-up. All procedure-related adverse events occurred acutely, and no new events were observed during extended follow-up. At 36-months post-procedure, 57% of baseline PPI-dependent patients remained off daily PPI therapy. Treatment effect remained stable from 12–36 months, with 21/29 patients off daily PPI at 12 months compared to 17/29 patients at 36 months. Median GERD-Health Related Quality of Life (HRQL) scores remained significantly improved at 36 months versus baseline off meds scores (8 versus 19, $p < 0.001$). In addition, the proportion of patients achieving $\geq 50\%$ improvement in GERD-HRQL score was consistent from 12 months (59%) to 36 months (55%). No long-term procedural adverse effects were reported. The results of the prospective, uncontrolled studies suggested that endoscopic full-thickness plication was effective, reducing symptoms and medication use associated with GERD. Treatment effect was stable for at least five years postprocedure. The authors considered the procedure safe, despite a few complications (gastric perforation, dyspnea, and mucosal abrasion in the fundus). The studies

were limited by small sample size and lack of a control group. In addition, due to termination of the initial 64-subject study and the challenge of retaining subject contact during the extended time period since initial Plicator treatment, only a subset of subjects who had originally undergone the Plicator procedure were enrolled in this 60-month follow-up study, therefore, the potential for a referral bias exists. Another limitation of this study design is its exclusion criteria. Potential GERD subjects excluded from this study are those frequently encountered in a practice setting. Their characteristics may include presenting with a large hiatal hernia, advanced erosive esophagitis, and/or nonresponse to antisecretory therapy. A final limitation of this study is that evidence of long-term Plicator integrity was not assessed.

Studies of the Plicator procedure to date have been limited to placement of a single transmural suture to create the endoscopic gastroplication. Further studies are needed to evaluate the safety and efficacy of this device.

Transoral Incisionless Fundoplication

Transoral Incisionless Fundoplication (TIF) can be performed by either EsophyX® device or the Medigus Ultrasonic Surgical Endostapler (MUSE™). The EsophyX® device (EndoGastric Solutions, Inc., Redmond, WA) creates a transoral incisionless fundoplication® (TIF). The system deploys multiple full thickness serosa-to-serosa fasteners into the gastric wall to form an interrupted suture line at the base of the gastroesophageal junction, thus recreating the gastroesophageal valve (GEV) mechanically. This is sometimes referred to as the endoluminal fundoplication (ELF) technique. The predicate device to the EsophyX system is the StomaphyX™ (EndoGastric Solutions, Inc., Redmond, WA). There are two models of EsophyX devices – EsophyX2 HD and ExophyX Z. Earlier studies used the TIF 1.0 protocol which involved gastro-gastric plications below the gastroesophageal junction and 220 degrees of circumference of the re-established valve compared to the current TIF 2.0 protocol which involves esophago-gastric plications above the Z-line and 240-degree circumference.

The MUSE™ (Medigus, Omer, Israel) creates a 180° fundoplication by stapling the gastric fundus to the esophagus below the diaphragm under ultrasound guidance.

Literature Review - EsophyX system - Transoral Incisionless Fundoplication: Evidence in the published, peer-reviewed scientific literature on the efficacy of transoral incisionless fundoplication (TIF) using the EsophyX system largely consists of case series with small patient populations (n=10–151). While these case series report improvements in outcomes following treatment with EsophyX, the lack of control group precludes the ability to generalize findings and draw strong conclusions regarding the impact on health outcomes (Testoni, et al., 2019; Bell, et al., 2014; Wilson, et al., 2014; Muls, et al., 2013; Trad, et al., 2012; Narsule, et al., 2012; Testoni, et al., 2012; Frazzoni, et al., 2011; Bell, et al., 2011). Randomized controlled trials are needed to determine whether EsophyX improves outcomes compared to the standard of care which is open or laparoscopic Nissen fundoplication.

Hajjar et al. (2023) conducted a systematic review and meta-analysis that evaluated patient selection and outcomes for patients undergoing GERD treatment with endoscopic plication (transoral incisionless fundoplication) compared to laparoscopic fundoplication. Studies that compared endoscopic plication to laparoscopic fundoplication with > 5 patients, > age 18 years were included. Primary outcome measured PPI cessation and secondary outcomes measured the complications, procedure duration, length of stay, change in lower esophageal sphincter (LES) tone, and DeMeester score. Five studies (one-single-center randomized controlled open trial, two non-randomized prospective trials, one non-randomized case series, and one case control study) met the established inclusion criteria with 105 (46.1%) patients receiving endoscopic plication (ENDO) and 123 (53.9%) undergoing laparoscopic fundoplication (LAP). EsophyX Endoscopic fundoplication was used in two studies contributing 30 (28.6%) to the total endoscopic plication

cohort. Other endoscopic interventions included the endoscopic SRS Stapling System™, Ethicon's The Plicator and the Endocinch, comprising 11 (10.5%), 37 (35.2%), 27 (25.7%), and 30 (28.6%) patients, respectively, to the endoscopic plication cohort. Two types of fundoplication were employed, with three studies including both Nissen and Toupet fundoplication, and two limited to Nissen. Nissen was the more common operation and was used in 78 (63.4%) patients undergoing fundoplication, compared to Toupet in 45 (36.6%). Overall, 69.4% of patients undergoing endoscopic plication discontinued PPI following their procedure compared to 89.2% of those undergoing fundoplication. Meta-analysis of the primary outcome demonstrated that those undergoing endoscopic plication had reduced odds of PPI discontinuation compared to laparoscopic fundoplication. The procedure duration, complication rates and the odds of dysphagia did not differ significantly based on the results of the meta-analysis. Changes in DeMeester score and LES pressures were compared between groups, with laparoscopic fundoplication showing superior results with respect to these objective measures. The authors concluded that laparoscopic fundoplication is a superior treatment modality in the cessation of PPI use compared to endoscopic plication. Despite similar patient selection, endoscopic and laparoscopic procedures had similar post-procedural risk. Ongoing optimization of plication techniques and devices are needed prior to widespread implementation in clinical practice. No health disparities were identified by the investigators.

Ramai et al. (2022) assessed the complications associated with TIF using post-marketing surveillance data from the FDA Manufacturer and User Facility Device Experience (MAUDE) database from Jan 2011 through Jan 2021. There were approximately 95 events reported to the FDA with approximately 131 patient complications identified. The number of adverse events declined from 2011 to 2016 but increased from 2016 to 2020. The study reported that the most common adverse event was perforation (19.8%), followed by laceration (17.6%), bleeding (9.2%), and pleural effusion (9.2%). The complications were treated using endoscopic clips (12.3%), chest tube or drain insertion (12.3%), use of endoscopic retriever device (11.1%), esophageal stent (8.6%) and emergent or open surgery (11.1%). The authors concluded that adverse events related to the TIF procedure range from mild to severe. Additional research is needed to develop approaches aimed at reducing patient risks.

Bell et al. (2021) conducted a single institution prospective registry that assessed the long-term results of transoral incisionless fundoplication (TIF 2). Included patients were age 18 years and older with objective documentation of GERD. Patients (n=151) underwent TIF 2 with the EsophyX2 without hiatal hernia repair. Outcomes measured: GERD-HRQL and regurgitation scores, use of PPI, perioperative complications, and need for re-intervention. At a median of 4.92 years (0.7–9.7 years), 131 of the 151 patients (86%) were available for follow-up. Five years or greater follow-up was obtained on 51% (62) of the 120 total patients. The median GERD-HRQL scores significantly decreased from 21 off PPI and 14 on PPI at baseline to four at 4.92 years and five at 5–9 years post-TIF. The authors reported that (> 50%) reductions in GERD-HRQL scores were seen in 64% at 4.92 years and 68% of patients followed for ≥ 5 years. Median regurgitation decreased from 15 off PPI and 11 on PPI at baseline to 0 at 4.92 years and one at 5–9 years post-TIF. Dysphagia and abdominal bloating/distention assessed by GERD-HRQL significantly decreased from baseline to a median of 0 and one respectively at 4.92 years' follow-up ($p<0.0001$). Adverse events reported that two patients experienced localized perforation and recovered uneventfully after laparoscopic surgery. Thirty-three patients (22%) required revision to laparoscopic fundoplication. Long-term quality of life outcomes was equivalent when compared to those patients who did not undergo reoperation. Author noted limitations included: incomplete follow-up on all patients (however a mixed effect model was used to analyze the data to address the potential selective dropout) and the lack of long-term objective outcome data, specifically regarding esophageal acid exposure. Additional limitations include the small patient population and lack of a comparator. No health disparities were identified by the investigators.

Testoni et al. (2019) conducted a prospective observational study that assessed the long-term clinical efficacy of transoral incisionless fundoplication (TIF 2) with EsophyX for gastroesophageal reflux disease. Patients (n=50) received TIF 2 with EsophyX with follow-ups occurring at two, three, five, seven and 10 years. There were 35/50 males and 15/50 females enrolled in the study. Included patients had pathological gastroesophageal reflux (GER) with a positive correlation between symptoms and GER, documented by 24-hour pH-impedance. Primary outcomes measured clinical efficacy using Health-Related Quality-of-Life (GERD-HRQL), Gastroesophageal Reflux Disease Quality-of-Life (GERD-QUAL), heartburn and regurgitation scores and daily PPI consumption. Outcomes were measured using telephone interview or office consultation. The TIF 2.0 was successful in 49/50 patients. One patient had a pneumothorax and the other case was due to a device malfunction. The latter procedure was repeated with success for a total of 51 TIF procedures were performed in 50 patients. Forty-nine patients were available for follow-up at two and three years, 41 after five years, 30 after seven years and 14 after 10 years. Seven patients were unresponsive to endoscopic fundoplication and underwent surgical fundoplication. The mean scores at two years were significantly lower than before the procedure and did not change substantially during the follow-up. Patients who had stopped or halved antisecretive therapy at two, three, five, seven and 10 years after the procedure were 86.7%, 84.4%, 73.5%, 83.3%, and 91.7%, respectively. Pneumothorax occurred in two of the 51 procedures (3.9%). Author noted limitations included the small patient population clinically assessed at seven and 10 years and there were not any endoscopic and functional evaluations performed. An additional limitation included the lack of a comparator and the disproportionate number of females included in the study. The results may not be applicable to other sexes, races or ethnic groups.

Janu et al. (2019) examined the safety and efficacy of laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication with the EsophyX device. Data was prospectively collected from patients (n=99) who underwent hiatal hernia repair immediately followed by the TIF procedure (HH + -TIF) at two community hospital settings in Indiana and Wisconsin. Patients aged 18 to 75 years with moderate to severe typical or atypical GERD symptoms for > 1 year, a hiatal hernia between 2 and 5 cm on endoscopy and ongoing daily PPI use for more than six months with either complete or partial symptom control were included in the study. Three validated questionnaires, GERD Health-Related Quality of Life Questionnaire (GERD-HRQL), Gastroesophageal Reflux Symptom Score (GERSS) and laryngopharyngeal reflux (LPR) questionnaire Reflux Symptom Index (RSI) were administered before the procedure and mailed at six- and 12-months post-procedure. The questionnaire response rate was 73% at 6 months, 67% at 12 months, and 48%. The average age of subjects was approximately 53 years and 55% of subjects were female. All measures were statistically improved ($p < 0.05$) at 12 months. There were no adverse effects reported. Author noted limitations included short-term follow-up, objective evidence of GERD preoperatively and lack of objective outcomes data. Objective longer-term studies with post-procedure testing with either pH testing, endoscopy, or esophagram is needed. No health disparities were identified by the investigators.

Richter et al. (2018) conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to compare the relative efficacies of transoral incisionless fundoplication (TIF) and laparoscopic Nissen fundoplication (LNF) to sham or PPI in patients with GERD. Seven studies (n=1128) met inclusion criteria. RCTs were included if GERD was established by the presence of erosive esophagitis on endoscopy and/or abnormal ambulatory esophageal pH monitoring (Demeester score > 14.7 and/or percentage total time pH < 4 of $\geq 4.0\%$) and quality of life surveys or by symptom scores of patients who were previously on PPIs. The primary outcome measures were decrease in proportion of a 24-hour time period spent at pH < 4 and augmentation of the lower esophageal sphincter pressure (LESP). Secondary outcomes included decreased symptom scores reported as health-related quality of life (HRQOL) and serious adverse events. Two RCTs compared TIF to proton pump inhibitors (PPI) (n=123), two compared TIF to sham (n=173) and three compared LNF to PPIs (n=875). Study durations were 6-12 months in the TIF

studies and 1–5 years in the LNF vs PPI studies. The probability of best treatment was ranked using the Surface Under the Cumulative Ranking (SUCRA), a parameter to rank treatments based on their probability of ranking first, second, third, etc. The SUCRA ranges between 0% (the treatment always ranks last) to 100% (the treatment always ranks first). Analysis revealed the following:

- LNF was statistically superior to TIF in percent time pH was < 4 and had the highest probability of being the best treatment for improvement in percent time spent in pH < 4 (SUCRA, 0.99), PPI (SUCRA, 0.64), TIF (SUCRA, 0.32), and sham (SUCRA, 0.05).
- LNF was superior to TIF in increasing esophageal sphincter pressure (LESP), but the difference was not significant. LNF had the highest probability of being the best treatment for improvement in LESP (SUCRA, 0.78), followed by TIF (SUCRA, 0.72) and PPI (SUCRA, 0.01).
- TIF was superior to LNF in improved health-related quality of life (HRQOL), but the difference was not significant. TIF had the highest probability of being the best treatment for improvement in HRQOL (SUCRA, 0.96), followed by LNF (SUCRA, 0.66), sham (SUCRA, 0.35), and PPI (SUCRA, 0.042).
- LNF was superior to TIF re incidence of persistent esophagitis, but the difference was not significant. PPI had the lowest probability of being the treatment associated with persistent esophagitis (SUCRA, 0.19), followed by LNF (SUCRA, 0.38), TIF (SUCRA, 0.68), and sham.

Data on harm was not consistently reported and meta-analysis could not be done. The results showed that LNF fundoplication had the highest ability to improve physiologic parameters associated with GERD, including LES pressure and decreasing the percentage of time that the pH < 4. PPIs were superior for reducing esophagitis, possibly due to dose escalation if symptoms persisted. TIF had the highest probability of symptom improvement based on HRQOL likely related to shorter follow-up time compared to LNF or PPIs. Author-noted limitations of this analysis included: lack of data on individual patients, difference in follow-up time and number of subjects (n=875 LNF; n=293, TIF); and moderate to low quality of the included studies. The authors concluded that endoscopic therapy cannot be recommended as an alternative to medical or traditional surgical treatment of GERD.

Gerson et al. (2018) conducted a systematic review and meta-analysis of randomized controlled trials that compared outcomes of the TIF 2.0 procedure with EsophyX to controls for the treatment of GERD. According to the author, the TIF 2.0 procedure is significantly different the TIF 1.0 procedure. In the TIF 2.0 procedure there is a single insertion of the device, which performs esophagogastric plications around the intra-abdominal lengthened esophagus (as opposed to gastro-gastric plications performed in ELF or TIF 1.0). The apposed fundus is wrapped around the distal esophagus, secured with fasteners placed above the Z-line (as opposed to below the Z-line), with an average of more than 20 fasteners (instead of 10 or 12). Comparators were PPI therapy or sham (with or without PPI). Patients had chronic long-term refractory GERD on optimized PPI therapy. Outcomes were esophageal pH, PPI utilization and quality of life at postoperative year three. Three studies (n=233) met inclusion criteria. One study (n=63) compared TIF2 to PPIs and two compared TIF2 to sham. At 6–12-months follow-up, a higher proportion of patients with an esophageal pH < 3 was reported in the PPI group compared to TIF patients, but the difference was not significant. For patients who crossed over to TIF At three years follow-up, patients who did not undergo the TIF continued to take higher doses of PPIs than patient who had the TIF procedure (Trad study), but the difference was not significant (p=0.1967). The group mean was 8.0 mg per day for the TIF 2.0 group and 15.8 mg for the PPI group. There was a significant difference in quality-of-life outcomes in the TIF patients one year after the procedure (p<0.0001), but not at year three. A significant number of PPI patients either crossed over to TIF 2.0 or did not attend a substantive number of visits beyond six months. Limitations of the analysis include the

small heterogeneous patient population, short-term follow-up, patients lost to follow-up and study bias ranged from low to high.

McCarthy et al. (2018) conducted a systematic review and meta-analysis of the literature to evaluate the feasibility, efficacy, and tolerability of transoral incisionless fundoplication (TIF) (Esophyx and MUSE) for the treatment of refractory GERD. Thirty-two studies (n=1475) including five randomized controlled trials, 21 prospective studies, and 6 retrospective reviews were included. The analysis included two MUSE studies (n=85), four TIF1 studies (n=158) and the remaining studies used TIF2. Patient populations ranged from 13–127. Inclusion criteria were studies that with human subjects treated for GERD with TIF. Patients with a body mass index (BMI) < 35 kg/m²; hiatal hernia ≤ 2 cm; grade A, B, or C esophagitis according to the Los Angeles classification; and no underlying esophageal motility disorder (e. g. achalasia, diffuse esophageal spasm) at the time of the procedure. The primary outcome measures were feasibility, efficacy, and tolerability of TIF in patients with refractory, symptomatic GERD complaints. Mean follow-up time was 15.8 months. Significant improvement was reported in the mean GERD HRQL (25 studies; n=1236) compared to baseline scores (p<0.001) and GERD-associated symptoms measured by Gastroesophageal Reflux Symptom Score (GERSS) (p<0.001). Complete discontinuation of PPI therapy was achieved in a significant number of patients following TIF (p<0.001) (28 studies; n=1407). Hiatal hernia reduction or complete resolution was achieved in 91% of patients (p<0.001). Esophageal acid exposure time (i.e., percent time with pH< 4) was reported in 15 studies (n=722) and significantly improved following TIF (p<0.001). There was also a significant improvement in the number of reflux episodes in a 24-hour period (p<0.001) and DeMeester scores (p<0.001) (11 studies; n=647). A total of 7.5% patients required further endoscopic or surgical intervention (21 studies; n=1176) primarily in the first six months following surgery. Author-noted limitations of this analysis include heterogeneity of patient populations, short-term follow-ups, and inclusion of first- and second-generation devices (Esophyx/Esophyx2), as well as heterogeneity by the use of TIF 1.0 and TIF 2.0 protocols. Randomized controlled trials with large patient populations and long-term follow-up are needed to valid the effectiveness of ESOPHX.

Trad et al. (2018) reported the five-year observational outcomes (n=44) of the TEMPO multicenter, randomized controlled trial. In the original RCT (Trad, et al., 2015) TIF outcomes were compared to PPIs. At the six-month follow-up all patients crossed over to TIF. Patients were originally included who had chronic GERD with daily troublesome regurgitation and/or atypical symptoms refractory to PPI therapy, pathological esophageal acid exposure confirmed by 48-hour pH monitoring off PPI therapy (percentage time pH <4 greater than 5.3%), and PPI use for at least six months. Primary outcomes for this five-year follow-up were elimination of daily troublesome regurgitation and atypical symptoms. Secondary outcomes were improvement in symptom scores, PPI use, reoperations, and patient health satisfaction. Troublesome symptoms were defined as mild symptoms occurring ≥ 2 days a week, or moderate to severe symptoms more than one day a week. At the 5-year follow-up, elimination of troublesome regurgitation was achieved in 86% of patients (37/43) compared to 90% at year 3 (37/41) and 88% at year 1 follow-up (42/48). Elimination of troublesome atypical symptoms occurred in 80% of patients at year five (31/39), 88% at three years (42/48) and 82% at one year (45/55). No statistically significant differences in elimination of troublesome regurgitation or atypical symptoms were found between assessments at years one, three and five. Results were reported regardless of PPI use at the time of assessment (on or off PPI therapy). One additional patient underwent reoperation for recurrent daily troublesome GERD on PPI therapy, making a total of 3 (5%) after five years. No serious adverse events occurred. Limitations of the study included: small patient population, loss to follow-up, all patient crossed over to TIF at six months, functional tests and endoscopies were not performed at five years, and the results were reported regardless of PPI use at the time of post procedure assessment (on or off PPI therapy).

Stefanidis et al. (2017) conducted a prospective case series (n=45) to evaluate the long-term efficacy and safety of the TIF procedure in patients with a history of esophagitis or proven chronic GERD who had achieved symptom control with the administration of proton pump inhibitors (PPIs) but did not wish to continue receiving medications for life. Patients were included if they were age 18–60 years, BMI < 36 Kg/m², had typical GERD symptoms (heartburn, regurgitation, chest pain) for more than six months for at least three times per week, and a history of esophagitis grade A and B or proven GERD by esophageal pH monitoring. Patients were excluded if they had esophagitis grade C or D or hiatal hernias > 2 cm in length. The primary outcome was GERD symptom elimination at follow up based on normalization of the GERD health related quality of life (GERD-HRQL) questionnaire. Follow-up ranged from 36–75 months (median 59 months). GERD-HRQL scores significantly improved compared to baseline (p<0.001). Heartburn was eliminated in 57.1% of patients (12/21), regurgitation was eliminated in 88.2% (15/17) and chest pain was eliminated in 83.3% (5/6) patients. Overall, 72.7% (32/44) reported elimination of their main symptom with no PPI usage. The rest of the patients reported a decreased daily dose of PPI. Adverse events included one pneumothorax and one event of hematemesis. Other events included epigastric pain and pharynx irritation. Limitations of the study include the small patient population, short-term follow-up and lack of a comparator.

Trad et al. (2017) reported on three-year follow-up data for 52 patients who underwent transoral esophagogastric fundoplication (TF) using the EsophyX device. The initial randomized controlled trial (TEMPO) (n=63) (Trad, et al., 2015) was conducted to assess the safety and efficacy of transoral esophagogastric fundoplication (TF) using the EsophyX device (n=40) vs. high dose proton pump inhibitors (PPI) (n=23). Included patients were ≥ age 18 years, had no hiatal hernia or hiatal hernia < 2 cm, had troublesome GERD symptoms while on proton pump inhibitors (PPI) for at least six month and had abnormal esophageal acid exposure (EAE). Abnormal EAE was defined as pH < 4 for more than 5.3% of total recorded time using 48-h Bravo pH testing. After the six-month evaluation period, the remaining 21 PPI patients elected to crossover to TF. Two patients were included in analysis that had undergone revisional procedures. Outcomes included: GERD symptom resolution using three GERD specific quality of life questionnaires; healing of esophagitis using endoscopy; EAE using 48-h Bravo testing; and discontinuation of PPI use. At the three-year follow-up (n=52), 90% (37/41) of patients reported elimination of troublesome regurgitation, 88% (42/28) patients reported elimination of all atypical symptoms. The mean Reflux Symptom Index score improved from 22.2 on PPIs at screening to 4.0 off PPIs following TF (p=0.0001). The mean total time pH < 4 was improved significantly from 10.5% to 7.8% (p=0.0283). Esophagitis was healed in 86% (19/22) of patients and 71% (37/52) of patients had discontinued PPI therapy. Limitations of the study include: the small patient population; short-term follow-up; potential of bias due to the open-label crossover study design; and 11 patients lost to follow up (17%). According to the authors this 3-year report represents the longest follow-up on the TF procedure performed with the EsophyX device in the US to date.

Huang et al. (2016) conducted a systematic review and meta-analysis to evaluate the safety and efficacy of transoral incisionless fundoplication (TIF) performed with the EsophyX device for the treatment of GERD. A total of 18 studies (n=963) (five randomized controlled trials [RCTs] and 13 prospective observational studies) met inclusion criteria. The study subjects had GERD requiring PPIs and TIF with/without PPIs and primarily had hiatal hernias less than 2–3 cm and BMI < 30 or 35 kg/m². The average follow-up duration was more than three months. Outcomes included: esophageal acid exposure time (% time pH < 4); 24-hour total number of refluxes; 24-hour acid reflux episodes; number of patients with complete discontinuation or reduction in proton pump inhibitors (PPIs) usage; overall response rate to TIF; and patient satisfaction. Responsiveness to TIF was defined as an improvement of at least 50% in the GERD health related quality of life (GERD-HRQL) scores or remission of heartburn and regurgitation; and/or complete cessation of PPIs use. The pooled relative risk of response rate (n=4 RCTs) to TIF versus PPIs/sham was 2.44 (95 % CI 1.25–4.79; p=0.0009) in RCTs in the intention-to-treat analysis. Analysis of five RCTs

showed no significant difference in percent of acid exposure ($p=0.85$). Sub analysis of two studies that compared TIF to sham without PPIs, showed a significant improvement following TIF in acid exposure ($p=0.02$). Analysis of three RCTs ($n=73$) evaluated the total reflux episodes before and after TIF procedure showing a significant reduction in reflux episode following TIF ($p<0.00001$). Two RCTs ($n=71$) reported no significant improvement in acid reflux episodes following TIF vs. PPIs ($n=0.16$). The effects of TIF decreased over time and PPIs usage led to dependence and increased dosage. Patient satisfaction from ten observational studies ranged from 45%–86% (weighted average 69.15%) at a mean six months. Severe adverse events included: seven perforations, five cases of post-TIF bleeding, and four cases of pneumothorax. One death was reported 20 months after TIF. The authors noted that there was a high degree of heterogeneity of the studies and data analysis was hampered by a lack of standardization in primary and secondary outcomes. Additional limitations of the studies included: variation in exclusion criteria and TIF technique; short-term follow-ups (range 3–36 months); and the small sample sizes used in outcome analysis.

Hunter et al. (2015) conducted a multicenter, randomized controlled trial ($n=129$) to determine if transoral fundoplication (TF) (EsophyX-2) ($n=87$) was better than PPI ($n=42$) for the treatment of troublesome GERD, particularly with regurgitation, in chronic PPI users. Patients were randomly assigned to groups that underwent TF and then received 6 months of placebo ($n=87$), or sham surgery and 6 months of once- or twice-daily omeprazole (controls, $n=42$). Patients were age 18–80 years, with more than a six-month history of GERD symptoms and troublesome regurgitation, despite a minimum PPI dose of 40 mg per day. Treatment included TF followed by six months of placebo or sham followed by six months of PPI (omeprazole) therapy. Troublesome regurgitation was defined as mild symptoms for ≥ 2 days per week or moderate to severe symptoms more than one day per week, per Montreal consensus criteria. Symptom assessment was obtained by the Reflux Disease Questionnaire (RDQ), the Gastroesophageal Reflux Symptom Score, and the GERD-Health Related Quality of Life on PPI and off PPI for at least seven days. Exclusion criteria included: systemic disease not well controlled, body mass index >35 , esophageal ulcer, stricture, Barrett's esophagus > 2 cm in length, hiatal hernia > 2 cm in length, Los Angeles grade C or D esophagitis, esophageal dysmotility, previous esophageal or gastric surgery, peptic ulcer disease, gastric outlet obstruction, gastroparesis, pregnancy or plans for pregnancy in the next 12 months, immunosuppression, portal hypertension, and coagulopathy. If troublesome symptoms persisted at three months, despite twice a day medication use, the patient was declared a failure, the blind was broken and the patient was offered the opposite treatment. The primary outcome measure was the elimination of troublesome regurgitation. Secondary outcomes measures included: early failure (i.e., moderate to severe regurgitation at any time > 12 weeks after surgery and after doubling medication, PPI, or placebo), control of intraesophageal acid exposure, improvement in various symptom scores (particularly heartburn), healing of esophagitis, common side effects associated with treatment (bloating and dysphagia), and significant adverse events. At six months follow-up significant improvement in troublesome regurgitation was reported in the TF group compared to PPI group ($p=0.023$). RDQ results were similar in both groups. In TF patients significant improvements were seen in mean number of reflux episodes ($p<0.001$), mean percent total time pH <4 ($p<0.001$) and mean DeMeester ($p<0.001$). Only the number of reflux episodes was normalized by the performance of TF. Esophagitis was healed in 10/13 TF patients vs. one sham patient. There was no significant difference between the groups in de novo esophagitis at six months. There were no significant changes in the sham group. Significantly more patients in the sham/PPI group (30/42) crossed over to TF compared to 24/87 TF patients who resumed PPI ($p<0.001$). Limitations of the study include: the small patient population, short-term follow-up, number lost to follow-up (19%) (11/87 in study group and 14/42 in sham group); unequal number of patients in each group; and incomplete follow-up data on 12 patients.

Håkansson et al. (2015) conducted a randomized controlled trial to compare outcomes of TIF with EsophyX ($n=22$) to sham procedure ($n=22$). The sham procedure consisted of upper GI

endoscopy under general anesthesia. The primary outcome measure was the proportion of patients in clinical remission after 6-month follow-up. Inclusion criteria were age 18–80 years, on daily PPIs for > 6 months, documented PPI-dependent, and persistent GERD symptoms without PPI therapy (during the titration phase of the study). Subjects also showed evidence of two or more of the following for more than ten days while off PPI therapy; erosive esophagitis (Los Angeles [LA] grade A, B or C); abnormal ambulatory pH study; moderate to severe GERD symptoms, normal or near normal esophageal motility by manometry or impedance. Patients were excluded if they had a BMI > 35, Hill grade IV, hiatal hernia > 3 CM, esophagitis LA grade D, Barrett's esophagus and other comorbidities. Patients underwent a two-month run-in period for testing the lowest possible PPI dose needed to control GERD symptoms. The primary outcome measure was time to treatment failure during the first six months after intervention. Treatment failure was defined as the need for PPI to control reflux disease. At six months follow-up, there was a significant difference in time in remission following TIF (197 days) vs. sham (107 days). Fourteen TIF patients were Hill grade I-II on endoscopic exam vs. no improvement seen in the sham group. The median GERD symptoms scores, based on the Quality of Life in Reflux and Dyspepsia (QOLRAD) estimates, improved significantly compared to baseline ($p=0.0005$) vs no improvement in sham group. The median GSRS score ($p=0.004$), median reflux dimension of Gastrointestinal Symptom Rating Scale (GSRS) score ($p<0.001$) was significantly improved vs. no change in the sham group. Significantly more TIF patients were off PPI therapy vs. sham ($p=0.001$) with a significant reduction in total acid reflux time ($p=0.003$). There was no significant difference in adverse events between TIF and sham. Adverse events included dysphagia, bloating, flatulence, post-operative epigastric pain, abdominal and musculoskeletal pain and vomiting and diarrhea. Limitations of the study include the small patient population and short-term follow-up.

Trad et al. (2015) conducted a multicenter randomized controlled trial to evaluate the efficacy of transoral incisionless fundoplication (TIF) using EsophyX2 ($n=40$) compared to proton pump inhibitors (PPIs) ($n=23$) for the treatment of GERD. Patients met the following criteria: age 18–80 years; GERD for > 1 year; > 6-month history of PPI use; troublesome atypical symptoms and/or regurgitation, with or without heartburn, while on daily PPI therapy; abnormal esophageal acid exposure (EAE); and Hill grade I or II. Abnormal EAE was defined as $\text{pH} < 4$ for more than 5.3 % of total recorded time using 48-h Bravo pH testing). Patients were excluded if they had a body mass index (BMI) > 35 kg/m²; hiatal hernia > 2 cm in axial length and/or > 2 cm in greatest transverse dimensions, esophagitis grade C or D; Barrett's esophagus > 2 cm; esophageal ulcer; fixed esophageal stricture or narrowing. Primary outcome was elimination of daily troublesome regurgitation or extraesophageal symptoms. Secondary outcomes were normalization of esophageal acid exposure (EAE), PPI usage and healing of esophagitis. Symptom assessment was conducted by using Gastroesophageal Health-Related Quality of Life (GERD-HRQL), Reflux Symptom Index (RSI), and the Reflux Disease Questionnaire (RDQ). At six-month's follow-up, per the RDQ questionnaire 97% of TIF patients vs. 50% of PPI patients had elimination of troublesome regurgitation ($p<0.001$). Overall, 62% of TIF patients vs. 5% of PPI patients experienced elimination of regurgitation and extraesophageal symptoms ($p<0.001$). EAE was normalized in 54% of TIF patients (off PPIs) vs. 52% of PPI patients on maximum standard dose ($p=0.914$). Ninety percent of TIF patients were completely off PPIs, 3% were taking PPIs on demand and 8% were on daily PPIs. Endoscopic exam showed complete healing or reduction in reflux esophagitis in 90% of TIF patients compared to 38% PPI patients ($p=0.018$). In addition, 90% (28/31) of TIF patients (off PPIs) reported elimination of daily troublesome heartburn vs. 13% (2/16) PPI patients ($p=0.003$). Patient satisfaction with current health condition, as evaluated by GERD-HRQL, improved significantly in the TIF group compared to PPI group ($p<0.001$). No serious adverse events were reported following TIF. Limitations of the study include: heterogeneous small patient population, short-term follow-up, variety of PPIs used; and 2:1 randomization (TF:PPI). The authors noted that there could have been a potential placebo effect in the TIF group and stated that long-term follow-up was needed.

Witteaman et al. (2015) conducted a randomized controlled trial (n=60) to evaluate TIF in patients with GERD who were controlled with PPI but chose TIF over lifelong PPI therapy. Patients remained with PPI (n=20) or underwent TIF (n=40) with EsophyX. Criteria for study participation included: age 18–75 years, hiatal hernia ≤ 2 cm, proven reflux while off PPIs, on daily PPIs for ≥ 1 year, recurrence of GERD symptoms after cessation of PPIs, and normal or reduced lower esophageal sphincter resting pressure (5–40 mm Hg) at manometry. Patients with body mass index ≥ 35 kg/m² and hiatal hernia > 2 cm, esophagitis grade D, Barrett's esophagus and other comorbidities were excluded. At the six-month following-up (n=57) there was a significant improvement in quality-of-life scores in the TIF group ($p<0.001$) and an increase in lower esophageal sphincter resting pressure ($p=0.004$). There were no significant differences between the two groups in esophageal acid exposure time ($p=0.228$), normalization of pH, total number of reflux episodes at impedance measurements ($p=0.058$) or healing of esophagitis. Following TIF, cessation of PPIs occurred in 74% of patients, 17% used PPIs occasionally and 9% used PPIs daily at six months. At the end of six months the 20 PPI patients crossed over to TIF. Twelve months (n=45) following crossover, quality of life ($p<0.05$), number of reflux episodes and the increase of lower esophageal sphincter pressure showed a significant improvement compared to baseline. There was no significant improvement in distal esophageal acid exposure ($p=0.06$). Normalization of pH was accomplished in 44% of TIF patients at six months but dropped to 29% at 12 months. The use of PPIs was discontinued by 39% of patients with 44% needing PPIs on a daily basis at 12 months. At 12-months follow-up, 5% of patients had undergone revisional surgery to control their symptoms. TIF adverse events included an incident of pneumoperitoneum, three cases of pneumonia and a readmission for severe epigastric pain. Milder adverse events (dysphagia and gas bloating) resolved within a short period of time. Limitations of the study include the small patient population; 2:1 randomization; short-term follow-up and number of patients lost to follow-up.

Wendling et al. (2013) conducted a systematic review of the impact of TIF with the EsophyX system on subjective and objective GERD indices. A total of fifteen observational, retrospective or prospective studies were included in this review from 2006 up to March 2012. No randomized controlled trials were found in the literature. Data collected included GERD-health related quality of life (HRQL) and reflux system index (RSI) scores, PPI discontinuation and patient satisfaction rates, pH study metrics, treatment failures and complications. Both GERD-HRQL scores (21.9 vs. 5.9, $p<0.0001$) and RSI scores (24.5 vs 5.4, $p\geq 0.0001$) were significantly reduced after TIF. Overall patient satisfaction was 72%. The overall rate of PPI discontinuation was 67% across all studies, with a mean follow-up of 8.3 months. pH metrics were not consistently normalized. The major complication rate was 3.2 % and the failure rate was 7.2% across all studies. The authors noted that additional studies of TIF, particularly in patients with moderate GERD symptoms and minimal anatomic degradation at the gastroesophageal junction, are required to identify the optimal target population for the procedure. Also, well-designed prospective clinical trials are needed to assess the effectiveness and durability of TIF compared to sham procedures and current gold standard GERD therapies prior to making any definitive recommendations for its widespread clinical use.

In a multicenter prospective, noncomparative study, Bell et al. (2012) evaluated the safety and efficacy of TIF using the EsophyX system within different GERD subgroups (n=100) at six-month follow-up. In addition, the authors attempted to identify factors associated with clinical success in patients undergoing TIF. Inclusion criteria: age 18–75 years, GERD duration > 1 year, moderate to severe typical or atypical GERD symptoms off proton pump inhibitor (PPI)s, complete (responders) or partial (nonresponders) symptom control on PPIs. Primary outcomes measured included the elimination of daily typical or atypical GERD symptoms or clinically significant improvement in global symptoms at six-month follow-up compared with baseline. The secondary effectiveness endpoints were: elimination of PPI usage; normalization or clinically significant improvement in esophageal acid exposure or number of reflux episodes measured objectively by

48-hour pH or 24-hour impedance/pH testing; healing of reflux esophagitis; and reduction of hiatal hernia. Intraoperative and postoperative serious adverse events were evaluated and patients were evaluated for common postfundoplication side effects of dysphagia, bloating, and flatulence. No adverse events were reported. Median heartburn and regurgitation scores improved significantly, from 18 (range 0-30) and 15 (range 0-30) on PPIs before TIF to 3 (range 0-25) and 0 (range 0-25), respectively; $p < 0.001$. Median Reflux Symptom Index scores were reduced after TIF from 24 (range 14-41) to 7 (range 0-44); $p < 0.001$. Eighty percent of patients were completely off PPIs after TIF versus 92% of patients on PPIs before TIF. Preoperative factors associated with clinical outcomes were less severe heartburn (total GERD-HRQL ≤ 30 , $p = 0.02$) and the presence of esophagitis ($p < 0.02$). Reported limitations include the duration of follow-up and possibility of patient selection bias.

Literature Review - Medigus ultrasonic surgical endostapler (MUSE) - Transoral Incisionless Fundoplication:

There is a lack of studies in the peer-reviewed literature investigating the safety and efficacy of the Muse System. The studies in the peer-reviewed literature are primarily in the form of prospective reviews and case series with small patient populations ($n = 14-66$). Randomized controlled trials with long term follow-up are needed to determine whether the Muse System improves outcomes compared to alternative treatment modalities (Peng, et al., 2022; Testoni, et al., 2022; Testoni, et al., 2020; Kim, et al., 2016; Roy-Shapira, et al., 2015; Zacherl, et al., 2014)

Testoni et al. (2022) conducted a single-center, prospective observational study that assessed the clinical, functional, and endoscopic effects of transoral incisionless fundoplication (TIF) by Medigus ultrasonic surgical endostapler (MUSE) on the use of proton pump inhibitor (PPI) medication and gastro-esophageal reflux disease (GERD) related symptoms. The study included adults ($n = 46$) aged 18–70 years experiencing chronic (at least six months) GERD-related symptoms, both esophageal and extra-esophageal, with endoscopic findings of GERD or Barrett's esophagus < 3 cm and with complete or partial response to PPI therapy. Additionally, the study included patients with evidence of non-erosive reflux disease (NERD) or hypersensitive esophagus and a body mass index < 40 kg/m². The primary outcome measured the effect of a TIF performed using the MUSE™ device on use of proton pump inhibitor (PPI) medication and GERD-related symptoms. GERD-health-related quality of life (HRQL) and reflux symptom index (RSI) questionnaires were scheduled to be assessed before TIF-MUSE, six and 12 months, and then yearly after the procedure, for at least five years. The secondary outcomes measured functional and upper gastrointestinal (GI) endoscopic findings up to one year. Functional parameters were assessed before TIF using high resolution esophageal manometry (HRM) and 24-h ambulatory esophageal pH-impedance recording (always off-PPI). Endoscopy assessed the presence and grade of esophagitis, hiatal hernia and Hill's grade of the gastroesophageal valve. The study also examined the feasibility, durability and safety of TIF by MUSE. TIF by MUSE was able to be performed in 45/46 patients. After TIF, all hiatal hernias were reduced and the Hill's grade of the newly created valve was I in all cases. There were two major complications (4.4%) requiring surgical repair occurred: one delayed (48 hours after TIF) esophageal perforation and one intra-operative gastric fundus perforation. One patient was unresponsive to TIF and underwent Nissen fundoplication within six months after the procedure. These patients were excluded from the follow-up.

Clinical follow-up was carried out on 42 patients at six months and one year, 35/42 patients (83.3%) at two years and 31/42 patients (71.4%) at three years. Ten patients were in follow-up at five years, but they were not considered in this study because of the small numbers. The PPI consumption was stopped in 64.3% of cases at six months and one year, 62.9% of cases at two years and 74.2% of cases at three years. GERD-HRQL and RSI scores decreased at least 50% resulting in a significant improvement of both scores at six months ($p < 0.0001$ for both) up to three years ($p = 0.007$ for GERD-HRQL score; $p = 0.01$ for RSI score). There were four patients at six months and 11 patients at one year that refused to repeat the upper GI endoscopy because of

symptoms improvement. Therefore, 38/42 (90.5%) patients and 31/42 (73.8%) patients completed the six months and one year scheduled endoscopic follow-up, respectively. The results of the endoscopy showed grade A esophagitis in 7/38 (18.4%) patients at six months. Grade A persisted in 5/14 (35.7%) patients with prior esophagitis and was seen first in two other patients. At one year esophagitis persisted in 6/31 (19.3%) patients. Recurrent hiatal hernia < 2.5 cm was seen in 2/38 (5.3%) patients and further confirmed in 2/31 (6.5%) patients at six months and one year, respectively. Hill's grade of the gastro-esophageal valve was I in 24/38 (63.2%) and 21/31 (67.7%) patients, was II in 13/38 (34.2%) and 9/31 (29.0%) patients and was III in 1/38 (2.6%) and 1/31 (3.3%) patients at six months and one year, respectively. Eleven and twenty-two patients with symptomatic improvement refused to undergo functional investigation at the scheduled times therefore, 31/42 (73.8%) patients and 20/42 (47.6%) patients underwent functional investigation at six-month and one year follow-up, respectively. The median LES length and peristaltic waves rate increased significantly ($p=0.03$ and $p=0.025$, respectively) compared to baseline. There were no significant differences in DCI and LES basal pressure. Esophageal pH-impedance recording found significantly fewer acid, proximal and total refluxes, and percentage of esophageal pH < 4 total time at six months, but not at one year. At six month and 1-year pH-metric evaluations the DeMeester score decreased in 14/31 (45.2%) and 11/20 (55%) patients, without significant changes compared with baseline. Author noted limitations included the lack of a control group, short term follow-up and that TIF was only done on patients with grade A esophagitis and in those with non-erosive reflux disease (NERD) or hypersensitive esophagus and might not be applicable in patients with more severe degrees of esophagitis or anatomical changes. An additional limitation is the small patient population. The study concluded that TIF by MUSE achieved significant and persistent improvement of GERD-related symptoms and allowed to stop or halve PPI consumption in about 65% and 77% of patients up to 3 years in a selected subset of symptomatic GERD patients. However, the procedure did not appear to be as effective in controlling esophagitis and improving functional parameters. Larger well-designed controlled trials with long-term follow-up are needed. No health disparities were identified by the investigators.

Injection/Implantation Techniques

Bulking agents are substances injected under endoscopic guidance into the esophageal wall at the level of the esophagogastric junction to impede reflux. In the 2006 American Gastroenterological Association (AGA) technical review on the use of endoscopic therapy for GERD, the authors reported that "there are no longer any devices that require injection of bulking agents or implantation of a bioprosthesis in the lower esophageal sphincter zone" (Falk, et al., 2006). Implantable products/devices include:

- Expandable hydrogel prosthesis (Gatekeeper™ Reflux Repair System; Medtronic, Inc., Minneapolis, MN): It has been reported that the device was withdrawn in late 2005 before U.S. Food and Drug Administration (FDA) approval. A European sham-controlled single-blind multicenter study randomized 118 patients into Gatekeeper or sham treatment. The study was terminated early due to a lack of efficacy (Fockens, et al., 2010).
- Ethylene vinyl alcohol copolymer with tantalum dissolved in dimethyl sulfoxide (Enteryx™; Boston Scientific Corp, Natick, MA).
- Plexiglas polymethylmethacrylate microspheres (PMMA).
- Pyrolytic carbon-coated graphite beads suspended in a water-based carrier gel suitable for suspending the carbon-coated beads (Durasphere™, Carbon Medical Technologies, St Paul, MN). Durasphere is an injectable bulking agent that is being proposed in the treatment of mild-moderate GERD. A small nonrandomized study ($n=10$) was conducted by Ganz et al. (2009). This study is the first report of Durasphere for the treatment of GERD. Based on the findings and limitations of this study, further investigation of this agent is warranted including large, controlled studies with long-term outcomes.

U.S. Food and Drug Administration (FDA): Durasphere™ received PMA-Premarket Approval in 1999. The FDA approval order statement states that, “this device is indicated for use in the treatment of adult women with stress urinary incontinence due to intrinsic sphincter deficiency” (FDA, 1999). There is no FDA indication for the treatment of GERD.

The Gatekeeper Reflux Repair System and plexiglas or polymethylmethacrylate (PMMA), are not FDA-approved devices.

Magnetic Sphincter Augmentation

LINX™ Reflux Management System (Johnson & Johnson, Inc; St Paul, MN): The LINX Reflux Management System is an implant that consists of a small flexible band of interlinked titanium beads with magnetic cores. The magnetic attraction is proposed to help the lower esophageal sphincter (LES) resist opening to gastric pressures, preventing reflux from the stomach into the esophagus. A surgeon uses a laparoscopic incision to implant the device around the patient’s esophagus just above the stomach while the patient is under general anesthesia.

U.S. Food and Drug Administration (FDA): Torax Medical, Inc; obtained FDA Premarket Approval (PMA) in March 2012 to market the LINX Reflux Management System. According to documents submitted to FDA, the device “is intended for people diagnosed with gastroesophageal reflux disease who continue to have chronic symptoms, despite the use of maximum medical therapy for the treatment of reflux” (FDA, 2012). Johnson & Johnson acquired Torax Medical in 2017. On Feb 22, 2024, the FDA approved a labeling change: “Removal of Barrett's Esophagus (BE) from a precaution statement in the instructions for use. LINX has not been demonstrated to be an effective treatment that leads to BE regression or prevention of progression to cancer. As such, patients with BE who are treated with LINX for management of GERD symptoms should consult with their physician for continued treatment of BE (including PPI use).

Literature Review - Magnetic Sphincter Augmentation Device (MSDA) (LINX™ Reflux Management System): Overall, studies in the peer-reviewed literature are primarily in the form of systematic reviews with meta-analysis, case series and retrospective reviews. Large, well-designed, controlled trials showing long-term safety and efficacy are lacking (Skubleny, et al., 2017; Schwameis, et al., 2014; Ganz, et al., 2013; Lipham, et al., 2012).

Puri et al. (2023) conducted a single-center retrospective cohort study, from a prospectively maintained database, that assessed the effectiveness of magnetic sphincter augmentation (MSA) in the management of GERD, assess the QOL outcomes and report long-term safety outcomes in patients undergoing MSA. Patients (n=202) that failed medical management were included in the study and underwent placement of the LINX device. The primary outcome measured the quality of life in patients receiving MSA using the GERD-Health Related Quality of Life (HRQL) tool and Reflux Symptom Index (RSI) score, with focus on regurgitation, dysphagia, and gas bloating symptoms, in addition to assessing use of antacids. The secondary outcomes measured the short- and long-term outcomes associated with MSA. Severe reflux was measured using a DeMeester score. Patients were routinely discharged from clinical care at six months following the operation if they were symptom-free. Following six months, patients were contacted at one year, two years, three years, and five years postoperatively to obtain symptom scores. Median follow-up was 2 years (IQR: 1–3). There were 184 patients eligible for follow-up at two years and three years following the operation, and data were available in 68% and 41% of patients, respectively; 88 patients were operated on ≥ 5 years ago, and in this population, 38 provided HRQL scores (43%). The median preoperative GERD-HRQL score was 31, and the median RSI score was 17. There was a reduction in all scores from preoperative values to each time point, which was sustained at 5-year follow-up; 13% of patients had a preoperative DeMeester score of > 50 , and their median preoperative GERD-HRQL and RSI scores were 32 and 15.5, respectively. These were reduced to 0

at the most recent follow-up. There was a significant reduction in antacid use at all postoperative time points. There was one postoperative death unrelated to the procedure and one patient was diagnosed with a deep vein thrombosis and subsequent small volume pulmonary emboli. Four patients required readmission to hospital postoperatively with fever, chest pain (two), and nausea secondary to transient gastroparesis, but none required operative intervention. Fifteen patients required dilatation of the gastroesophageal junction following insertion of the implant (7.43%), of whom 2 required a second dilatation. Four patients (1.98%) underwent device explantation. There were not any reported of device erosion. Author noted limitations included the lack of comparison with other surgical interventions, the retrospective reviewing of patient case notes and the difficulty in following up patients to obtain QOL scores after discharge from routine clinical care. Additional limitation is that the population only included patients from the United Kingdom (UK) and the results may not be applicable to other races or ethnic groups. The authors concluded that randomized control trials are needed to compare the use of MSA with laparoscopic fundoplication in order to demonstrate efficacy, safety, and improvement in patient reported QOL outcomes.

DeMarchi et al. (2021) explored the safety perspective of magnetic sphincter augmentation with the LINX® device (Ethicon Incorporated, Cincinnati, OH) and the evolution of the procedure with an emphasis on the removals and associated characteristics that may guide future clinical practice. The Manufacturer and User Facility Device Experience (MAUDE) and Ethicon's complaint databases were queried for all surgical device explants since January 2013. The endpoint was based upon the time from implant to explant. Explant and erosion rates were calculated at yearly intervals. The total number of devices distributed during this period (2013–2020) was 27,779 with 609 devices reported as having been removed (2.2%). The rate of explant varied by implant year, with implants placed in 2015 having the highest explant rate (5.8%), while the explant rates of implants placed in 2013, 2014 and 2016 were in the 3–4% range with rates $\leq 2.1\%$ for more recent years. There were 27 devices were removed due to part of the device eroding through the esophageal wall and into the lumen. The cumulative risk of erosion at seven years was 0.28%. The seven-year cumulative risk of removal was 4.81 and the likelihood of removal was significantly related to the device size ($p < 0.0001$), with smaller sizes being more likely to be explanted. The primary reasons for device removal and relative percentages were dysphagia/odynophagia (47.9%), persistent gastroesophageal reflux disease (20.5%) and unknown/other (11.2%). The average device size increased from 14.2 beads ± 1.0 in 2013 to 15.3 beads ± 1.2 in 2019 ($p < 0.001$). Surgical technique and perioperative management play an important role in the outcomes. Limitations reported by the authors included the potential for underreporting device complications due to various factors, such as not understanding the importance of reporting or how to report a complication. It is possible that there may be devices removed in centers that were not formally trained on MSA implantation and there is a higher likelihood that such a removal may not be reported to the company or to MAUDE. Completeness of data is another limitation of this study, given the reliance on site-reported product complaints and the MAUDE database. No health disparities were identified by the investigators.

Bonavina et al (2021) reported the three-year outcomes for magnetic sphincter augmentation (MSA) and laparoscopic fundoplication (LF) in patients with gastroesophageal reflux disease (GERD). Twenty-two medical centers in four countries (Austria, Germany, Italy, and the United Kingdom) enrolled patients ($n=631$; 465 MSA and 166 LF) for a prospective, multi-center, observational registry study who were candidates for a surgical anti-reflux procedure. Included patients had a confirmed diagnosis of GERD confirmed and chronic reflux symptoms despite the daily use of medical therapy with PPIs. The type of anti-reflux procedure performed (MSA or LF [Nissen, Toupet or Other/Unspecified]) was determined by the surgeon and patient. If a patient met the labeling requirements for MSA (hiatal hernia ≤ 3 cm, esophagitis less than Grade C, absence of Barrett's esophagus, absence of motility disorders), MSA was recommended. Measured outcomes included clinical effectiveness and Health Related Quality of Life (GERD-HRQL), duration of surgery, length of stay, complications, and healthcare resource use. Baseline characteristics

that were statistically significantly different between patients with MSA vs. LF (all $p < 0.0001$) were patient age (LF 56.3 years vs. MSA 46.6 years), BMI (LF 27.8 vs MSA 25.7), frequency of large hiatal hernias (LF 48.1% vs. MSA 1.4%) and the presence of Barrett's esophagus at the time of surgery (LF 12.7% vs MSA 1.7%). Also, a greater proportion of patients with MSA had no esophagitis ($p = 0.0130$). Both MSA and LF resulted in substantial improvements in quality of life and satisfaction over study period. Both groups experienced a decrease in PPI usage and appear to be able to belch as needed. MSA allowed a higher percentage of patients the ability to vomit as needed with 91.2% of patients noting the ability to vomit at 36 months compared to 68% of the LF patients. The mean procedure time was shorter (43.2 min) for MSA compared to LF (79.7 min). Complications and outpatient clinic visits similar between groups. The surgical intervention rate for the MSA group at 3 years was 2.4% (11/459) and the LF group was 1.9% (3/157). Limitations noted by the authors included: the outcomes are not generalizable to all settings of care, implantation of MSA is only available in select centers, the LF group had different procedures performed and the non-randomized study design was not intended to detect statistically significant clinical outcomes between MSA and LF. No health disparities were identified by the investigators.

Bell et al. (2019) conducted a randomized, controlled, prospective, double-arm, crossover study to compare the effectiveness of increased proton-pump inhibitor (PPI) dosing to laparoscopic magnetic sphincter augmentation (MSA). One hundred fifty-two patients with GERD, aged ≥ 21 years with moderate-to-severe regurgitation despite eight weeks of once-daily PPI therapy, were prospectively enrolled at 21 U.S. sites. Participants were randomized 2:1 to treatment with twice-daily (BID) PPIs ($n = 102$) or to laparoscopic MSA ($n = 50$) using the LINX system. The primary outcome measured the percent of patients in both treatment arms who achieved elimination of moderate-to-severe regurgitation at six months, as reported on the Foregut Symptom Questionnaire (FSQ). The secondary outcomes measured the following at six months: (1) changes in baseline scores (while on PPIs) in the GERD-Health-Related Quality of Life (GERD-HRQL) questionnaire, the Reflux Disease Questionnaire (RDQ), and the percentage of patients achieving $\geq 50\%$ decrease in GERD-HRQL score from baseline; (2) differences between treatment arms at six months in esophageal reflux parameters (number of reflux episodes and percentage of time with $\text{pH} < 4$); and (3) PPI use. Three participants withdrew before undergoing the MSA procedure, and one participant failed to start BID PPI therapy, which made up the analysis population for the primary efficacy endpoint ($n = 101/\text{PPI group}$; $n = 47/\text{MSA group}$). All other analyses were performed with data available at the follow-up visit. Intention-to-treat (ITT) was also performed. At the six-month follow-up, 89% of patients treated with MSA reported clinically significant relief of regurgitation compared to 10% of the patients in the BID PPI group ($p < 0.001$). Eighty-one percent of patients with MSA had significant improvement in GERD-HRQL scores ($\geq 50\%$) versus 8% of patients with BID PPI ($p < 0.001$), and 91% remained off of PPI therapy. At six months, a normal number of reflux episodes was clinically significant in 91% of MSA patients compared to 58% of BID PPI patients ($p < 0.001$). Acid exposure did not reach clinical significance ($p = 0.065$). No significant safety issues were observed. Author noted limitations included: the subjective nature of using patient reported questionnaires for outcome measurement, although impedance-pH testing added some objective measure of the control of reflux. Also, there was potential referral bias as recruitment began with patients presenting to a surgical clinic. Another reported limitation could be the use of 20 mg omeprazole BID as the control treatment, given that 40 mg BID PPI is commonly considered for refractory GERD symptoms.

After six months of PPI therapy, MSA was offered to patients with persistent moderate to severe regurgitation and excess reflux episodes during impedance or pH testing on medication. In a separate publication, Bell et al. (2020) reported the outcomes for the crossover portion of the randomized controlled trial. Thirty-one patients met the crossover requirements and were included in the analysis as the MSA crossover arm ($n = 75$). Forty-three patients did not qualify for crossover and were placed on a reduced dose of 20-mg omeprazole daily (the step-down PPI

cohort). Regurgitation, foregut scores, esophageal acid exposure, and adverse events were evaluated at one year. Patients were assessed by the quality-of-life metrics and underwent esophagogastroduodenoscopy with telemetry capsule esophageal pH monitoring. Assessments were performed in the MSA patients off PPIs (if being taken) for seven days, and on once-daily PPI in the step-down PPI cohort. Any other GERD medications were stopped seven days before testing, with the exception of antacids which were allowed until the morning of assessment. At study completion, resolution of regurgitation was seen in 96% of MSA patients and in 19% of the PPI group. Among the patients who received MSA, 81% had improvements in GERD health-related quality of life improvement scores (greater than 50%) and 91% discontinued daily PPI use. There was no improvement in these parameters in the PPI group. Proportions of patients with dysphagia significantly decreased from 15% to 7% ($p<0.005$), bloating decreased from 55% to 25%, and esophageal acid exposure time significantly decreased from 10.7% to 1.3% ($p<0.001$) from study entry to one year after MSA. Seventy percent of all patients had pH normalization at study completion. MSA was not associated with any peri-operative events, device explants, erosions, or migrations. Author noted limitations included the limited duration of follow-up and use of different pH testing methods at the six- and 12-month follow-ups.

Guidozzi et al. (2019) conducted a systematic review and meta-analysis to compare the magnetic sphincter augmentation (MSA) to laparoscopic fundoplication for the treatment of GERD. Six cohort studies ($n=1099$ /patients) that directly compared magnetic sphincter augmentation to fundoplication ($n=632$ /MSA and $n=467$ /fundoplication). Thirteen single-cohort studies ($n=11,598$ /patients) were included that evaluated clinical outcomes from magnetic sphincter augmentation. The primary outcome measured the postoperative requirement for PPI therapy. Secondary outcomes measured the postoperative GERD-health-related quality of life (GERD-HRQOL) score, gas bloating, ability to belch, dysphagia, and the need for reoperation. Outcomes were measured using a random-effects meta-analysis. Following MSA, 13.2% required post-operative PPI, 7.8% dilatation, 3.3% device removal or reoperation, and esophageal erosion was seen in 0.3%. There were no significant differences between the groups in postoperative PPI therapy, GERD-HRQOL score, dysphagia and reoperation. However, when compared to fundoplication, MSA was associated with significantly less gas bloating and a greater ability to belch. The authors concluded that magnetic sphincter augmentation achieves good GERD symptom control similar to that of fundoplication, with the benefit of less gas bloating. The safety of MSA appears acceptable with only 3.3% of patients requiring device removal. Author noted limitations included the potential underreporting of complications associated with device implantation, small patient population and limited follow-up. Well-designed multicenter randomized controlled trials are needed to fully evaluate the effectiveness of MSA in comparison to laparoscopic fundoplication.

Aiolfi et al. (2018) conducted a systematic review and meta-analysis to compare outcomes of laparoscopic Nissen and Toupet fundoplication (LF) to Magnetic Sphincter Augmentation (MSA) using the LINX device. All articles comparing MSA and laparoscopic partial or total fundoplication were included in the systematic review. Six retrospective reviews and one registry study ($n=1211$) were included. No randomized controlled trials were found. The patient populations of the individual studies ranged from 24 to 415. A total of 686 patients (56%) received the LINX and 525 (44%) patients underwent laparoscopic total (Nissen) or partial (Toupet) fundoplication. The operative time was 42–73 min in the MSA group and 76–118 in the LF group. Overall postoperative morbidity was 0–3% in the MSA group and 0–7% in the LF group. There was no mortality. The hospital length of stay was 13–48 hours in the MSA group and 26–48 hours in the LF group. The postoperative follow-up ranged from 6–12 months. Compared to preoperative baseline, a statistically significant improvement was noted for both procedures. Reoperation was required in 13 MSA patients including 12 device removals, one for erosion and one crural release. There were 11 reoperations in the LF group. Dysphagia requiring endoscopic dilatation occurred in 9.3% of patients in the MSA group compared to 6.6% of LF patients ($p=0.119$), not statistically

significant. The pooled odds ratio of gas/bloat symptoms, ability to vomit, and ability to belch were 0.39 ($p<0.001$), 10.10 ($p<0.001$), and 5.53 ($p<0.001$), respectively. The postoperative quality of life score was similar between groups ($p=0.101$). There were no significant differences in the pooled odds ratio of PPI suspension, endoscopic dilation, and reoperation ($p=0.548$, $p=0.119$, $p=0.183$, respectively). Postoperative morbidity was 0%–3% in the MSA group and 0–7% in the LF group. There was no mortality. The author's noted that the difference in outcomes between the two patient groups should be interpreted with caution since no comparative randomized clinical trials existed to provide strong evidence and subgroup analysis according to baseline variables was not possible because all outcomes were aggregated in the analyzed studies. This analysis is also limited by the retrospective and registry study designs, small patient populations and short-term follow-ups. Prospective randomized controlled trials with large patient populations and long-term follow-ups are needed to support the safety and efficacy of LINX.

Chen et al. (2017) conducted a systematic review and meta-analysis to compare the safety and efficacy of the LINX magnetic sphincter augmentation system (MSA) to Nissen Fundoplication (NF). Four retrospective studies ($n=624$) met inclusion criteria. A total of 299 patients were in the MSA group and 325 in the NF group. Outcomes included differences in the use of proton-pump inhibitors, complications, and adverse events. There were no significant differences between the groups in resumption of PPIs ($p=0.23$), severe dysphagia for dilation ($p=0.74$), ability to belch ($p=0.13$), ability to vomit ($p=0.38$) and adverse events ($p=0.49$). A lower trend toward gas or bloating was seen in the MSA group ($p=0.02$). Operative time ($p=0.001$) and length of stay ($p=0.005$) were significantly shorter in the MSA group. Limitations of the studies include: the retrospective study design, small patient populations; and two trials did not match the size of hiatal hernias. Prospective studies with long-term follow-ups are needed to establish the safety and efficacy of MSA for the treatment of GERD.

Skubleny et al. (2017) conducted a systematic review and meta-analysis to compare the LINX-magnetic sphincter augmentation system to Laparoscopic Nissen fundoplication (LNF) for the treatment of GERD. Randomized controlled trials, non-randomized comparison study and case series with greater than five patients were included. Primary outcomes included: GERD-Health-Related Quality of Life scores, DeMeester scores, operative times, ability to belch, ability to emesis, discontinuation of proton pump inhibitor (PPI), need for endoscopic dilation, procedural satisfaction, presence of gas/bloating and dysphagia. Secondary outcomes included mortality and morbidity. Two retrospective cohort comparative studies and one case series ($n=688$) met inclusion criteria. Mean duration of follow-up ranged from 7–16 months for LNF and 7–12 months for LINX. There was a statistically significant improvement reported with LINX in preserving the patient's ability to belch ($p=0.00001$) and ability to emesis ($p=0.06$). However, there was no statistically significant difference between the groups in gas/bloating ($p=0.06$), postoperative dysphagia ($p=0.43$) and discontinuation of PPI use ($p=0.68$). Six patients required endoscopic balloon dilation following LINX vs. zero dilations post-LNF. Major morbidity for LNF included one case of intraoperative pleural injury, two cases of retroesophageal abscesses and four cases of revision due to hiatal hernia recurrence. The LINX group morbidity included one pleural injury, two episodes of intraoperative bleeding, one pneumothorax and one gastroesophageal junction obstruction. Two LINX devices were removed due to treatment failure and device erosion 20 months after surgery. Limitations of the studies included: lack of randomization; short-term follow-up; loss to follow-up (7.7%–10.6%); and heterogeneity in the size of hiatal hernia and grade of esophagitis accepted within treatment arms. The authors noted that the validity of many of the primary outcomes was decreased due to their subjective nature and lack of clear medical definition. Additional studies are needed to assess the long-term outcomes of LINX. The long-term implications of reversal of the LINX are unknown.

Asti et al. (2016) conducted an observational cohort study to assess and compare health-related quality of life over time in two concurrent cohorts of patients undergoing laparoscopic Toupet

fundoplication (LTF) (n=103) or LINX (n=135). Inclusion criteria were age > 18 years, chronic GERD symptoms despite PPI use for at least six months, objective evidence of reflux at the pH study, and normal esophageal motility documented by manometry. The primary outcome was postoperative quality of life measured by the Gastro-Esophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) questionnaire. Secondary outcomes were PPI use, presence of gas-related symptoms or dysphagia, and reoperation-free probability. Patients in both groups were evaluated at 3–12 months, and then every 12 months with the GERD-HRQL survey plus questions about PPI use, gas-related symptoms and dysphagia. All patients had a minimum of one-year follow-up. The mean postoperative follow-up was 42 months in the LTF group and 44 months in the LINX groups. The GERD-HRQL score significantly decreased within normal values in both groups with no significant difference between the groups. There were no significant differences between the groups in PPI use ($p=0.388$), gas-related symptoms ($p=0.532$), or dysphagia ($p=0.241$). The duration of the surgical procedure was 87 minutes in the LTF group vs. 42 minutes in the LINX group ($p<0.001$). One patient in the LINX group had a respiratory arrest within the first hour postoperatively and was successfully resuscitated without consequences. Postoperative morbidity consisted of atrial fibrillation (n=1), urinary retention (n=1), and bleeding from a trocar site (n=1), all occurring in the LTF group. Author-noted limitations of the study included the fact that the GERD-HRQL is a subjective test and the LINX procedures were not standardized regarding large hernia repair (crural repair). There is also a risk of bias due to the observational design of the study. Further research is needed to investigate correlation between longitudinal quality of life data with objective long-term outcomes of these procedures.

Ganz et al. (2015) reported the five-year outcomes from a multicenter, prospective study (n=85) conducted to evaluate the safety and efficacy of LINX for the treatment of GERD. This is a follow-up to the study submitted for FDA approval. Patients were 18 to 75 years old, had GERD for at least six months, were partially responsive to daily PPIs, had not achieved adequate reflux control and had evidence of pathologic esophageal acid exposure. Patients were excluded for the following: evidence of hiatal hernia greater than 3 cm, esophagitis grade C or D according to the Los Angeles classification, body mass index > 35, Barrett's esophagus, or motility disorder. Outcomes included reflux symptoms, quality of life, and use of PPIs. Following treatment, a 50% or greater reduction in GERD-HRQL score was achieved in 83% of patients (70/84). A reduction of 50% or more in the average daily dose of PPIs occurred in 89.4% of patients (75/85) ($p<0.001$). Patients with moderate or severe heartburn had a decrease from 89% to 11.9%. Moderate or severe regurgitation occurred in 57% of patients at baseline and 1.2% ($p<0.001$). Healing of esophagitis was seen in 26 of 34 patients. All patients reported the ability to belch and vomit if needed. Symptoms of bloating/gas decreased significantly ($p<0.0001$). No device erosions, migrations, or malfunctions occurred. Six devices were removed at three years (7%). Reoperation rates were not available. Limitations of the study included: lack of a comparator; 15 of the original 100 patients were lost to follow-up (15%); esophageal pH testing and manometry were not performed beyond one year.

Saino et al. (2015) reported five-year data from a multicenter, prospective case series (n=33) of patients with GERD, age 18–75 years, who underwent MSAD with LINX. Patients had abnormal esophageal pH, exhibited typical GERD symptoms, and had been taking daily proton pump inhibitors (PPIs). Patients were excluded if they had a large hernia (> 3 cm), Grade B or higher esophagitis, a body mass index of >35 kg/m², Barrett's esophagus, motility disorders, gross esophageal anatomic abnormalities or a known allergy to titanium, stainless steel, nickel, or ferrous materials. Outcomes included: gastroesophageal reflux disease (GERD)-Health Related Quality of Life (HRQL) questionnaire score, esophageal pH, PPI use, and complications. Compared to baseline, there were significant improvements in mean total percentage of time with pH < 4 ($p<0.001$) and mean total GERD-HRQL score ($p<0.001$) and 85% of patients achieved pH normalization or at least a 50% reduction. Complete discontinuation of PPIs was achieved by 87.8% of patients. The re-operation rate was 6.8% and due to dysphagia, continued reflux

symptoms, and planned MRI imaging. There were no device erosions, malfunctions, or migrations at any point and no other long-term complications. Limitations of the study include the small patient population, lack of a comparator; loss of 12 patients from the original pilot study; failure of all sites to perform pH monitoring after the first year and no manometric evaluations were performed after the first year.

Bonavina et al. (2013) reported on 100 consecutive patients who underwent magnetic sphincter augmentation (MSA) for the treatment of GERD. Implant duration ranged from 378 days to six years (median 3 years). Patients were included if they were age 18 years and older, had GERD for at least six months, had persistent reflux symptoms despite daily proton pump inhibitors (PPIs), and pathologic reflux was confirmed by ambulatory esophageal pH monitoring. Following implant median total acid exposure time was significantly reduced from 8.0% to 3.2% ($p < 0.001$). The median GERD Health Related Quality of Life score improved from 16 on PPIs at baseline to 24 off PPIs and significantly improved to a score of 2 ($p < 0.001$). A total of 85% of patients achieved freedom from daily dependence on PPIs. There were no reported events of device migrations or erosions. Three patients had the device laparoscopically removed for persistent GERD, painful swallowing (odynophagia), or dysphagia with subsequent resolution of symptoms.

Resection and Plication (RAP)

Resection and Plication (RAP) is a procedure that has been proposed to treat GERD. The procedure utilizes limited mucosal resection and full-thickness plication using the OverStitch device (Apollo Endosurgery). The RAP suturing protocol is proposed to recreate a functional valve that would be seen in patients without GERD or a hiatal hernia. The protocol allows for a tightening of the gastro-esophageal junction (GEJ) to reduce reflux events, which does not prevent normal esophageal motility and distensibility (Raphael, et al., 2020; Benias, et al., 2018).

U.S. Food and Drug Administration (FDA): The Overstitch Endoscopic Suturing System is FDA approved for "endoscopic placement of suture(s) and approximation of soft tissue." (FDA, 2018, 2021). In 2019 the FDA approved OverStitch™ Endoscopic Suturing System for the same indication, but with a modification. "The OverStitch Endoscopic Suturing System has been modified to add a new product code option for the OverStitch 2-0 Polypropylene Suture-Anchor Assembly. The remaining components of the system remain unchanged" (FDA, 2019).

Literature Review - Resection and Plication (RAP): There is currently a paucity of evidence in the published peer-reviewed medical literature evaluating the safety and effectiveness of the resection and plication procedure using the OverStitch device for treatment-of GERD. Benias, et al. (2018) evaluated the success of a novel resection and plication (RAP) anti-reflux procedure. Ten patients with symptoms and objective findings of GERD underwent RAP using the Apollo Overstitch. Follow-up ranged from 5–24 months. The authors reported that all patients had a significant improvement in their GERD-HRQL scores ($p < 0.0001$) and eight patients eliminated daily PPI use. The authors concluded that the RAP method has potential as an effective anti-reflux option, however additional long-term studies are required.

Walsh et al. (2021) assessed the safety, feasibility, and efficacy of a novel endoscopic resection and plication (RAP) anti-reflux procedure for management of medically refractory GERD in patients with altered gastric anatomy. Twenty consecutive patients with previous gastric surgery underwent RAP using the Apollo overstitch device with a median clinical follow-up of 5.7 months. RAP was technically successful in 19 patients. One patient developed gastric hemorrhage from suture dehiscence, which was managed endoscopically, and four patients developed esophageal stricture requiring endoscopic dilation. Following the RAP procedure, significant improvement in GERD-HRQL score was observed ($p < 0.01$). Sixteen of 18 patients reported reduction in requirement for or cessation of antacid therapy. Eighteen patients were on PPI therapy pre-procedure, after the RAP procedure, six patients reported complete cessation of PPI use, while

another 10 patients reported reduction in PPI dosage after the RAP procedure. Author acknowledged limitations included that a 24-hour pH study and manometry were not used to assess change from baseline in LES function and quantitative assessment of reflux after the RAP procedure along with the short-term follow-up. No health disparities were identified by the investigators.

Additional well-designed studies with long-term follow-up are needed to establish safety and effectiveness of the RAP procedure using the OverStitch device for treatment-of GERD.

Technology Assessments/Systematic Reviews of Multiple Systems

Coronel et al. (2018) conducted a systematic review and meta-analysis of randomized controlled trials (n=16) to evaluate the safety and efficacy of endoscopic treatment for GERD. Endoscopic therapies included: transoral incisionless fundoplication (TIF2) using EsophyX; surgical plication by NDO surgical device; Stretta radiofrequency therapy; EndoCinch endoscopic suturing system; injectable esophageal prostheses by Gatekeeper device, and biocompatible non-resorbable copolymer Enteryx device. Controls included: sham procedure, proton pump inhibitors (PPIs) or laparoscopic anti reflux surgery (LARS). Inclusion criteria were randomized controlled trials with patients over 18 years of age, undergoing endoscopic procedures for chronic GERD (symptoms $\geq$ 6 months in duration), and follow-ups of $\geq$ 3 months. Sixteen RCTs (n=1085) met inclusion criteria. The primary outcome measure was overall efficacy of endoscopic treatments versus controls. A total of 221 patients underwent TIF2, 145 surgical plications, 81 Stretta; 42 endoscopic suturing, 32 injectable esophageal prostheses and 75 biocompatible non-resorbable copolymer. Control groups (n=312) included 294 patients who underwent a sham procedure, 120 received PPIs and 63 underwent LARS. Overall, there was a statistically significant difference in treatment efficacy in favor of endoscopic treatment ($p < 0.00001$). At three months follow-up, three trials (n=263) showed a significant difference in two endoscopic groups ($p < 0.00001$). At six months, six trials (n=377) also showed a statistically significance difference for endoscopic subjects ($p < 0.00001$). At 12 months follow-ups in two trials (n=67) showed no statistically significant difference ($p < 0.06$). Regarding efficacy of endoscopic treatments (ET) versus pharmacological (PPI) four studies (n=320) were analyzed. At six months (n=277) statistically significant difference was seen in favor of ET (Stretta, TIF2) ($p < 0.00001$). One trial (n=43) showed no difference at the 12-month follow-up. In studies comparing ET with sham, at six months two RCTs (n=100) showed a significant difference ($p < 0.0001$) but at 12 months there was no significant difference (1 RCT; n=24). The outcomes of normalization of esophageal acid pH ($p < 0.03$); lower esophageal sphincter resting pressure (LESRP) ($p < 0.00001$); mean percent of total time of esophageal pH < 4 ($p < 0.00001$); and mean number of reflux episodes ($p < 0.00001$) were statistically significant in favor to the ET. Overall, there was high heterogeneity between the trials in up to 12 months of follow up. The time in remission ($p < 0.00001$), number of patients with GERD HRQL score > 50 % improvement ($p < 0.00001$), elimination of troublesome regurgitation ($p < 0.00001$) was statistically significant in favor of ET with very low heterogeneity between the trials at six and 12 months follow up. The mean GERD HRQL score ($p < 0.00001$), the heartburn score ($p < 0.00001$) and DeMeester score ($p < 0.00001$) showed statistically significance improvement following ET up to six and 12 months but there was high heterogeneity. The SF-36 score showed improvement in favor of controls at 12 months follow up, but also with high heterogeneity between studies. When comparing endoscopic therapies only to sham, the results were similar. Most studies reported clinically significant moderate to severe post-procedure related adverse events (n=312 events) such as epigastric pain, musculoskeletal pain, dysphagia, sore throat, chest pain, nausea and vomiting, bloating and flatulence that were treated clinically, with complete resolution and no major sequelae. The event rate was 38% for ET, 24% for sham, 4% for PPI and 2% for the LARS group. Author noted limitations included a high degree of heterogeneity in outcomes, short-term follow-ups (< 6 months) and many patients were offered alternative interventions during follow-ups and the actual benefit of the endoscopic intervention was compromised. The authors noted that to date, there are no randomized studies evaluating the

efficacy of endoscopic procedures with over 12 months of follow up. The role of ET for the treatment of GERD remains unclear.

Chen et al. (2009) conducted a systematic review of 33 studies examining seven endoscopic treatments for GERD. A total of 33 studies examining seven endoscopic procedures (Stretta procedure, Bard EndoCinch, Wilson-Cook Endoscopic Suturing Device, NDO Plicator, Enteryx, Gatekeeper Reflux Repair System and Plexiglas) were included in the review. Of the three procedures that were tested against sham controls (Stretta procedure, Bard EndoCinch and Enteryx), patient outcomes in the treatment group were either as good as, or significantly better than, those of control patients in terms of heartburn symptoms, quality of life and medication usage. However, for the two procedures that were tested against laparoscopic fundoplication (Stretta) procedure and Bard EndoCinch, outcomes for patients in the endoscopic group were either as good as, or inferior to, those for the laparoscopic group. The authors concluded that, despite the potential benefits of these procedures, there was insufficient evidence to establish their safety and efficacy, particularly in the long-term.

Professional Societies/Organizations

American College of Gastroenterology (ACG): In 2022, the ACG updated their clinical guideline for the diagnosis and management of gastroesophageal reflux disease. The ACG stated the following (Katz, et al., 2022):

- Magnetic sphincter augmentation (MSA) can be considered as an alternative to laparoscopic fundoplication for patients with regurgitation who fail medical management (strong recommendation, moderate quality evidence).
- Radiofrequency energy (Stretta) is not recommended as an antireflux procedure as an alternative to medical or surgical antireflux therapies (conditional recommendation, low quality evidence).
- Transoral incisionless fundoplication (TIF) can be considered for patients with troublesome regurgitation or heartburn who do not wish to undergo antireflux surgery and who do not have severe reflux esophagitis (LA grade C or D) or hiatal hernias > 2 cm (conditional recommendation, low quality evidence).

In 2022, the ACG updated their clinical guideline for gastroparesis. The ACG stated the following (Camilleri, et al., 2022):

- Pyloromyotomy is suggested over no treatment for symptom control in patients with gastroparesis and symptoms refractory to medical therapy (conditional recommendation, low quality of evidence).

The ACG stated that this suggestion is based on open-label studies that report symptom improvement and improved gastric emptying (GE), however, most studies were of only 3–6 months' duration. A 12-month study showed 56% patients improved at one year. Symptom control after endoscopic pyloromyotomy is comparable with surgical myotomy; however, endoscopic myotomy has been associated with fewer postprocedural complications and shorter length of hospital stay.

In the 2020 clinical guideline for the diagnosis and management of achalasia, the American College of Gastroenterology (ACG) stated the following (Vaezi, et al., 2020a):

- POEM or LHM is more effective for type III achalasia when compared to PD
- POEM and PD have comparable symptom improvement in patients with types I or II achalasia
- POEM and LHM have comparable symptom improvement in patients with achalasia

- POEM is a safe option in patients with achalasia who have failed PD or LHM
- POEM is associated with a higher incidence of GERD when compared to LHM with fundoplication or PD

American Gastroenterological Association (AGA): In 2023, the AGA published a commentary on gastric peroral endoscopic myotomy for gastroparesis which outlined advice on performing G-POEM for patients with gastroparesis. The commentary discussed patient selection, the G-POEM procedure, post-procedural care, adverse events along with patient follow-up and clinical efficacy. Khashab et al. (2023) acknowledged that heterogeneous meta-analyses, largely lacking longer term follow-up, have reported pooled clinical success rates ranging from 71% to 82% after G-POEM. The authors also noted that a sizable minority of patients undergoing G-POEM for refractory gastroparesis will not achieve a clinically satisfactory response. This commentary does not address a recommendation based on the quality of evidence, but provided expert advice (Khashab et al., 2023).

In 2022, the AGA clinical practice update on management of medically refractory gastroparesis: expert review stated that “clinicians can consider G-POEM for select refractory gastroparesis patients with severe delay in gastric emptying, using a thoughtful team approach involving motility specialists and advanced endoscopists at a center of excellence”. The AGA reported that studies suggest a reduction in post-procedure GCSI scores and improved gastric emptying, with 6.8% overall adverse events. Additionally, the AGA recommended that G-POEM should not be used “as first-line therapy and should only be performed at tertiary care centers using a team approach of experts (motility specialists, advanced endoscopists) with extensive experience in treating refractory gastroparesis patients. Finally, G-POEM has the theoretical potential to induce dumping syndrome, which has a deleterious effect on food tolerance and quality of life” (Lacy et al., 2022).

The 2017 Clinical Practice Update by the Committee of the American Gastroenterological Association (AGA) (Kahrilas et al., 2017) on the use of per-oral endoscopic myotomy in achalasia proposes the following recommendations:

- “in determining the need for achalasia therapy, patient-specific parameters (Chicago Classification subtype, comorbidities, early vs late disease, primary or secondary causes) should be considered along with published efficacy data;
- given the complexity of this procedure, POEM should be performed by experienced physicians in high-volume centers because an estimated 20–40 procedures are needed to achieve competence;
- if the expertise is available, POEM should be considered as primary therapy for type III achalasia;
- if the expertise is available, POEM should be considered as treatment option comparable with laparoscopic Heller myotomy for any of the achalasia syndromes; and
- post-POEM patients should be considered high risk to develop reflux esophagitis and advised of the management considerations (potential indefinite proton pump inhibitor therapy and/or surveillance endoscopy) of this before undergoing the procedure”.

American Society for Gastrointestinal Endoscopy (ASGE): In 2025, the American Society for Gastrointestinal Endoscopy (ASGE) published an update to the 2014 ASGE guideline on the role of endoscopy in the management of GERD. The ASGE gave weak recommendations for the following:

- “In patients with confirmed GERD with a small hiatal hernia (≤ 2 cm) and Hill grade I or II who meet any of the following criteria, the ASGE suggests evaluation for transoral incisionless fundoplication as an alternative to chronic medical management (Strength of recommendation: Conditional; Quality of evidence: Low):
 - Chronic GERD (at least 6 months)
 - Chronic PPI use (≥ 6 mo) for management for GERD symptoms

- Refractory GERD
 - Regurgitation-predominant GERD
 - Patient prefers to avoid long-term PPI use
- In patients with confirmed GERD with a large hiatal hernia (>2 cm) and Hill grade III or IV, the ASGE suggests evaluation for combined hiatal hernia repair and transoral incisionless fundoplication in a multidisciplinary review (Strength of recommendation: Conditional; Quality of evidence: Very low)".

Additionally, the ASGE provided this "best practice advice: In patients with confirmed GERD, a small hiatal hernia (<2 cm), and Hill grade I or II, radiofrequency energy to the lower esophageal sphincter can be considered when other alternatives (endoscopic/surgical fundoplication) are not available or feasible (Strength of recommendation: Conditional; Quality of evidence: Very low)" (ASGE Standards of Practice Committee, 2025).

The 2020 ASGE guideline (Khashab, et al., 2020) on the management of achalasia focused on the treatment modalities currently used for managing most patients with achalasia. The ASGE suggested the following:

- Laparoscopic Heller myotomy, pneumatic dilation, and POEM are effective treatments for patients with achalasia. Achalasia type, local expertise, and patient preference should be used to decide between these treatments (strong recommendation based on high-quality evidence).
- POEM is the preferred treatment for management of patients with type III achalasia (weak recommendation, very-low quality evidence).
- Patients with failed initial myotomy (POEM or laparoscopic Heller myotomy), should undergo pneumatic dilation or redo myotomy using either the same or an alternative technique (weak recommendation based on very-low quality evidence).
- POEM patients should be counseled regarding the increased risk of postprocedure reflux compared with pneumatic dilation and laparoscopic Heller myotomy (weak recommendation based on low-quality evidence).
- POEM and laparoscopic Heller myotomy are comparable treatment options for management of patients with achalasia types I and II (weak recommendation based low-quality evidence).

The guideline noted that POEM is an intricate endoscopic procedure that requires advanced endoscopic skills, knowledge of surgical anatomy, and expertise in submucosal endoscopy and management of adverse events, such as bleeding, perforation, and leakage (Khashab, et al., 2020).

American Society of General Surgeons (ASGS): The ASGS issued a position statement on transoral fundoplication in 2016 stating that "the ASGS supports the use of transoral fundoplication by trained General Surgeons for the treatment of symptomatic chronic gastroesophageal reflux disease (GERD) in patients who fail to achieve satisfactory response to a standard dose of Proton Pump Inhibitor (PPI) therapy or for those who wish to avoid the need for a lifetime of medication dependence."

In a Statement of Support, ASGS (2014) stated that based on available information and the experience of their members, the Society supports LINX for controlling GERD "when it is placed by properly trained properly trained laparoscopic surgeons with experience in foregut surgery and the management of GERD patients".

Society of American Gastrointestinal Endoscopic Surgeons (SAGES): In 2023 SAGES published a multi-society consensus conference and guideline on the treatment of

gastroesophageal reflux disease (GERD) The panel suggested the following for the treatment of adult patients with GERD (Slater et al., 2023):

- patients may benefit from either MSA or Nissen fundoplication, based on surgeon and patient shared decision making (conditional recommendation, very low certainty of evidence)

SAGES noted that the evidence was based on short term, observational studies. Additionally, the certainty of evidence was evaluated as very low based on outcomes namely, symptom recurrence, complications, reoperation, long-term dysphagia(patient-reported), cost, QoL, symptom resolution, PPI use, dysphagia requiring intervention, and patient satisfaction. These outcomes were primarily limited by serious risk of bias and imprecision. The panel noted that current literature is lacking data comparing MSA to partial fundoplication.

- patients may benefit from MSA over continued PPI use (conditional recommendation, moderate certainty of evidence)

The consensus statement stated that while MSA has improved outcomes over PPI therapy in the short term, the negative effects and long-term data are unknown.

- patients may benefit from TIF 2.0 over continued PPI (conditional recommendation, moderate certainty of evidence)

The panel based this suggestion on the fact that TIF 2.0 is an intervention for those who want to avoid both traditional surgery and lifelong medication. TIF 2.0 can potentially be performed entirely by endoscopic and incisionless intervention. Given widely held opinions about the side effects and risks of traditional fundoplication procedures, additional long-term prospective comparative studies of TIF (and especially combined laparoscopic hiatal hernia repair and endoscopic TIF) versus fundoplication (partial fundoplication in particular) are needed.

- patients may benefit from Stretta over PPI (conditional recommendation, low certainty of evidence)

The panel evaluated the quality of evidence as low based on the reported outcomes for decision making. Initially the data originated from RCTs, these studies were mainly limited by small sample sizes, resulting in wide confidence intervals that spanned several clinically meaningful thresholds. The panel concluded that Stretta remains an evolving technology and has not been widely adopted. Increased training and proctoring in the technique are needed world-wide before the technology will improve.

In 2021 SAGES published guidelines for the use of peroral endoscopic myotomy (POEM) for the treatment of achalasia. The panel recommended that peroral endoscopic myotomy should be done over pneumatic dilatation in patients with achalasia. If there is concern about the continued use of PPI post-operatively, POEM or pneumatic dilatation can be used (Kohn, et al., 2021).

Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD		No Determination found'	

	Contractor	Determination Name/Number	Revision Effective Date
LCD	CGS Administrators, LLC	Stretta Procedure (L34540)	9/5/2024
LCD	National Government Services, Inc.	Select Minimally Invasive GERD Procedures (L35080)	2/10/2022
LCD	Palmetto GBA	Stretta Procedure (L34553)	9/1/2024
LCD	Palmetto GBA	Upper Gastrointestinal Endoscopy and Visualization (L34434)	6/5/2025
LCD	Palmetto GBA	Peroral Endoscopic Myotomy (POEM) (L38747)	9/12/2024
LCD	Wisconsin Physicians Service Insurance Corporation	Endoscopic Treatment of GERD (L34659)	8/29/2024

Note: Please review the current Medicare Policy for the most up-to-date information.
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

Coding Information

Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Peroral endoscopic myotomy (POEM)

Considered Medically Necessary for the treatment of achalasia when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
43497	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])

Gastric peroral endoscopic myotomy (G-POEM)

Considered Medically Necessary for the treatment of refractory gastroparesis when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
43999	Unlisted procedure, stomach

Considered Experimental/Investigational/Unproven when used to report diverticular peroral endoscopic myotomy (D-POEM):

CPT®* Codes	Description
43499	Unlisted procedure, esophagus

Considered Experimental/Investigational/Unproven when used to report endoscopic or laparoscopic anti-reflux procedures performed for the treatment or management of gastroesophageal reflux disease (GERD) or any other indication:

CPT®* Codes	Description
43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed
43289	Unlisted laparoscopy procedure, esophagus
43499	Unlisted procedure, esophagus
43659	Unlisted laparoscopy procedure, stomach

***Current Procedural Terminology (CPT®) ©2024 American Medical Association: Chicago, IL.**

References

1. Abdelfatah MM, Noll A, Kapil N, Shah R, Li L, Nustas R, et al. Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis. Clin Gastroenterol Hepatol. 2021 Apr;19(4):816-824.
2. Aghaie Meybodi M, Qumseya BJ, Shakoor D, Lobner K, Vosoughi K, Ichkhanian Y, et al. Efficacy and feasibility of G-POEM in management of patients with refractory gastroparesis: a systematic review and meta-analysis. Endosc Int Open. 2019 Mar;7(3):E322-E329
3. Ahmed Y, Othman MO. Peroral endoscopic myotomy (POEM) for achalasia. J Thorac Dis. 2019;11(Suppl 12):S1618-S1628.
4. Aiolfi A, Asti E, Bernardi D, Bonitta G, Rausa E, Siboni S, et al. Early results of magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: Systematic review and meta-analysis. Int J Surg. 2018 Apr;52:82-88.
5. Akintoye E, Kumar N, Obaitan I, Alayo QA, Thompson CC. Peroral endoscopic myotomy: a meta-analysis. Endoscopy. 2016 Dec;48(12):1059-1068.
6. American Society for Gastrointestinal Endoscopy (ASGE). Practice guideline. Role of endoscopy in the management of GERD. 2015. Accessed Aug 8, 2025. Available at URL address: [https://www.giejournal.org/article/S0016-5107\(15\)00147-9/fulltext](https://www.giejournal.org/article/S0016-5107(15)00147-9/fulltext)

7. ASGE Standards of Practice Committee; Desai M, Ruan W, Thosani NC, Amaris M, Scott JS, Saeed A, Abu Dayyeh B, Canto MI, Abidi W, Alipour O, Amateau SK, Cosgrove N, Elhanafi SE, Forbes N, Kohli DR, Kwon RS, Fujii-Lau LL, Machicado JD, Marya NB, Ngamruengphong S, Pawa S, Sheth SG, Thiruvengadam NR, Qumseya BJ; ASGE Standards of Practice Committee Chair. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations. *Gastrointest Endosc.* 2025 Feb;101(2):267-284. doi: 10.1016/j.gie.2024.10.008. Epub 2024 Dec 17. PMID: 39692638
8. American Society for Gastrointestinal Endoscopy (ASGE). The role of endoscopy in the evaluation and management of dysphagia. 2014. Accessed Aug 8, 2025. Available at URL address: <https://www.asge.org/home/resources/publications/guidelines#upper-gi>
9. American Society of General Surgeons. LINX statement of support from ASGS. 2014. Accessed Aug 8, 2025. Available at URL address: <https://theasgs.org/position-statements/linx-statement-of-support-from-asgs/>
10. American Society of General Surgeons. Position statement: Transoral fundoplication. 2016. Accessed Aug 8, 2025. Available at URL address: <https://theasgs.org/position-statements/american-society-of-general-surgeons-asgs-position-statement-transoral-fundoplication/>
11. Arts J, Bisschops R, Blondeau K, Farré R, Vos R, Holvoet L, Caenepeel P, et al. A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. *Am J Gastroenterol.* 2012 Feb;107(2):222-30.
12. Asti E, Bonitta G, Lovece A, Lazzari V, Bonavina L. Longitudinal comparison of quality of life in patients undergoing laparoscopic Toupet fundoplication versus magnetic sphincter augmentation: Observational cohort study with propensity score analysis. *Medicine (Baltimore).* 2016 Jul;95(30):e4366.
13. Asti E, Siboni S, Lazzari V, Bonitta G, Sironi A, Bonavina. Removal of the Magnetic Sphincter Augmentation Device: Surgical Technique and Results of a Single-center Cohort Study. *Ann Surg.* 2017 May;265(5):941-945.
14. Ayazi S, Schwameis K, Zheng P, Newhams K, Myers BM, Grubic AD, Hoppo T, Jobe BA. The Impact of Magnetic Sphincter Augmentation (MSA) on Esophagogastric Junction (EGJ) and Esophageal Body Physiology and Manometric Characteristics. *Ann Surg.* 2023 Mar 1;277(3):e545-e551.
15. Aziz AM, El-Khayat HR, Sadek A, Mattar SG, McNulty G, Kongkam P, et al. A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. *Surg Endosc.* 2010 Apr;24(4):818-25.
16. Aziz M, Gangwani MK, Haghbin H, Dahiya DS, Sohail AH, Kamal F, et al. Gastric peroral endoscopic myotomy versus surgical pyloromyotomy/pyloroplasty for refractory gastroparesis: systematic review and meta-analysis. *Endosc Int Open.* 2023 Apr 4;11(4):E322-E329.
17. Azzolini F, Testoni SG, Esposito D, Bonura GF, Pepe G, Testoni PA. Gastric peroral endoscopic myotomy (G-POEM) for refractory gastroparesis: 3-month follow-up results. *Dig Liver Dis.* 2020 Oct;52(10):1215-1218.

18. Bazerbachi F, Krishnan K, Abu Dayyeh BK. Endoscopic GERD therapy: a primer to the transoral incisionless fundoplication procedure. *Gastrointest Endosc.* 2019 Sep;90(3):370-383
19. Bell RC, Barnes WE, Carter BJ, Sewell RW, Mavrelis PG, Ihde GM, et al. Transoral incisionless fundoplication: 2-year results from the prospective multicenter U.S. study. *Am Surg.* 2014 Nov;80(11):1093-105.
20. Bell RC, Freeman KD. Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. *Surg Endosc.* 2011 Jun;25(6):1975-84.
21. Bell RCW, Freeman K, Heidrick R, Ayazi S. Transoral incisionless fundoplication demonstrates durability at up to 9 years. *Therap Adv Gastroenterol.* 2021 Apr 16;14:17562848211004827.
22. Bell R, Lipham J, Louie B, Williams V, Luketich J, Hill M, et al. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. *Gastrointest Endosc.* 2019 Jan;89(1):14-22.e1.
23. Bell R, Lipham J, Louie BE, Williams V, Luketich J, Hill M, et al. Magnetic Sphincter Augmentation Superior to Proton Pump Inhibitors for Regurgitation in a 1-Year Randomized Trial. *Clin Gastroenterol Hepatol.* 2020 Jul;18(8):1736-1743.e2.
24. Bell RC, Mavrelis PG, Barnes WE, Dargis D, Carter BJ, Hoddinott KM, et al. A prospective multicenter registry of patients with chronic gastroesophageal reflux disease receiving transoral incisionless fundoplication. *J Am Coll Surg.* 2012 Dec;215(6):794-809.
25. Benias PC, D'Souza L, Lan G, Gluckman C, Inamdar S, Trindade AJ, et al. Initial experience with a novel resection and plication (RAP) method for acid reflux: a pilot study. *Endosc Int Open.* 2018 Apr;6(4):E443-E449.
26. Birk J, Pruitt R, Haber G, Raijman I, Baluyut A, Meiselman M, et al. The Plicator procedure for the treatment of gastroesophageal reflux disease: a registry study. *Surg Endosc.* 2009 Feb;23(2):423-31.
27. Bonavina L, Horbach T, Schoppmann SF, DeMarchi J. Three-year clinical experience with magnetic sphincter augmentation and laparoscopic fundoplication. *Surg Endosc.* 2021 Jul;35(7):3449-3458.
28. Bonavina L, Saino G, Bona D, Sironi A, Lazzari V. One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center. *J Am Coll Surg.* 2013 Oct;217(4):577-85.
29. Buckley FP 3rd, Bell RCW, Freeman K, Doggett S, Heidrick R. Favorable results from a prospective evaluation of 200 patients with large hiatal hernias undergoing LINX magnetic sphincter augmentation. *Surg Endosc.* 2017 Sep 21.
30. Camilleri M, Kuo B, Nguyen L, Vaughn VM, Petrey J, Greer K, Yadlapati R, Abell TL. ACG Clinical Guideline: Gastroparesis. *Am J Gastroenterol.* 2022 Aug 1;117(8):1197-1220. doi:

10.14309/ajg.0000000000001874. Epub 2022 Jun 3. PMID: 35926490; PMCID: PMC9373497.

31. Chen D, Barber C, McLoughlin P, Thavaneswaran P, Jamieson GG, Maddern GJ. Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. *Br J Surg*. 2009 Feb;96(2):128-36.
32. Chen MY, Huang DY, Wu A, Zhu YB, Zhu HP, Lin LM, et al. Efficacy of Magnetic Sphincter Augmentation versus Nissen Fundoplication for Gastroesophageal Reflux Disease in Short Term: A Meta-Analysis. *Can J Gastroenterol Hepatol*. 2017;2017:9596342.
33. Chimukangara M, Jalilvand AD, Melvin WS, Perry KA. Long-term reported outcomes of transoral incisionless fundoplication: an 8-year cohort study. *Surg Endosc*. 2019 Apr;33(4):1304-1309.
34. Choi AY, Roccato MK, Samarasena JB, Kolb JM, Lee DP, Lee RH, et al. Novel Interdisciplinary Approach to GERD: Concomitant Laparoscopic Hiatal Hernia Repair with Transoral Incisionless Fundoplication. *J Am Coll Surg*. 2021 Mar;232(3):309-318.
35. Chung CS, Huang TY, Lin CL, Chiang CH, Chen KC, Wu JM, et al. Efficacy and safety of gastric peroral endoscopic myotomy (G-POEM) for refractory gastroparesis: 3-year follow up results. *J Formos Med Assoc*. 2022 Jul;121(7):1334-1341.
36. Conchillo JM, Straathof JWA, Mujagic Z, Brouns JH, Bouvy ND, Keszthelyi D, et al. Gastric peroral endoscopic pyloromyotomy for decompensated gastroparesis: comprehensive motility analysis in relation to treatment outcomes. *Endosc Int Open*. 2021 Feb;9(2):E137-E144.
37. Coronel MA, Bernardo WM, Moura DTH, Moura ETH, Ribeiro IB, Moura EGH. The Efficacy of the Different Endoscopic Treatments Versus Sham, Pharmacologic or Surgical Methods for Chronic Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. *Arq Gastroenterol*. 2018 Jul-Sep;55(3):296-305.
38. Costantini A, Familiari P, Costantini M, Salvador R, Valmasoni M, Capovilla G, et al. Poem Versus Laparoscopic Heller Myotomy in the Treatment of Esophageal Achalasia: A Case-Control Study From Two High Volume Centers Using the Propensity Score. *J Gastrointest Surg*. 2020 Mar;24(3):505-515.
39. Crespín OM, Liu LWC, Parmar A, Jackson TD, Hamid J, Shlomovitz E, et al. Safety and efficacy of POEM for treatment of achalasia: a systematic review of the literature. *Surg Endosc*. 2017 May;31(5):2187-2201.
40. Dacha S, Mekaroonkamol P, Li L, Shahnavaz N, Sakaria S, Keilin S, et al. Outcomes and quality-of-life assessment after gastric per-oral endoscopic pyloromyotomy (with video). *Gastrointest Endosc*. 2017 Aug;86(2):282-289.
41. de Moura ETH, Jukemura J, Ribeiro IB, Farias GFA, de Almeida Delgado AA, Coutinho LMA, et al. Peroral endoscopic myotomy vs laparoscopic myotomy and partial fundoplication for esophageal achalasia: A single-center randomized controlled trial. *World J Gastroenterol*. 2022 Sep 7;28(33):4875-4889.

42. DeMarchi J, Schwiers M, Soberman M, Tokarski A. Evolution of a novel technology for gastroesophageal reflux disease: a safety perspective of magnetic sphincter augmentation. *Dis Esophagus*. 2021 Nov 11;34(11):doab036.
43. Dirks RC, Kohn GP, Slater B, Whiteside J, Rodriguez NA, Docimo S, et al. Is peroral endoscopic myotomy (POEM) more effective than pneumatic dilation and Heller myotomy? A systematic review and meta-analysis. *Surg Endosc*. 2021 May;35(5):1949-1962.
44. Dughera L, Navino M, Cassolino P, De Cento M, Cacciotella L, Cisarò F, et al. Long-Term Results of Radiofrequency Energy Delivery for the Treatment of GERD: Results of a Prospective 48-Month Study. *Diagn Ther Endosc*. 2011;2011:507157.
45. Dughera L, Rotondano G, De Cento M, Cassolino P, Cisarò F. Durability of Stretta Radiofrequency Treatment for GERD: Results of an 8-Year Follow-Up. *Gastroenterol Res Pract*. 2014;2014:531907.
46. EndoGastric Solutions®. About TIF®. Accessed Aug 8, 2025. Available at URL address: <http://www.gerdhelp.com/about-tif/>
47. Falk GW, Fennerty MB, Rothstein RI. AGA Institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. *Gastroenterology*. 2006 Oct;131(4):1315-36.
48. Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. *Surg Endosc*. 2017 Dec;31(12):4865-4882.
49. Fernandez-Ananin S, Fernández AF, Balagué C, Sacoto D, Targarona EM. What to do when Heller's myotomy fails? Pneumatic dilatation, laparoscopic remyotomy or peroral endoscopic myotomy: A systematic review. *J Minim Access Surg*. 2018 Jul-Sep;14(3):177-184.
50. Ferrari D, Asti E, Lazzari V, Siboni S, Bernardi D, Bonavina L. Six to 12-year outcomes of magnetic sphincter augmentation for gastroesophageal reflux disease. *Sci Rep*. 2020 Aug 13;10(1):13753.
51. Ferrari D, Siboni S, Riva CG, Guerrazzi G, Lovece A, Bonavina L. Magnetic Sphincter Augmentation Outcomes in Severe Gastroesophageal Reflux Disease. *Front Med (Lausanne)*. 2021 Nov 2;8:645592.
52. Fockens P, Cohen L, Edmundowicz SA, Binmoeller K, Rothstein RI, Smith D, et al. Prospective randomized controlled trial of an injectable esophageal prosthesis versus a sham procedure for endoscopic treatment of gastroesophageal reflux disease. *Surg Endosc*. 2010 Jun;24(6):1387-97.
53. Frazzoni M, Conigliaro R, Manta R, Melotti G. Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERD. *Aliment Pharmacol Ther*. 2011 Jul;34(1):67-75.
54. Ganz RA, Fallon E, Wittchow T, Klein D. A new injectable agent for the treatment of GERD: results of the Durasphere pilot trial. *Gastrointest Endosc*. 2009 Feb;69(2):318-23.

55. Ganz RA, Peters JH, Horgan S, Bemelman WA, Dunst CM, Edmundowicz SA, et al. Esophageal sphincter device for gastroesophageal reflux disease. *N Engl J Med*. 2013 Feb 21;368(8):719-27.
56. Ganz RA, Edmundowicz SA, Taiganides PA, Lipham JC, Smith CD, DeVault KR, et al. Long-Term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. *Clin Gastroenterol Hepatol*. 2015 Jun 2.
57. Gawron AJ, Bell R, Abu Dayyeh BK, Buckley FP, Chang K, Dunst CM, et al. Surgical and endoscopic management options for patients with GERD based on proton pump inhibitor symptom response: recommendations from an expert U.S. panel. *Gastrointest Endosc*. 2020 Jul;92(1):78-87.e2.
58. Gerson L, Stouch B, Lobontiu A. Transoral Incisionless Fundoplication (TIF 2.0): A Meta-Analysis of Three Randomized, Controlled Clinical Trials. *Chirurgia (Bucur)*. 2018 Mar-Apr;113(2):173-184.
59. Gong EJ, Park CH, Jung DH, Kang SH, Lee JY, Lim H, et al. Efficacy of Endoscopic and Surgical Treatments for Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-Analysis. *J Pers Med*. 2022 Apr 12;12(4):621.
60. Gonzalez JM, Benezech A, Vitton V, Barthet M. G-POEM with antro-pyloromyotomy for the treatment of refractory gastroparesis: mid-term follow-up and factors predicting outcome. *Aliment Pharmacol Ther*. 2017 Aug;46(3):364-370.
61. Gregor L, Wo J, DeWitt J, Yim B, Siwiec R, Nowak T, et al. Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: a prospective single-center experience with mid-term follow-up (with video). *Gastrointest Endosc*. 2021 Jul;94(1):35-44.
62. Grössmann N, Wolf S, Wild C. Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD). *AIHTA Decision Support Documents No. 127*; 2021. Vienna: Austrian Institute for Health Technology Assessment GmbH.
63. Guidozzi N, Wiggins T, Ahmed AR, Hanna GB, Markar SR. Laparoscopic magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: systematic review and pooled analysis. *Dis Esophagus*. 2019 Nov 13;32(9):doz031.
64. Hajjar A, Verhoeff K, Jogiat U, Mocanu V, Birch DW, Switzer NJ, Wong C, Karmali S. Endoscopic plication compared to laparoscopic fundoplication in the treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. *Surg Endosc*. 2023 Aug;37(8):5791-5806.
65. Håkansson B, Montgomery M, Cadiere GB, Rajan A, Bruley des Varannes S, Lerhun M, et al. Randomised clinical trial: transoral incisionless fundoplication vs. sham intervention to control chronic GERD. *Aliment Pharmacol Ther*. 2015 Dec;42(11-12):1261-70.
66. Haseeb M, Brown JRG, Hayat U, Bay C, Bain PA, Jirapinyo P, Thompson CC. Impact of second-generation transoral incisionless fundoplication on atypical GERD symptoms: a systematic review and meta-analysis. *Gastrointest Endosc*. 2023 Mar;97(3):394-406.e2.

67. He S, Xu F, Xiong X, Wang H, Cao L, Liang N, et al. Stretta procedure versus proton pump inhibitors for the treatment of nonerosive reflux disease: A 6-month follow-up. *Medicine (Baltimore)*. 2020 Jan;99(3):e18610
68. Hernández Mondragón OV, Contreras LFG, Velasco GB, Pineda OMS, Carrillo DMC, Perez EM. Gastric peroral endoscopic myotomy outcomes after 4 years of follow-up in a large cohort of patients with refractory gastroparesis (with video). *Gastrointest Endosc*. 2022 Sep;96(3):487-499.
69. Hu Z, Wu J, Wang Z, Zhang Y, Liang W, Yan C. Outcome of Stretta radiofrequency and fundoplication for GERD-related severe asthmatic symptoms. *Front Med*. 2015 Dec;9(4):437-43.
70. Huang X, Chen S, Zhao H, Zeng X, Lian J, Tseng Y, et al. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis. *Surg Endosc*. 2016 Aug 5.
71. Hunter JG, Kahrilas PJ, Bell RC, Wilson EB, Trad KS, Dolan JP, et al. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. *Gastroenterology*. 2015 Feb;148(2):324-333.e5.
72. Hušťák R, Vacková Z, Krajčiová J, Janicko M, Buncová M, Kieslichová E, Spicak J, Martínek J. Per-oral endoscopic pyloromyotomy (g-poem) for the treatment of gastroparesis – a pilot single-centre study with mid-term follow-up. *Rozhl Chir*. 2020 Winter;99(3):116-123. English.
73. Ichkhanian Y, Vosoughi K, Aghaie Meybodi M, Jacques J, Sethi A, Patel AA, et al. Comprehensive Analysis of Adverse Events Associated with Gastric Peroral Endoscopic Myotomy: An International Multicenter Study. *Surg Endosc*. 2021 Apr;35(4):1755-1764.
74. Inoue H, Shiwaoku H, Iwakiri K, Onimaru M, Kobayashi Y, Minami H, et al. Clinical practice guidelines for peroral endoscopic myotomy. *Dig Endosc*. 2018 Sep;30(5):563-579.
75. Jacques J, Pagnon L, Hure F, Legros R, Crepin S, Fauchais AL, et al. Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. *Endoscopy*. 2019 Jan;51(1):40-49.
76. Janu P, Shughoury AB, Venkat K, Hurwich D, Galouzis T, Siatras J, et al. Laparoscopic Hiatal Hernia Repair Followed by Transoral Incisionless Fundoplication With EsophyX Device (HH + TIF): Efficacy and Safety in Two Community Hospitals. *Surg Innov*. 2019 Dec;26(6):675-686.
77. Jiang YX, Dong ZY, Wang JW, Chen Y, Sun HH, Xu SC. Efficacy of Endoscopic Radiofrequency Ablation for Treatment of Reflux Hypersensitivity: A Study Based on Rome IV Criteria. *Gastroenterol Res Pract*. 2022 Mar 27;2022:4145810
78. Joel A, Konjengbam A, Viswanath Y, Kourounis G, Hammond E, Frank H, et al. Endoscopic radiofrequency Stretta therapy reduces proton pump inhibitor dependency and the need for anti-reflux surgery for refractory gastroesophageal reflux disease. *Clin Endosc*. 2023 May 2.

79. Johnson & Johnson. LINX™ Reflux Management System. Accessed Aug 8, 2025. Available at URL address: <https://www.jnjmedicaldevices.com/en-US/product/linx-reflux-management-system>
80. Kahaleh M, Gonzalez JM, Xu MM, Andalib I, Gaidhane M, Tyberg A, et al. Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: a multicenter international experience. *Endoscopy*. 2018 Nov;50(11):1053-1058.
81. Kahrilas PJ, Katzka D, Richter JE. Clinical practice update: The use of per-oral endoscopic myotomy in achalasia: expert review and best practice advice from the AGA institute. *Gastroenterology*. 2017 Nov;153(5):1205-1211.
82. Kalapala R, Karyampudi A, Nabi Z, Darisetty S, Jagtap N, Ramchandani M, et al. Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: results from a randomised, sham controlled trial. *Gut*. 2021 Apr 13:gutjnl-2020-321811.
83. Kalapala R, Shah H, Nabi Z, Darisetty S, Talukdar R, Nageshwar Reddy D. Treatment of gastroesophageal reflux disease using radiofrequency ablation (Stretta procedure): An interim analysis of a randomized trial. *Indian J Gastroenterol*. 2017 Sep;36(5):337-342.
84. Kamal F, Khan MA, Lee-Smith W, Sharma S, Acharya A, Jowhar D, et al. Systematic review with meta-analysis: one-year outcomes of gastric peroral endoscopic myotomy for refractory gastroparesis. *Aliment Pharmacol Ther*. 2022 Jan;55(2):168-177.
85. Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol*. 2022 Jan 1;117(1):27-56.
86. Khashab MA. Peroral endoscopic myotomy (POEM). In: UpToDate, Louie BE, Chen W. (Eds). Aug 11, 2023. UpToDate, Waltham, MA. Accessed Aug 8, 2025.
87. Khashab MA, Vela MF, Thosani N, Agrawal D, Buxbaum JL, Abbas Fehmi SM, et al. ASGE guideline on the management of achalasia. *Gastrointest Endosc*. 2020 Feb;91(2):213-227.e6.
88. Khashab MA, Wang AY, Cai Q. AGA Clinical Practice Update on Gastric Peroral Endoscopic Myotomy for Gastroparesis: Commentary. *Gastroenterology*. 2023 Jun;164(7):1329-1335.e1.
89. Kim HJ, Kwon CI, Kessler WR, Selzer DJ, McNulty G, Bapaye A, et al. Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device. *Surg Endosc*. 2016 Aug;30(8):3402-8.
90. Kirkham EN, Main BG, Jones KJB, Blazeby JM, Blencowe NS. Systematic review of the introduction and evaluation of magnetic augmentation of the lower oesophageal sphincter for gastro-oesophageal reflux disease. *Br J Surg*. 2020 Jan;107(1):44-55.
91. Kohn GP, Dirks RC, Ansari MT, Clay J, Dunst CM, Lundell L, et al. SAGES guidelines for the use of peroral endoscopic myotomy (POEM) for the treatment of achalasia. *Surg Endosc*. 2021 May;35(5):1931-1948.

92. Labonde A, Lades G, Debourdeau A, Ragi O, Lehmann L, Vitton V, et al. Gastric peroral endoscopic myotomy in refractory gastroparesis: long-term outcomes and predictive score to improve patient selection. *Gastrointest Endosc.* 2022 Apr 9:S0016-5107(22)00256-5.
93. Lacy BE, Tack J, Gyawali CP. AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review. *Clin Gastroenterol Hepatol.* 2022 Mar;20(3):491-500.
94. Landreneau JP, Strong AT, El-Hayek K, Tu C, Villamere J, Ponsky JL, et al. Laparoscopic pyloroplasty versus endoscopic per-oral pyloromyotomy for the treatment of gastroparesis. *Surg Endosc.* 2019 Mar;33(3):773-781.
95. Laurino-Neto RM, Herbella F, Schlottmann F, Patti M. Evaluation of Esophageal Achalasia: From Symptoms To The Chicago Classification. *Arq Bras Cir Dig.* 2018;31(2):e1376.
96. Lee Y, Brar K, Doumouras AG, Hong D. Peroral endoscopic myotomy (POEM) for the treatment of pediatric achalasia: a systematic review and meta-analysis. *Surg Endosc.* 2019 Jun;33(6):1710-1720.
97. Li H, Peng W, Huang S, Ren Y, Peng Y, Li Q, et al. The 2 years' long-term efficacy and safety of peroral endoscopic myotomy for the treatment of achalasia: a systematic review. *J Cardiothorac Surg.* 2019 Jan 3;14(1):1.
98. Li P, Ma B, Gong S, Zhang X, Li W. Gastric per-oral endoscopic myotomy for refractory gastroparesis: A meta-analysis. *J Gastrointest Surg.* 2021;25(5):1108-1116.
99. Li QL, Wu QN, Zhang XC, Xu MD, Zhang W, Chen SY, et al. Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months. *Gastrointest Endosc.* 2018 Jun;87(6):1405-1412.e3.
100. Liang WT, Yan C, Wang ZG, Wu JM, Hu ZW, Zhan XL, et al. Early and Midterm Outcome After Laparoscopic Fundoplication and a Minimally Invasive Endoscopic Procedure in Patients with Gastroesophageal Reflux Disease: A Prospective Observational Study. *J Laparoendosc Adv Surg Tech A.* 2015 Aug;25(8):657-61.
101. Lipham JC, Demeester TR, Ganz RA, Bonavina L, Saino G, Dunn DH, et al. The LINX® reflux management system: confirmed safety and efficacy now at 4 years. *Surg Endosc.* 2012 Oct;26(10):2944-9.
102. Lipham JC, Taiganides PA, Louie BE, Ganz RA, DeMeester TR. Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease. *Dis Esophagus.* 2015 May-Jun;28(4):305-11.
103. Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2015 Jun;13(6):1058-67.e1.
104. Louie BE, Smith CD, Smith CC, Bell RCW, Gillian GK, Mandel JS, et al. Objective Evidence of Reflux Control After Magnetic Sphincter Augmentation: One Year Results from a Post Approval Study. *Ann Surg.* 2019 Aug;270(2):302-308.

105. Mahmood Z, McMahon BP, Arfin Q, Byrne PJ, Reynolds JV, Murphy EM, et al. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. *Gut*. 2003 Jan;52(1):34-9.
106. Malik Z, Kataria R, Modayil R, Ehrlich AC, Schey R, Parkman HP, et al. Gastric Per Oral Endoscopic Myotomy (G-POEM) for the Treatment of Refractory Gastroparesis: Early Experience. *Dig Dis Sci*. 2018 Sep;63(9):2405-2412.
107. Mandavdhare HS, Praveen Kumar M, Jha D, Kumar A, Sharma V, Desai P, Shumkina L, et al. Diverticular per oral endoscopic myotomy (DPOEM) for esophageal diverticular disease: a systematic review and meta-analysis. *Esophagus*. 2021 Jul;18(3):436-450.
108. Marano L, Pallabazzer G, Solito B, Santi S, Pigazzi A, De Luca R, et al. Surgery or Peroral Esophageal Myotomy for Achalasia: A Systematic Review and Meta-Analysis. *Medicine (Baltimore)*. 2016 Mar;95(10):e3001.
109. Martinek J, Hustak R, Mares J, Vackova Z, Spicak J, Kieslichova E, et al. Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial. *Gut*. 2022 Nov;71(11):2170-2178.
110. Maydeo A, Patil GK, Dalal A. Operative technical tricks and 12-month outcomes of diverticular peroral endoscopic myotomy (D-POEM) in patients with symptomatic esophageal diverticula. *Endoscopy*. 2019 Dec;51(12):1136-1140.
111. McCarty TR, Itidiare M, Njei B, Rustagi T. Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. *Endoscopy*. 2018 Jul;50(7):708-725.
112. Mekaroonkamol P, Dacha S, Wang L, Li X, Jiang Y, Li L, et al. Gastric Peroral Endoscopic Pyloromyotomy Reduces Symptoms, Increases Quality of Life, and Reduces Health Care Use For Patients With Gastroparesis. *Clin Gastroenterol Hepatol*. 2019 Jan;17(1):82-89.
113. Mekaroonkamol P, Patel V, Shah R, Li B, Luo H, Shen S, et al. Association between duration or etiology of gastroparesis and clinical response after gastric per-oral endoscopic pyloromyotomy. *Gastrointest Endosc*. 2019 May;89(5):969-976.
114. Modayil RJ, Zhang X, Rothberg B, Kollarus M, Galibov I, Peller H, et al. Peroral endoscopic myotomy: 10-year outcomes from a large, single-center U.S. series with high follow-up completion and comprehensive analysis of long-term efficacy, safety, objective GERD, and endoscopic functional luminal assessment. *Gastrointest Endosc*. 2021 Nov;94(5):930-942.
115. Mohan BP, Chandan S, Jha LK, Khan SR, Kotagiri R, Kassab LL, et al. Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. *Surg Endosc*. 2019 Oct 3.
116. Montgomery M, Hakanson B, Ljungqvist O, Ahlman B, Thorell A. Twelve months' follow-up after treatment with the EndoCinch endoscopic technique for gastro-oesophageal reflux disease: a randomized, placebo-controlled study. *Scand J Gastroenterol*. 2006 Dec;41(12):1382-9.

117. Muls V, Eckardt AJ, Marchese M, Bastens B, Buset M, Devière J, et al. Three-year results of a multicenter prospective study of transoral incisionless fundoplication. *Surg Innov*. 2013 Aug;20(4):321-30.
118. Nabi Z, Chavan R, Asif S, Ramchandani M, Basha J, Darisetty S, Goud R, Kotla R, Reddy DN. Per-oral Endoscopic Myotomy with Division of Septum (D-POEM) in Epiphrenic Esophageal Diverticula: Outcomes at a Median Follow-Up of Two Years. *Dysphagia*. 2022 Aug;37(4):839-847.
119. Nabi Z, Reddy DN. Endoscopic Management of Gastroesophageal Reflux Disease: Revisited. *Clin Endosc*. 2016 Sep;49(5):408-416.
120. Nabi Z, Reddy DN. Update on Endoscopic Approaches for the Management of Gastroesophageal Reflux Disease. *Gastroenterol Hepatol (N Y)*. 2019 Jul;15(7):369-376.
121. Narsule CK, Burch MA, Ebright MI, Hess DT, Rivas R Jr, Daly BD, Fernando HC. Endoscopic fundoplication for the treatment of gastroesophageal reflux disease: initial experience. *J Thorac Cardiovasc Surg*. 2012 Jan;143(1):228-34.
122. National Organization for Rare Disorders (NORD®). Rare Disease database. Achalasia. 2017. Accessed Aug 7, 2025. Available at URL address: <https://rarediseases.org/rare-diseases/achalasia/>
123. Nicolau AE, Lobonțiu A, Constantinoiu S. New Minimally Invasive Endoscopic and Surgical Therapies for Gastroesophageal Reflux Disease (GERD). *Chirurgia (Bucur)*. 2018 Jan-Feb;113(1):70-82.
124. Nevins EJ, Dixon JE, Viswanath YKS. The Outcome of Endoscopic Radiofrequency Anti-Reflux Therapy (STRETTA) for Gastro-Esophageal Reflux Disease in Patients with Previous Gastric Surgery: A Prospective Cohort study. *Clin Endosc*. 2021 Mar 24.
125. Noar M, Squires P, Noar E, Lee M. Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later. *Surg Endosc*. 2014 Aug;28(8):2323-33.
126. Noar M, Squires P, Khan S. Radiofrequency energy delivery to the lower esophageal sphincter improves gastroesophageal reflux patient-reported outcomes in failed laparoscopic Nissen fundoplication cohort. *Surg Endosc*. 2017 Jul;31(7):2854-2862.
127. Orlandini B, Barret M, Guillaumot MA, Léandri C, Leblanc S, Prat F, et al. Per-oral endoscopic myotomy for esophageal diverticula with or without esophageal motility disorders. *Clin Res Hepatol Gastroenterol*. 2020 Feb;44(1):82-89.
128. Oude Nijhuis RAB, Zaninotto G, Roman S, Boeckxstaens GE, Fockens P, Langendam MW, et al. European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and Motility recommendations. *United European Gastroenterol J*. 2020 Feb;8(1):13-33.
129. Park CH, Jung DH, Kim DH, Lim CH, Moon HS, Park JH, et al; Achalasia Research Group of the Korean Society of Neurogastroenterology and Motility. Comparative efficacy of per-oral endoscopic myotomy and Heller myotomy in patients with achalasia: a meta-analysis. *Gastrointest Endosc*. 2019 Oct;90(4):546-558.e3.

130. Peng L, Wan R, Chen S, Wu J, Yang J, Wang X, et al. Efficacy of endoscopic anterior fundoplication with a novel ultrasonic surgical endostapler for gastroesophageal reflux disease: Six-month results from a multicenter prospective trial. *Endosc Ultrasound*. 2022 Jun 8.
131. Perry KA, Banerjee A, Melvin WS. Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. *Surg Laparosc Endosc Percutan Tech*. 2012 Aug;22(4):283-8.
132. Pioppo L, Reja D, Gaidhane M, Bareket R, Tawadros A, Madrigal Méndez AL, et al. Gastric per-oral endoscopic myotomy versus pyloromyotomy for gastroparesis: An international comparative study. *J Gastroenterol Hepatol*. 2021 Nov;36(11):3177-3182.
133. Pleskow D, Rothstein R, Lo S, Hawes R, Kozarek R, Haber G, et al. Endoscopic full-thickness plication for the treatment of GERD: a multicenter trial. *Gastrointest Endosc*. 2004 Feb;59(2):163-71.
134. Pleskow D, Rothstein R, Lo S, Hawes R, Kozarek R, Haber G, et al. Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. *Gastrointest Endosc*. 2005 May;61(6):643-9.
135. Pleskow D, Rothstein R, Kozarek R, Haber G, Gostout C, Lembo A. Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results. *Surg Endosc*. 2007 Mar;21(3):439-44.
136. Pleskow D, Rothstein R, Kozarek R, Haber G, Gostout C, Lo S, et al. Endoscopic full-thickness plication for the treatment of GERD: Five-year long-term multicenter results. *Surg Endosc*. 2008 Feb;22(2):326-32.
137. Ponds FA, Fockens P, Lei A, Neuhaus H, Beyna T, Kandler J, et al. Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naïve Patients with Achalasia: A Randomized Clinical Trial. *JAMA*. 2019 Jul 9;322(2):134-144.
138. Puri A, Steven S, Markar SR, Boyle N. Longer-term outcomes of gastroesophageal reflux disease treated with magnetic sphincter augmentation. *Dis Esophagus*. 2023 Mar 20:doad014.
139. Ragi O, Jacques J, Branche J, Leblanc S, Vanbiervliet G, Legros R, Pioche M, Rivory J, Chaussade S, Barret M, Wallenhorst T, Barthet M, Kerever S, Gonzalez JM. One-year results of gastric peroral endoscopic myotomy for refractory gastroparesis: a French multicenter study. *Endoscopy*. 2021 May;53(5):480-490.
140. Ramai D, Shapiro A, Barakat M, Facciorusso A, Dull A, Chandan S, Adler DG. Adverse events associated with transoral incisionless fundoplication (TIF) for chronic gastroesophageal reflux disease: a MAUDE database analysis. *Surg Endosc*. 2022 Jul;36(7):4956-4959.
141. Raphael KL, Walsh P, Benias PC. Innovations in Endoscopic Therapy for Gastroesophageal Reflux Disease. *Gastrointest Endosc Clin N Am*. 2020 Apr;30(2):291-307.

142. Repici A, Fuccio L, Maselli R, Mazza F, Correale L, Mandolesi D, et al. GERD after per-oral endoscopic myotomy as compared with Heller's myotomy with fundoplication: a systematic review with meta-analysis. *Gastrointest Endosc.* 2018 Apr;87(4):934-943.e18.
143. Riegler M, Schoppman SF, Bonavina L, Ashton D, Horbach T, Kemen M. Magnetic sphincter augmentation and fundoplication for GERD in clinical practice: one-year results of a multicenter, prospective observational study. *Surg Endosc.* 2015 May;29(5):1123-9.
144. Respiratory Technology Corporation. Stretta Therapy for Reflux. Accessed Aug 8, 2025. Available at URL address: <https://www.refluxcompany.com/solutions/stretta/>
145. Reynolds JL, Zehetner J, Nieh A, Bildzukewica N, Sandhu K, Katkhouda N, et al. Charges, outcomes, and complications: a comparison of magnetic sphincter augmentation versus laparoscopic Nissen fundoplication for the treatment of GERD, *Surg Endosc.* 2016;30(8):3225-30.
146. Reynolds JL, Zehetner J, Wu P, Shah S, Bildzukewica N, Lipham JC. Laparoscopic Magnetic Sphincter Augmentation vs Laparoscopic Nissen Fundoplication: A Matched-Pair Analysis of 100 Patients, *J Am Coll Surg.* 2015; 221:123-128.
147. Richter JE, Vaezi MF. Gastroesophageal reflux disease. In: Feldman M, Friedman LS, Brandt LJ, editors. *Feldman: Sleisenger and Fordtran's Gastrointestinal and Liver Disease.* 11th ed. Philadelphia, PA: Elsevier; 2021. Ch 46.
148. Richter JE, Kumar A, Lipka S, Miladinovic B, Velanovich V. Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis. *Gastroenterology.* 2018 Apr;154(5):1298-1308.e7.
149. Rona KA, Reynolds J, Schwameis K, Zehetner J, Samakar K, Oh P, et al. Efficacy of magnetic sphincter augmentation in patients with large hiatal hernias. *Surg Endosc.* 2017 May;31(5):2096-2102.
150. Roy-Shapira A, Bapaye A, Date S, Pujari R, Dorwat S. Trans-oral anterior fundoplication: 5-year follow-up of pilot study. *Surg Endosc.* 2015; 29(12): 3717-3721.
151. Saino G, Bonavina L, Lipham JC, Dunn D, Ganz RA. Magnetic Sphincter Augmentation for Gastroesophageal Reflux at 5 Years: Final Results of a Pilot Study Show Long-Term Acid Reduction and Symptom Improvement. *J Laparoendosc Adv Surg Tech A.* 2015 Oct;25(10):787-92.
152. Saleh CMG, Familiari P, Bastiaansen BAJ, Fockens P, Tack J, Boeckxstaens G, et al. The Efficacy of Peroral Endoscopic Myotomy vs Pneumatic Dilation as Treatment for Patients With Achalasia Suffering From Persistent or Recurrent Symptoms After Laparoscopic Heller Myotomy: A Randomized Clinical Trial. *Gastroenterology.* 2023 Jun;164(7):1108-1118.e3.
153. Samanta J, Mandavdhare HS, Kumar N, Kumar-M P, Jafra A, Chauhan R, et al. Per Oral Endoscopic Myotomy for the Management of Large Esophageal Diverticula (D-POEM): Safe and Effective Modality for Complete Septotomy. *Dysphagia.* 2022 Feb;37(1):84-92.
154. Schaheen LW, Sanchez MV, Luketich JD. Peroral Endoscopic Myotomy for Achalasia. *Thorac Surg Clin.* 2018 Nov;28(4):499-506

155. Schiefke I, Zabel-Langhennig A, Neumann S, Feisthammel J, Moessner J, Caca K. Long term failure of endoscopic gastroplication (EndoCinch). *Gut*. 2005 Jun;54(6):752-8.
156. Schizas D, Mastoraki A, Papoutsis E, Giannakoulis VG, Kanavidis P, Tsilimigras D, et al. LINX® reflux management system to bridge the "treatment gap" in gastroesophageal reflux disease: A systematic review of 35 studies. *World J Clin Cases*. 2020 Jan 26;8(2):294-305.
157. Schlottmann F, Herbella FA, Patti, MG. Understanding the Chicago Classification: From Tracings to Patients *J Neurogastroenterol Motil*. 2017 Oct; 23(4): 487–494. Published online 2017 Oct 30.
158. Schlottmann F, Luckett DJ, Fine J, Shaheen NJ, Patti MG. Laparoscopic Heller Myotomy Versus Peroral Endoscopic Myotomy (POEM) for Achalasia: A Systematic Review and Meta-analysis. *Ann Surg*. 2018 Mar;267(3):451-460.
159. Schwameis K, Schwameis M, Zörner B, Lenglinger J, Asari R, Riegler FM, et al. Modern GERD treatment: feasibility of minimally invasive esophageal sphincter augmentation. *Anticancer Res*. 2014 May;34(5):2341-8.
160. Schwartz MP, Wellink H, Gooszen HG, Conchillo JM, Samsom M, Smout AJ. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. *Gut*. 2007 Jan;56(1):20-8.
161. Shah R, Chen H, Calderon LF, Gooden T, Mubashir M, Rashid S, Raza SM, Derise A, Mccurdy G, Sanders B, Keilin S, Cai Q. Safety and feasibility of same day discharge after per oral endoscopic pyloromyotomy in refractory gastroparesis: a pilot study. *Chin Med J (Engl)*. 2022 Jun 20;135(12):1432-1437.
162. Shen S, Yu G, Guo X, Zong G, Wang C, Bao J, Chen J, Cheng Z, Xiao W, Shen J, Jiang W, Wan R. The long-term efficacy of transoral incisionless fundoplication with Medigus Ultrasonic Surgical Endostapler (MUSE) for gastroesophageal reflux disease. *Esophagus*. 2023 Jul;20(3):581-586.
163. Sheu EG, Nau P, Nath B, Kuo B, Rattner DW. A comparative trial of laparoscopic magnetic sphincter augmentation and Nissen fundoplication. *Surg Endosc*. 2015 Mar;29(3):505-9.
164. Skubleny D, Switzer NJ, Dang J, Gill RS, Shi X, de Gara C, et al. LINX® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. *Surg Endosc*. 2017 Aug;31(8):3078-3084.
165. Slater BJ, Collings A, Dirks R, Gould JC, Qureshi AP, Juza R, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). *Surg Endosc*. 2023 Feb;37(2):781-806.
166. Snow GE, Dbouk M, Akst LM, et al. Response of laryngopharyngeal symptoms to transoral incisionless fundoplication in patients with refractory proven gastroesophageal reflux. *Ann Otol Rhinol Laryngol*. 2022;131(6):662-670.
167. Spadaccini M, Maselli R, Chandrasekar VT, Anderloni A, Carrara S, Galtieri PA, et al. Gastric peroral endoscopic pyloromyotomy for refractory gastroparesis: a systematic review of early outcomes with pooled analysis. *Gastrointest Endosc*. 2020 Apr;91(4):746-752.e5.

168. Society of American Gastrointestinal Endoscopic Surgeons (SAGES). SAGES Position Statement on Endolumenal Therapies for Gastrointestinal Diseases. November 2009. Accessed Aug 8, 2025. Available at URL address: <https://www.sages.org/publications/guidelines>
169. Society of American Gastrointestinal Endoscopic Surgeons (SAGES). SAGES Technology and Value Assessment Committee (TAVAC) Safety and Effectiveness Analysis. LINX® Reflux Management System. Mar 2017b. Accessed Aug 8, 2025. Available at URL address: <https://www.sages.org/publications/tavac/tavac-safety-and-effectiveness-analysis-linx-reflux-management-system/>
170. Spechler SJ and Pandolfino JE. Achalasia: Pathogenesis, clinical manifestations, and diagnosis. In: UpToDate, Talley NJ, Robson KM (EDs). Jul 24, 2025. UpToDate, Waltham, MA. Accessed Aug 7, 2025.
171. Spechler SJ and Pandolfino JE. Overview of the treatment of achalasia. In: UpToDate, Talley NJ (Ed). Jul 30, 2025. UpToDate, Waltham, MA. Accessed Aug 7, 2025.
172. Stanak M, Erdos J, Hawlik K, Birsan T. Novel surgical treatments for gastroesophageal reflux disease: Systematic review of magnetic sphincter augmentation and electric stimulation therapy. *Gastroenterology Res.* 2018;11(3):161-173.
173. Stefanidis G, Viazis N, Kotsikoros N, Tsoukalas N, Lala E, Theocharis L, et al. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy. *Dis Esophagus.* 2017 Feb 1;30(3):1-8.
174. Stojilkovic T, Staudinger K, Dennis J. A Systematic Review of the Long-Term Clinical Success of Gastric Peroral Endoscopic Myotomy for Refractory Gastroparesis. *Cureus.* 2023 May 30;15(5):e39709.
175. Strohmaier C, Erdös J. Lower Esophageal Sphincter Devices for Laparoscopic Surgery in Patients with Gastroesophageal Reflux Disease (GERD). AIHTA Decision Support Documents No. 134; 2022. Vienna: Austrian Institute for Health Technology Assessment GmbH.
176. Svoboda P, Kantorová I, Kozumplík L, Scheer P, Radvan M, Radvanová J, et al. Our experience with transoral incisionless plication of gastroesophageal reflux disease: NOTES procedure. *Hepatogastroenterology.* 2011 Jul-Aug;58(109):1208-13.
177. Tan J, Shrestha SM, Wei M, Wang P, Shi J, Lu Y, Gao Q, Lu T, Zhou J, Shi R. Feasibility, safety, and long-term efficacy of gastric peroral endoscopic myotomy (G-POEM) for postsurgical gastroparesis: a single-center and retrospective study of a prospective database. *Surg Endosc.* 2021 Jul;35(7):3459-3470.
178. Tefas C, Ababneh R, Tanțău M. Peroral Endoscopic Myotomy Versus Heller Myotomy for Achalasia: Pros and Cons. *Chirurgia (Bucur).* 2018 Mar-Apr;113(2):185-191.
179. Telem DA, Wright AS, Shah PC, Hutter MM. SAGES technology and value assessment committee (TAVAC) safety and effectiveness analysis: LINX® reflux management system. *Surg Endosc.* 2017 Oct;31(10):3811-3826.

180. Testoni PA, Mazzoleni G, Testoni SG. Transoral incisionless fundoplication for gastro-esophageal reflux disease: Techniques and outcomes. *World J Gastrointest Pharmacol Ther.* 2016 May 6;7(2):179-89.
181. Testoni PA, Testoni S, Distefano G, Mazzoleni G, Fanti L, Passaretti S. Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years. *Endosc Int Open.* 2019 May;7(5):E647-E654.
182. Testoni PA, Testoni S, Mazzoleni G, Pantaleo G, Cilona MB, Distefano G, et al. Transoral incisionless fundoplication with an ultrasonic surgical endostapler for the treatment of gastroesophageal reflux disease: 12-month outcomes. *Endoscopy.* 2020 Jun;52(6):469-473.
183. Testoni PA, Testoni S, Mazzoleni G, Vailati C, Passaretti S. Long-term efficacy of transoral incisionless fundoplication with Esophyx (Tif 2.0) and factors affecting outcomes in GERD patients followed for up to 6 years: a prospective single-center study. *Surg Endosc.* 2015 Sep;29(9):2770-80.
184. Testoni PA, Vailati C, Testoni S, Corsetti M. Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal reflux disease: long-term results and findings affecting outcome. *Surg Endosc.* 2012 May;26(5):1425-35.
185. Testoni S, Hassan C, Mazzoleni G, Antonelli G, Fanti L, Passaretti S, et al. Long-term outcomes of transoral incisionless fundoplication for gastro-esophageal reflux disease: Systematic-review and meta-analysis. *Endosc Int Open.* 2021;9(2):E239-E246
186. Testoni SGG, Cilona MB, Mazzoleni G, Fanti L, Ribichini E, Cavestro GM, et al. Transoral incisionless fundoplication with Medigus ultrasonic surgical endostapler (MUSE) for the treatment of gastro-esophageal reflux disease: outcomes up to 3 years. *Surg Endosc.* 2022 Jul;36(7):5023-5031.
187. Trad S K. Transoral incisionless fundoplication: current status. *Curr Opin Gastroenterol.* 2016 Jul;32(4):338-43.
188. Trad KS, Barnes WE, Prevou ER, Simoni G, Steffen JA, Shughoury AB, et al. The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective. *Surg Innov.* 2018 Apr;25(2):149-157.
189. Trad KS, Barnes WE, Simoni G, Shughoury AB, Mavrelis PG, Raza M, et al. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial. *Surg Innov.* 2015 Feb;22(1):26-40.
190. Trad KS, Fox MA, Simoni G, Shughoury AB, Mavrelis PG, Raza M, et al. Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm. *Surg Endosc.* 2017 Sep 21 Jun;31(6):2498-2508.
191. Trad KS, Turgeon DG, Deljkich E. Long-term outcomes after transoral incisionless fundoplication in patients with GERD and LPR symptoms. *Surg Endosc.* 2012 Mar;26(3):650-60.

192. Triadafilopoulos G. Radiofrequency treatment for gastroesophageal reflux disease. In: UpToDate, Saltzman JR, Robson KM (Eds), Jul 14, 2023. UpToDate, Waltham, MA. Accessed Aug 7, 2025.
193. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). PMA-Premarket Approval. Durasphere injectable bulking agent. September 13, 1999. P980053. Accessed Aug 7, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980053>
194. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). PMA-Premarket Approval. LINX™ Reflux Management System. March 22, 2012. P100049. Accessed Aug 7, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100049>
195. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Bard® Endoscopic Suturing System. March 20, 2000b. K994290. Accessed Aug 7, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K994290>
196. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. CSM Stretta™ System. April 18, 2000a. K000245. Accessed Aug 7, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K000245>
197. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. EndoGastric Solutions (EGS) EsophyX™ System with SerosaFuse™ Fastner and Accessories. Sep 14, 2007. K071651. Accessed Aug 8, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K071651>
198. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Endogastric Solutions EsophyX2 System with SerosaFuse Fastener and Accessories, Model 2.7.5. Nov 6, 2009b. K092400. Accessed Aug 8, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K092400>
199. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Endogastric Solutions EsophyX2 HD Device with SerosaFuse Fastener and Accessories. Sep 30, 2014. K142113. Accessed Aug 8, 2025. Available at URL address: <https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pmn&id=K142113>
200. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Endogastric Solutions EsophyX2 HD Device with SerosaFuse Fasteners and Accessories and EsophyX Z Device with SerosaFuse Fasteners and Accessories. June 22, 2017a. K171307. Accessed Aug 8, 2025. Available at URL address: <https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pmn&id=K171307>
201. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Endogastric Solutions EsophyX Z Device with SerosaFuse Fasteners and Accessories and EsophyX2 HD Device with SerosaFuse Fasteners and

Accessories. October 19, 2017b. K172811. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K172811>

202. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. EndoGastric Solutions StomaphyX™ Delivery Device, Fasteners and Accessories. June 27, 2008. K073644. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pmn&id=K073644>
203. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. EndoGastric Solutions StomaphyX™ Device and Implantable Fasteners. July 22, 2009a. K091832. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pmn&id=K091832>
204. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. EndoGastric Solutions StomaphyX™ endoluminal fastener and delivery system. March 9, 2007. K062875. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K062875>
205. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Endoscopic Plication System, Eps, Eplicator, Plicator Instrument. October 18, 2007. K072125. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K072125>
206. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Endoscopic Plication System; Eps; Plicator. September 18, 2007. K071553. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K071553>
207. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Mederi Therapeutics Stretta Catheter. 2015. K152317. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K152317>
208. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Medigus SRS Endoscopic Stapling System (MUSE). March 19, 2014. K132151. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K132151>
209. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. MUSE System. January 20, 2015a. K143634. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pmn&id=K143634>
210. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. MUSE System. June 5, 2015b. K151001. Accessed Aug 8, 2025. Available at URL address:

<https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pmn&id=K151001>

211. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Modification to Endoscopic Plication System. October 23, 2003. K032820. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K032820>
212. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. NDO Surgical Endoscopic Plication System. May 23, 2003. K031262. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K031262>
213. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. OverStitch Endoscopic Suturing System and Accessories. 2018. K181141. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K181141>
214. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. OverStitch 2-0 Polypropylene Suture. 2019. K191439. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K191439>
215. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. OverStitch Sx Endoscopic Suturing System. 2021. K21026. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pmn&id=K210266>
216. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Plicator Gsx Suturing System, Plicator Gsx, Plicator Instrument, Plicator Gsx Suture Cartridge. March 26, 2008. K073671. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K073671>
217. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. SRS™ Endoscopic Stapling System. May 18, 2012. K120299. Accessed Aug 8, 2025. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K120299>
218. Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. *Am J Gastroenterol*. 2020a Sep;115(9):1393-1411.
219. Vaezi MF, Shaheen NJ, Muthusamy VR. State of Evidence in Minimally Invasive Management of Gastroesophageal Reflux: Findings of a Scoping Review. *Gastroenterology*. 2020b Oct;159(4):1504-1525.
220. Viswanath Y, Maguire N, Obuobi RB, Dhar A, Punnoose S. Endoscopic day case antireflux radiofrequency (Stretta) therapy improves quality of life and reduce proton pump inhibitor (PPI) dependency in patients with gastro-oesophageal reflux disease: a prospective study from a UK tertiary centre. *Frontline Gastroenterol*. 2019 Apr;10(2):113-119.

221. Vosoughi K, Ichkhanian Y, Benias P, Miller L, Aadam AA, Triggs et al. Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial. *Gut*. 2021 Mar 19;gutjnl-2020-322756.
222. Walsh PR, Lamba M, Benias P, Lafta A, Hopkins G. Feasibility of resection and plication "RAP" technique for management of medically refractory GERD in patients with altered gastric anatomy. *Endosc Int Open*. 2021 Sep 16;9(10):E1549-E1555.
223. Weitzendorfer M, Spaun GO, Antoniou SA, Witzel K, Emmanuel K, Koch OO. Clinical feasibility of a new full-thickness endoscopic plication device (GERDx™) for patients with GERD: results of a prospective trial. *Surg Endosc*. 2018 May;32(5):2541-2549.
224. Wendling MR, Melvin WS, Perry KA. Impact of transoral incisionless fundoplication (TIF) on subjective and objective GERD indices: a systematic review of the published literature. *Surg Endosc*. 2013 Oct;27(10):3754-61.
225. Wessels EM, Schuitenmaker JM, Bastiaansen BAJ, Fockens P, Masclee GMC, Bredenoord AJ. Efficacy and safety of peroral endoscopic myotomy for esophageal diverticula. *Endosc Int Open*. 2023 May 26;11(5):E546-E552
226. Werner YB, Hakanson B, Martinek J, Repici A, von Rahden BHA, Bredenoord AJ, et al. Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia. *N Engl J Med*. 2019 Dec 5;381(23):2219-2229.
227. Wilson EB, Barnes WE, Mavrelis PG, Carter BJ, Bell RC, Sewell RW, et al. The effects of transoral incisionless fundoplication on chronic GERD patients: 12-month prospective multicenter experience. *Surg Laparosc Endosc Percutan Tech*. 2014 Feb;24(1):36-46.
228. Witteman BP, Conchillo JM, Rinsma NF, Betzel B, Peeters A, Koek GH, et al. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease. *Am J Gastroenterol*. 2015 Apr;110(4):531-42.
229. Xie P, Yan J, Ye L, Wang C, Li Y, Chen Y, et al. Efficacy of different endoscopic treatments in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis. *Surg Endosc*. 2021 Apr;35(4):1500-1510.
230. Xu J, Chen T, Elkholy S, Xu M, Zhong Y, Zhang Y, Chen W, Qin W, Cai M, Zhou P. Gastric Peroral Endoscopic Myotomy (G-POEM) as a Treatment for Refractory Gastroparesis: Long-Term Outcomes. *Can J Gastroenterol Hepatol*. 2018 Oct 22;2018:6409698.
231. Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. *Clin Gastroenterol Hepatol*. 2022 May;20(5):984-994.e1.
232. Yadlapati R, Vaezi MF, Vela MF, Spechler SJ, Shaheen NJ, Richter J, et al. Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel. *The American journal of gastroenterology*. 2018;113(7), 980–986.

233. Yan C, Liang W-T, Wang Z-G, Hu Z-W, Wu J-M, Zhang C, et al. Comparison of Stretta procedure and toupet fundoplication for gastroesophageal reflux disease-related extra-esophageal symptoms. *World J Gastroenterol*. 2015 Dec 7; 21(45): 12882–12887.
234. Yan J, Tan Y, Zhou B, Zhang S, Wang X, Liu D. Gastric per-oral endoscopic myotomy (G-POEM) is a promising treatment for refractory gastroparesis: a systematic review and meta-analysis. *Rev Esp Enferm Dig*. 2020 Mar;112(3):219-228.
235. Yang J, Zeng X, Yuan X, Chang K, Sanaei O, Fayad L, et al. An international study on the use of peroral endoscopic myotomy (POEM) in the management of esophageal diverticula: the first multicenter D-POEM experience. *Endoscopy*. 2019 Apr;51(4):346-349.
236. Zacherl J, Roy-Shapira A, Bonavina L, Bapaye A, Kiesslich R, Schoppmann SF, et al. Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial. *Surg Endosc*. 2014 Aug 19.
237. Zaninotto G, Bennett C, Boeckxstaens G, Costantini M, Ferguson MK, Pandolfino JE, et al. The 2018 ISDE achalasia guidelines. *Dis Esophagus*. 2018 Sep 1;31(9).
238. Zerbib F, Bredenoord AJ, Fass R, Kahrilas PJ, Roman S, Savarino E, Sifrim D, et al. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. *Neurogastroenterol Motil*. 2021 Apr;33(4):e14075.
239. Zerbib F, Sacher-Huvelin S, Coron E, Coffin B, Melchior C, Ponchon T, et al. Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn. *Aliment Pharmacol Ther*. 2020 Aug;52(4):637-645.
240. Zhang DF, Chen WF, Wang Y, Xu MD, Zhang XC, Cai MY, et al. Submucosal tunneling endoscopic septum division for esophageal diverticulum with a median follow-up of 39 months: a multicenter cohort study. *Gastrointest Endosc*. 2022 Oct;96(4):612-619.e1.
241. Zhang XC, Li QL, Xu MD, et al. Major perioperative adverse events of peroral endoscopic myotomy: a systematic 5-year analysis. *Endoscopy* 2016;48: 967–78.
242. Zhuang QJ, Tan ND, Chen SF, Zhang MY, Xiao YL. Magnetic sphincter augmentation in treating refractory gastroesophageal reflux disease: A systematic review and meta-analysis. *J Dig Dis*. 2021 Dec;22(12):695-705.

Revision Details

Type of Revision	Summary of Changes	Date
Annual review	Removed non-coverage statement for Zenker peroral endoscopic myotomy (Z-POEM)	9/15/2025
Annual review	No changes to coverage	8/15/2024
Annual review	- Updated to new template and formatting standards. - Changed from not covered to covered for gastric peroral endoscopic myotomy (G-POEM) for a small subset of patients.	10/15/2023

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.